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ABSTRACT 
PING MA: Drug-Loaded Lipid Nanoparticles for Improved Cancer Treatment:   
Engineering, In-Vitro, and In-Vivo Evaluation 
(Under the direction of Russell J. Mumper, Ph.D.) 
 
The objectives of these studies were to develop lipid-based nanoparticles (NPs) of 
anthracyclines (idarubicin, IDA and doxorubicin, DOX) and taxanes (paclitaxel, PX) for 
improved cancer treatment. Two types of lipid-based NPs were developed, one was solid 
lipid NPs (SLNs) for the delivery of IDA and DOX, and the other one was oil-filled 
nanocapsules for PX delivery. Both of the NPs were engineered using a warm 
microemulsion precursor method, and polyoxyl 20-stearyl ether (Brij 78) and D-alpha-
tocopheryl polyethylene glycol succinate (TPGS) were utilized in NPs as the surfactants in 
both NPs. The difference between the NPs was that the emulsifying wax was used as the oil 
phase in SLNs, while Miglyol 812 was utilized in oil-filled NPs.  
In the studies of IDA and DOX SLNs, anionic ion-pairing agents of sodium 
taurodeoxycholate (STDC) and sodium tetradecyl sulfate (STS) were used to neutralize the 
charges of the cationic anthracyclines and enhance the entrapment of the drugs in the 
SLNs. The IC50 value of DOX NPs was 9-fold lower than that of free DOX solution in 
resistant P388/ADR cell line. In contrast, free IDA had comparable IC50 values as IDA NPs 
in P-gp-overexpressing P388/ADR and HCT-15 cells. The in-vivo results were well 
correlated with the in-vitro studies, where the DOX NPs resulted significantly prolonged 
survival time than free DOX and controls in a P388/ADR leukemia mouse model but IDA
iv 
 
NPs were as effective as free IDA in P-gp-overexpressing mouse tumor models. The 
present studies suggest that the SLNs may offer potential to deliver anticancer drugs for the 
treatment of P-gp-mediated multiple drug resistance; however, selection of target drug may 
be very important. 
In the studies of PX oil-filled nanocapsules, a novel 2’-behenoyl-paclitaxel (C22-PX) 
was synthesized to increase the lipophilicity of PX and facilitate its retention within the core 
of the oil-filled nanocapsules. The solubility of C22-PX in Miglyol 812 increased 25-fold 
compared to PX. C22-PX was less active than PX which was confirmed by the in-vitro 
cytotoxicity and tubulin polymerization studies. The maximum tolerated dose (MTD) of C22-
PX nanocapsules increased 6-fold compared to Taxol in a 4T1 mouse model, and at MTD 
C22-PX nanocapsules exhibited significantly better in-vivo antitumor efficacy than all control 
groups. In-vivo pharmacokinetic and biodistribution studies, the C22-PX nanocapsules 
demonstrated dramatically improved pharmacokinetic and tumor uptake profiles than Taxol, 
where the plasma and tumor AUCs of C22-PX from C22-PX nanocapsules were 186- and 
24.4-fold greater than PX from Taxol at MTD, respectively. The present studies suggest that 
C22-PX nanocapsules may offer the potential to treat metastatic breast cancer.  
In summary, the lipid-based NPs may serve as an alternative platform for the delivery 
of hydrophobic drugs for improved cancer treatment as compared to the standard of care 
therapy.
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Chapter I 
 
Anthracycline Nanoparticle Formulations to Overcome  
Multiple Drug Resistance (MDR) 
 
1.1    Anthracyclines in Cancer Treatment  
Anthracyclines are among the most effective and commonly used chemotherapeutic 
drugs [1]. The first anthracyclines of doxorubicin (DOX, Figure 1.1) and daunorubicin (DNR, 
Figure 1.1) were isolated from the bacterium of Streptomyces peucetius, which could 
produce a red pigment and was found to have good activity against murine tumors back to 
the 1950s [2, 3]. DOX is widely used to treat various cancers, including leukemia, Hodgkin’s 
lymphoma, bladder and breast cancers, while DNR is to treat some types of leukemias, such 
as acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). In order to find 
better anthracyclines, a great deal of research has been conducted to establish the 
structure-activity relationships of anthracyclines and this research has guided identification 
and synthesis of better anthracyclines. In last two decades there have been hundreds of 
DOX and DNR analogs reported in different laboratories to chemically modify their 
tetracyclic ring, the side chain, and/or aminosugar [4, 5]. However, only a few of the analogs 
were approved for clinic use and among them, idarubicin (IDA, 4-demethoxydaunorubicin, 
Figure 1.1) is the most successful alternative to DNR [6]. It was approved by the US FDA in 
1990 [3]. The absence of the methoxy group at position 4 of IDA results in significantly 
enhanced lipophilicity [7], which results in more rapid cellular uptake, superior DNA-binding
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capacity, and consequently greater cytotoxicity compared to DOX and DNR. The 
physicochemical properties of these three anthracyclines are summarized in Table 1.1. For 
use in the clinic, they are formulated as their hydrochloride salt forms dissolved in an 
aqueous solution for intravenous injection. 
The mechanisms of antitumor activity of anthracyclines are well characterized and 
documented, where they are able to diffuse across the cell membrane, intercalate between 
DNA base pairs, target topoisomerase II (TOPO II), and induce cell apoptosis [7]. As 
effective anticancer agents, however, the clinical use of anthracyclines has been limited by 
their severe cardiotoxicity and the development of multiple drug resistance (MDR) [8, 9]. To 
overcome these problems, the use of nanoparticle (NP) delivery systems has been shown to 
be promising carriers to improve the cancer therapy of anthracyclines mainly due to the 
enhanced permeability and retention (EPR) effect [10-12]. Doxil, a DOX-encapsulated 
polyethylene glycol (PEG)-coated liposome formulation with the particle size of ~100 nm, 
was approved in 1995 for the treatment of ovarian cancer, AIDS-related Kaposi’s sacoma, 
and multiple myeloma. The DOX PEGylated liposomes demonstrated slower plasma 
clearance rate, prolonged circulation time in blood, and decreased volume of distribution 
than either traditional DOX liposomes or free DOX. Importantly, Doxil was proved to have 
less cardiotoxicity as compared to free DOX [13-15]. However, the liposome formulation has 
not addressed MDR which continues to be a major hurdle in cancer therapy.  
The MDR mechanisms of anthracyclines are complicated and not fully understood. 
The most established mechanism of resistance is over-expression of drug efflux proteins, 
particularly members of the ATP-binding cassette (ABC) superfamily: P-glycoprotein (P-gp, 
MDR1), multidrug resistance protein 1 (MRP1), and breast cancer resistance protein 
(BCRP). Anthracyclines are known to be efficient substrates for ABC transporters. For 
example, P-gp, a membrane transporter encoded by MDR1 gene, could actively pump 
anthracyclines out of the cells resulting in drug resistance [16, 17]. Other mechanisms have 
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also been reported, such as alteration in TOPO II, free-radical formation, up-regulation of B-
cell lymphoma 2 (BCL-2) family members, down-regulation of tumor suppressor protein p53 
[18-21]. In this review, different NP systems for the delivery of anthracyclines, as well as the 
mechanisms of these NP formulations to overcome MDR, will be addressed. 
1.2    Anthracycline Nanoparticles to Overcome MDR 
1.2.1   Liposomes 
Thierry and his colleagues [22] developed DOX encapsulated liposomes with 
cardiolipin/phosphatidylcholine/cholesterol (CL/PC/CHOL) and demonstrated both DOX 
encapsulated liposomes and free DOX spiked into a suspension of empty liposomes could 
reverse MDR and had comparable activity in MDR Chinese hamster LZ cells. The efficacy of 
free DOX spiked into a suspension of empty liposomes was probably due to the high binding 
affinity (1.6 × 106 M-1) of positive charged DOX to the negatively-charged CL. However, 
neither pretreatment with empty liposomes before drug treatment nor the combination of 
vincristine and empty liposomes could reverse MDR, which suggested DOX must be 
incorporated or complexed with liposomes to overcome MDR. The authors suggested the 
DOX in liposomes would alter intracytoplasmic vesicles to transport DOX in MDR cells, and 
the modulation of MDR could be due to the increase of drug accumulation or the intracellular 
drug redistribution in MDR cells. Rahman et al. [23, 24] prepared DOX-loaded liposomes 
composed of CL/PC/CHOL (molar ratio 2:10:6.8) and compared the cytotoxicity of the 
liposomes versus free DOX in P-gp resistant HL-60/VCR and its parental HL-60 cell lines. 
The results showed that the IC50 values of free DOX (30 nM) and DOX liposomes (20 nM) 
were comparable in HL-60 cells, while in HL-60/VCR cells the IC50 values of free DOX and 
DOX liposomes were 0.9 and 0.17 µM, respectively, which indicated the liposome 
formulation was 5-fold more toxic than free DOX in HL-60/VCR cells. The mechanisms of 
DOX liposomes to overcome MDR were investigated and concluded that the empty 
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liposomes can direct interact with P-gp based on their competitive inhibition of [3H]-
vincristine binding to P-gp. In addition, the membrane fluidity of the resistant cells was 
different from the sensitive cells. Therefore, it was concluded that liposomes probably 
interact and modify the environment of the plasma membrane, resulting in more drug uptake 
in resistant cells. In contrast, Hu et al. [25] formulated three different DOX liposomes, 
however, none of them showed MDR circumvention in-vitro in rat glioblastoma cells, and the 
empty liposomes were unable to inhibit [3H]-azidopine binding to P-gp. It was suggested that 
the different results were probably due to the different compositions in the liposome 
formulations where they included lower amounts of lipids and higher DOX/lipid molar ratios. 
In addition, the origin of the lipids in liposomes was different. All of these may lead to the 
avoidance of the interaction between lipids/liposomes and cell plasma membrane. More 
recently, Riganti et al. [26] formulated DOX containing anionic liposomes (Lipodox) and 
demonstrated that the Lipodox was significantly more effective than free DOX in resistant 
HT29-dx cells. The P-gp inhibition mechanisms of Lipodox were summarized in two aspects: 
1) indirect effect, which is due to the interaction between liposomes and cell membrane (e.g. 
change in the composition of lipid rafts and P-gp localization); 2) direct effect, which is due 
to the direct interaction between liposome and P-gp (e.g. direct inhibition of ATPase 
activity).  
Co-delivery of DOX and a P-gp inhibitor was also reported to overcome MDR. Krishna 
et al. [27] developed DOX liposomes with 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) and CHOL at the lipid molar ratio of 55:45. The DOX liposomes or free DOX (i.v.) 
and P-gp inhibitor PSC 833 (p.o.) were co-administered in normal BDF1 mice. It was found 
that the maximum tolerated dose (MTD) was reduced by 2.5-3-fold with free drug while only 
20% reduction for DOX liposomes compared to i.v. alone. Furthermore, in a murine 
P388/ADR solid tumor model, the tumor inhibition of DOX liposomes combined with PSC 
833 was comparable to the sensitive P388/WT tumors, while a modest modulation was 
5 
 
observed for the co-administration of free DOX with PSC 833 at the MTD. It was also 
confirmed that the antitumor efficacy was PSC 833 dependent because the DOX liposomes 
alone provided significantly less activity. It should be noted that the DOX liposomes 
demonstrated a comparable pharmacokinetic profile and tissue biodistribution with or 
without PSC 833 p.o. administration, while free DOX altered pharmacokinetics in the 
presence of PSC 833. In similar, Wang et al. [28] co-encapsulated DOX and another P-gp 
inhibitor, verapamil, into stealth liposomes composed of egg phosphatidylcholine (EPC), 
CHOL, and PEG2000-DSPE (molar ratio 50:45:5). The results showed the stealth liposomes 
with DOX and verapamil overcame MDR in both DOX-resistant rat prostate cancer Mat-
LyLu-B2 and human uterus sarcoma MES-SA/DX5 cells, while the stealth liposomes with 
DOX alone were not effective enough to reverse MDR. To further target the tumor cells, the 
Robert group [29] synthesized transferrin immunoliposomes encapsulating both DOX and 
verapamil (Tf-L-DOX/VER), and this formulation increased the cytotoxicity by 5.2- and 2.8-
fold over that of L-DOX/VER and Tf-L-DOX, respectively, in DOX-resistant K562 leukemia 
cells.  
Since the mechanisms of MDR are multifactorial, the ideal delivery system should 
address different MDR pathways. In order to do so, the Minko group [30] developed a 
complex liposome system which included: 1) a chemotherapeutic drug of DOX; 2) antisense 
oligonucleotides (ASO) targeted to MDR1 mRNA; and 3) ASO targeted to BCL-2 mRNA. 
They showed this complex system was more toxic in-vitro in resistant A2870/AD human 
ovarian carcinoma cells when compared to free DOX, DOX liposomes, and DOX liposomes 
with either one type of ASOs. In addition, the complex liposomes were shown to be 
internalized into the cancer cells both in-vitro and in-vivo and even penetrated into nucleus, 
but the mechanisms were not clear. It was also suggested that both of the membrane fusion 
and endocytosis may be involved in liposome internalization into the tumor cells. Later on 
the Minko group successfully prepared a series of complex liposomes co-delivery of DOX 
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and ASO targeted to hypoxia-inducible factor 1α (HIF1A) mRNA [31] or siRNA targeted to 
MRP1 and BCL-2 mRNA [32]. All of them showed the enhanced chemotherapeutic efficacy 
with the combination of DOX and ASO or siRNA in resistant cells both in-vitro and in-vivo. 
Chen et al. [33] developed even more complex DOX liposome systems, namely cationic 
liposome-polycation-DNA (LPD) and anionic liposome-polycation-DNA (LPD-II), and showed 
a significant antitumor inhibition in an NCI/ADR-RES xenograft mouse model. In their DOX 
liposome systems, they co-delivered the following cargos to overcome MDR: 1) a 
guanidinium-containing cationic lipid, N,N-distearyl-N-methyl-N-2-(N’-arginyl) aminoethyl 
ammonium chloride (DSAA), which could induce reactive oxygen species (ROS), inhibit 
MDR transporters, and enhance DOX uptake in NCI/ADR-RES cells; 2) a vascular 
endothelial growth factor (VEGF) siRNA, to increase DOX uptake and therapeutic efficacy 
via targeting tumor vasculature, disrupting local blood supply and blocking angiogenesis; 3) 
a therapeutic c-Myc siRNA, where the c-Myc is a well-known oncogene and shown to 
positively control the expression of MDR. Thus, the silencing of c-Myc may result in both a 
direct therapeutic effect and down-regulation of MDR. 
1.2.2   Polymeric Nanoparticles 
The Couvreur group [34] entrapped DOX into biodegradable 
polyisobutylcyanoacrylate (PIBCA) polymers to form DOX-PIBCA NPs and showed the 
complete reversion of drug resistance in-vitro in several resistant cell lines. The laser 
microspectrofluorometry technique was utilized to investigate the mechanisms of the NPs to 
overcome MDR. It was proposed that the DOX-PIBCA NPs entered the cells by endocytosis 
and DOX was transported to the lysosomes and further released close to the nuclear 
membrane, followed by interaction with DNA. It was also suggested that the DOX-PIBCA 
NPs bypassed the P-gp pump which was probably due to the molecular structure or the 
ionic charge of the NPs. Interestingly, this group suggested in another paper [35] that the 
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DOX-PIBCA NPs did not enter the cells by endocytosis pathway at all. In contrast, the 
results demonstrated that the NPs were first adsorbed on the cell membrane, followed by 
the degradation of polymer close to cell membrane, and the drug was then released and 
entered the cells by simple passive diffusion. Compared to free DOX, the massive DOX 
concentration gradient from PIBCA NPs saturated P-gp and its pharmacological function. It 
was also suggested that PIBCA or its degradation products modified cell membrane, which 
led the permeation of more DOX into cells. In addition to NP-cell direct interaction, another 
mechanism was proposed where DOX formed ion pairs with the polyalkylcyanoacrylate 
(PACA) degradation product of polycyanoacrylic acid. This DOX-polycyanoacrylic acid ion-
pair complex increased the apparent lipophilicity of DOX, and allowed the drug entering the 
cells bypass the recognition of P-gp. It was concluded that the reversal of MDR with DOX-
PACA NPs was the result of both the adsorption of NPs on the cell surface and the 
formation of DOX-polycyanoacrylic acid ion-pair complex at the plasma membrane [36].  
Henry-Toulmé et al. [37] demonstrated that DOX-polyisohexylcyanoacrylate (DOX-
PIHCA) NPs were not endocytosed by the cells, which supported the results from the 
Couvreur group. Barraud and colleagues [38] also developed DOX-PIHCA NPs and 
compared their antitumor efficacy versus free DOX both in-vitro and in-vivo in a resistant 
hepatocellular carcinoma (HCC) model. The IC50 of NPs was reduced by 1.5-4.5-fold in in-
vitro studies in several resistant HCC cells. In-vivo HCC transgenic mouse model, DOX-
PIHCA NPs had significantly improved tumor inhibitory effect compared to free DOX (p = 
0.01). The mechanisms by which DOX-PIHCA NPs bypass P-gp efflux were the same as 
DOX-PIBCA NPs discussed above. In similar, the Robert group [39] prepared DOX-PIHCA 
NPs and showed its complete reversal of MDR in resistant C6 0.001 cells. It was found that 
only drug tightly associated with DOX-PIHCA NPs overcame P-gp resistance but empty NPs 
did not, while the empty liposomes alone blocked P-gp function, which indicated the different 
mechanisms to overcome P-gp resistance between the delivery systems. It was also 
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suggested that the mechanism by which DOX-PIHCA NPs bypassed P-gp rather than direct 
inhibit P-gp. In order to investigate whether free DOX or DOX-PIHCA NPs used different 
mechanisms to acquire MDR, two human tumor cell lines, K562 and MCF7, were selected 
and DOX concentration in both formulations was gradually increased. It was found that 
DOX-PIHCA NPs were more difficult to generate resistant cell lines and P-gp expression 
was consistently lower than that in free DOX selected cells, while breast cancer resistance 
protein (BCPR) expression was in a reverse order. It was suggested different mechanisms 
may be involved in the acquisition of drug resistance [40]. Soma [41, 42] prepared PACA 
NPs co-encapsulated of DOX and cyclosporine A (CyA, a P-gp inhibitor) and showed that 
the NPs had the most effective cell growth inhibition compared to other combinations of both 
drugs in solution or NPs with single drug alone in resistant P388/ADR cells.  
In addition to DOX-PACA NPs, Susa et al. [43] successfully formulated DOX into a 
stearylamine-modified dextran NPs and demonstrated enhanced drug accumulation in 
nucleus compared to free DOX in resistant osteosarcoma cell lines. It was found that the 
fluorescence of free DOX was mainly in the nucleus in sensitive cells but mainly in the 
cytoplasm in resistant cells, while the drug distribution of NP formulation was mainly in the 
nucleus even in resistant cells. This indicated that the NP formulations were able to deliver 
DOX into nucleus in resistant cells and the mechanisms may be due to bypassing of P-gp. 
Khdair et al. [44, 45] co-delivered DOX and methylene blue into Aerosol OT (AOT)-alginate 
NPs and this combination therapy significantly increased the in-vitro cytotoxicity in resistant 
NCI/ADR-RES cells and improved tumor growth inhibition in-vivo. Methylene blue is a 
photosensitizer and it is suggested to generate ROS and inhibit P-gp, although the 
mechanism is not fully understood [46]. It was hypothesized the P-gp inhibition and induced 
ROS of methylene blue increased the cytotoxicity of DOX in resistant cancer cells. Misra et 
al. [47] also proposed dual drugs of DOX and curcumin co-encapsulated into poly(lactic-co-
glycolic acid) (PLGA) NPs. The application of curcumin helped the retention of DOX in 
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nucleus, as well as down-regulated the expression of P-gp and BCL-2 in K562 cells. The 
combination of both drugs in NP formulations had enhanced in-vitro cytotoxicity compared to 
single drug alone in either solution or NP formulations. Lei developed [48] non-targeted and 
HER2 antibody conjugated DOX-loaded PLGA NPs and compared the cellular uptake and 
cytotoxicity to free DOX in resistant ovarian SKOV-3 and uterine MES-SA/Dx5 cells. Results 
showed the higher cellular uptake of targeted NPs than both of free drug or non-targeted 
NPs in SKOV-3 cells. It was suggested that the major mechanism of targeted PLGA NPs 
was receptor-mediated endocytosis. Shieh et al. [49] developed more complex DOX NPs, 
where the chemotherapeutic agent DOX and a photosensitizer were co-incorporated into 4-
armed porphyrin-polylactide (PPLA) NPs with D-α-tocopheryl polyethylene glycol 1000 
succinate (TPGS, a P-gp inhibitor) coated on the NP surface. It was concluded the 
combined agents showed a synergistic effect and increased DOX delivery to the nucleus in 
resistant MCF-7/ADR cells.  
1.2.3   Polymeric Micelles 
Alakhov et al. [50] demonstrated that DNR-loaded poly(oxyethylene-b-oxypropylene-b-
oxyethylene) (Pluronic P85) block copolymer micelles increased the in-vitro cytotoxicity up to 
3- and 700-fold than free DNR in sensitive SKOV3 and resistant SKVLB cells, respectively. 
Based on the results from the cytotoxicity, influx and efflux, and drug-copolymer binding 
studies, it was hypothesized that the copolymer affected P-gp function by direct interacted 
with P-gp and/or changed the structure of the plasma membrane. In addition, the copolymer 
may induce the permeability of cell membrane. Lee et al. [51] developed DOX-encapsulated 
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) micelles 
and the micelle formulation exhibited 15-fold greater cytotoxicity compared to free DOX in 
MCF-7 cells. The flow cytometry analysis and confocal images suggested micelles entered 
the cells via the endocytosis pathway. Once inside cells, the micelles were initially localized 
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in endosomes and then DOX was released in a sustained manner in the cytosol. The 
copolymer itself may also contribute to sensitization of cells and to the enhancement of 
DOX-induced cell apoptosis. Li and colleagues [52] synthesized poly(L-lactide)-vitamin E 
TPGS (PLA-TPGS) block copolymer and used this as the carrier for DOX. The results 
indicated that the PLA-TPGS micelles inhibited P-gp, enhanced drug cellular uptake, and 
facilitated translocation of DOX into the nucleus, all of which were responsible for MDR 
circumvention. Zhao and co-workers [53] added TPGS into PLGA-PEG-folate polymeric 
micelles and showed increased DOX cellular uptake compared to the micelles without 
TPGS, which may be due to the P-gp inhibition of TPGS. Other possible mechanisms of 
TPGS to overcome MDR may include inhibition of efflux pump ATPase and substrate 
binding, generation of ROS, and alteration of membrane fluidity [54-57]. Zheng et al. [58] 
synthesized pH-sensitive polymers by linking N,N-diisopropylethylenediamine (DPA) onto 
the backbone of PEGylated polyphosphazene. DOX was entrapped in the polymer to form 
self-assembled micelles and the IC50 value of this formulation was 60-fold lower than free 
DOX against resistant MCF-7/ADR cells. The cellular uptake and intracellular distribution of 
DOX micelles were evaluated by confocal microscopy, and it was found that much more 
DOX was in the nucleus compared to free DOX and that majority of free DOX was 
entrapped in the intracellular compartments. Furthermore, DND-26 (an acidic organelle-
selective fluorescent probe) was incorporated into the micelles to investigate whether the 
pH-sensitive polymeric micelles could help DOX escape from endosomes and lysosomes. 
The results demonstrated the fluorescence of DND-26 micelles was spread over the cells 
while free DND-26 was mainly located in the endosomes and lysosomes. Pre-incubation of 
the polymer solution followed by the addition of free DND-26 showed that the polymer and 
free DND-26 entered the cells via endocytosis and passive diffusion pathways, respectively. 
All these suggested the pH-sensitive polymeric micelles disrupted endosomes and released 
the drug after they were endocytosed into the cells, and the mechanisms may be due to the 
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proton-sponge effect and/or polymer-endosomal membrane interaction. Yuan et al. [59, 60] 
synthesized linoleic acid-grafted chitosan oligosaccharide (CSO-LA) and incorporated DOX 
into CSO-LA micelles. The results demonstrated a significant enhancement in the 
internalization of the micelles in both sensitive MCF-7 and K562 and their resistant cells 
compared to free DOX. In addition, paclitaxel (PX) and DOX were successfully co-loaded in 
the stearic acid-grafted CSO micelles and showed that this formulation were able to 
completely reverse the MDR in resistant cells [61]. The following mechanisms were 
proposed for the fatty acid-grafted CSO micelles (CSO-FA) to overcome MDR: 1) positively-
charged CSO-FA micelles facilitate the interaction between micelles and negatively-charged 
cell membrane; 2) the alkyl side chain on chitosan backbone favors its fusion and 
hydrophobic interactions with cell membrane and this effect was alkyl chain dependent; 3) 
the fatty acid forms hydrophobic microdomains near the surface of the micelle due to the 
stereo resistance effect, which enhances the hydrophobility of the micelle and further favor 
the internalization of micelles into cells because of the lipophilic property of the cell 
membrane. 
Bae group [62-64] developed DOX-loaded pH-sensitive polymeric micelles with folate 
(PHSM/f), which was a mixture of two block copolymers of poly(L-histidine) (Mn: 5K)-b-PEG 
(Mn: 2K) (polyHis/PEG) or polyHis/PEG with folate (polyHis/PEG-folate) and poly(L-lactic 
acid) (Mn: 3K)-b-PEG (Mn: 2K)-folate (pLLA/PEG-folate). The mixed copolymers in the 
micelle formulation improved the micelle stability in pH 7.4 due to the hydrophobic property 
of pLLA [65]. This formulation overcame MDR both in-vitro and in-vivo in several resistant 
cell models. The results showed that the micelles entered the cells via folate receptor-
mediated endocytosis pathway, and then DOX escaped from endosomes and was released 
into the cytoplasma due to the positively-charged polyHis which fused and destabilized the 
negatively-charged endosomal membrane at low pH of 6.5-7.2. To better understand the 
mechanism of the micelles, FITC-pLLA/PEG with folate (FITC-pLLA/PEG-folate) was 
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synthesized as a pH-insensitive micelle control (PHIM/f). In contrast to PHSM/f, PHIM/f was 
found to be mostly entrapped into sub-organelles, such as endosomes, and had much less 
antitumor efficacy compared to PHSM/f. Taken together, the active folate receptor-mediated 
endocytosis, triggered drug release at low pH, and the interaction between polyHis group 
and endosomal membrane may be responsible for the MDR reversal effect. Later on, it was 
noticed that a fraction of the loaded DOX was released in tumor extracellular space (pH 6.5-
7.2) before actively internalized into the cells; therefore, the released drug had the potential 
to be pumped out by P-gp and attenuated its efficacy. To prevent DOX releasing in tumor 
extracellular space, L-phenylalanine (Phe) was introduced to the copolymer of polyHis/PEG 
to form poly(His-co-Phe)/PEG [66, 67]. The Phe group in the copolymers significantly 
dropped the pKa values and allowed the destabilization of micelles at even the lower pH of 6 
to avoid the tumor extracellular pH. The mixture of poly(His-co-Phe)/PEG and pLLA/PEG-
folate formed the second generation of pH-sensitive micelles which precisely target the early 
endosomes at pH of 6. 
It has been shown that an NF-ĸB inhibitor enhanced tumor cell sensitivity of apoptosis 
induced by chemotherapeutic agents, such as DOX and PX [68, 69]. Fan et al. [70] co-
loaded DOX and pyrrolidinedithiocarbamate (PDTC, a NF-ĸB inhibitor) in folate-chitosan 
(FA-CS) polymeric micelles, and the micelles showed significantly lower IC50 values and 
enhanced cellular uptake in resistant cells. Lee et al. [71] co-delivered human tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) and DOX with self-
assembled micelles from cationic copolymer of poly{N-methyldietheneamine sebacate)-co-
[(cholesteryl oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate} 
(P(MDS-co-CES)). It was demonstrated that the co-delivery of DOX and TRAIL in P(MDS-
co-CES) micelles entered the cells via receptor-mediated endocytosis and enhanced the 
cytotoxicity against resistant tumor cells. Benoit et al. [72] developed cationic micelles from 
copolymers of poly(dimethylaminoethyl methacrylate) (pDMAEMA) and poly(butyl 
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methacrylate) (pDbB). DOX was loaded into the hydrophobic core of pDbB. A siRNA against 
polo-like kinase 1 (PLK1), a gene up-regulated in many cancers and responsible for cell 
cycle progression, was condensed with positively-charged pDMAEMA. A pH-sensitive 
copolymer of poly(styrene-alt-maleic anhydride) (pSMA) was further complexed with 
positively-charged PLK1 siRNA/DOX micelles to form a ternary complex for escape of the 
drug from endosomes. The co-delivery of PLK1 siRNA and DOX using this ternary complex 
system exhibited synergistic effect in resistant NCI/ADR-RES cells. Xiong et al. [73] 
constructed poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) micelles for the 
co-delivery of MDR1 siRNA and DOX. Two ligands, integrin αvβ3-specific ligand (RGD4C) 
and TAT peptide, were attached on the shell of the micelles for active targeting and cell-
penetration purpose, respectively. This multifunctional polymeric micellar system was able to 
deliver both of DOX and MDR1 siRNA into intracellular compartments, and overcame P-gp-
mediated resistance in-vitro and targeted αvβ3-positive tumors in-vivo. Nakanishi et al. [74] 
prepared a polymeric micelle formulation of NK911 for DOX. NK911 consisted of block 
copolymers of PEG (Mw: 5K) and poly(aspartic acid) (~30 units). DOX was partially 
conjugated to the side chain of aspartic acid (~45%) to enhance the hydrophobicity of the 
inner core of the micelles. Therefore, although two types of DOX, incorporated and 
conjugated DOX, were in NK911 formulation, the conjugated DOX did not show any 
antitumor activity. The preclinical studies demonstrated much stronger tumor inhibitory effect 
against several tumor models compared to free DOX and currently NK911 is in a phase I 
trial. 
In order to better understand the mechanism of polymeric micelle mediated drug 
delivery, Chen et al. [75] investigated the cellular uptake of monomethoxy poly(ethylene 
glycol)-block-poly(D,L-lactic acid) (PEG-PDLLA) micelles. Fluorescein isothiocyanate (FITC) 
was used to label micelle itself and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine 
perchlorate (DiIC18(3)) was used as a hydrophobic model molecule encapsulated in the 
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micelle. It was found that the cellular uptake of DiIC18(3) was much faster than that of FITC-
labeled PEG-PDLLA micelles, which indicated their different cell entry pathways. Moreover, 
förster resonance energy transfer (FRET) imaging and spectroscopy were utilized to monitor 
the cellular uptake of PEG-PDLLA micelles in real time loaded with a FRET pair of DiIC18(3) 
and 3,3'-dioctadecyloxacarbocyanine perchlorate (DiOC18(3)). The FRET results confirmed 
that both of the hydrophobic dyes entrapped in the core of the micelles and were released to 
the plasma membrane and then internalized by the cells. PEG on the shell of the micelles 
facilitated the release of the dyes because of the PEG-induced fusion to the cell membrane. 
In contrast, Allen et al. [76] evaluated polycaprolactone-block-poly(ethylene oxide) (PCL20-b-
PEO44) copolymer micelles in PC12 cells and strongly suggested the micelles entered the 
cells via endocytosis pathway based on a series of cellular uptake studies. Savić et al. [77] 
triple-labeled PCL-b-PEO micelles, nucleus, and plasma membrane (or cytoplasmic 
organelles, such as mitochondria, Golgi) and showed that the micelles were endocytosed 
into the cells and distributed into several cytoplasmic compartments, including mitochondria, 
Golgi apparatus, but not the nucleus. 5-dodecanoylaminofluorescein (DAF), a model 
molecule, was incorporated into PCL-b-PEO micelles and the results suggested the micelle 
formulation enhanced the delivery of the agent into the cells and increased its efficacy. 
Venne et al. [78] demonstrated that the DOX-loaded poly(oxypropylene)-poly(oxyethylene) 
block copolymer pluronic L61 micelles enhanced by 290- and 700-fold the cytotoxicity in 
resistant CHRC5 and MCF-7/ADR cells, respectively, but were comparable with free DOX in 
their matched sensitive cell lines. The micelle formulation was found to shift the distribution 
of DOX from the cytoplasmic compartment to the nucleus, and the copolymer increased the 
drug uptake and inhibited the drug efflux. All of these contributed to the ability of pluronic 
L61 micelles to overcome MDR. 
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1.2.4   Polymer Conjugates 
The Kopeček and Duncan groups collaboratively developed two N-(2-
hydroxypropyl)methacrylamide (HPMA)-DOX conjugates, namely PK1 and PK2, and both of 
the conjugates were tested in phase I/II clinical trials. The HPMA-DOX conjugates had the 
following three components: 1) a water-soluble polymeric carrier of HPMA; 2) an anticancer 
drug of DOX; 3) biodegradable polymer-drug linker. In the PK1 conjugate, the linker was a 
tetrapeptide of GFLG, which was stable in the blood circulation but susceptible to cleavage 
by enzymes in the lysosomes. In contrast, PK2 had additional galactose residues that were 
recognized by the asialoglycoprotein receptor on hepatocytes for targeted therapy of 
hepatocellular carcinoma. The IC50 value of HPMA-DOX conjugate in resistant A2780/AD 
cells was only about 20% higher than in sensitive A2780 cells (the resistance index of free 
DOX in A2780/AD cells: 40), which indicated that the conjugate formulation at least partially 
overcame P-gp-mediated resistance. The analysis of P-gp gene expression showed that 
free DOX at high doses induced P-gp expression in sensitive A2780 cell, while HPMA-DOX 
conjugate inhibited P-gp and β2-microglobulin (β2m) genes in resistant A2780/AD cells [79].  
The mechanisms of action of HPMA-DOX conjugates have been extensively studied 
and well established [80-85]. The HPMA-DOX conjugates entered the cells via endocytosis 
pathway and DOX was then released from the lysosomes in the perinuclear regions due to 
the lysosomally degradable spacer of GFLG between DOX and the polymer. Then, the 
released DOX entered the nucleus and exerted its pharmacological function. In-vivo the 
conjugates demonstrated prolonged blood circulation, enhanced tumor-to-blood ratio as a 
function of time, and Cmax at 48 h in tumors after i.v. administration, all of which indicated the 
conjugates passively accumulated in tumor tissues via the EPR effect. It is important to note 
that the particle size of HPMA-DOX conjugates was less than 10 nm. Interestingly, the 
concentration gradient of HPMA-DOX conjugates was found to be decreased from the 
perinuclear region to the plasma membrane. In contrast, the concentration gradient of free 
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DOX was in the opposite direction, where it decreased from the plasma membrane to the 
perinuclear region. Consequently, DOX in the conjugate formulation had increased ability to 
interact with nuclear DNA and/or topoisomerase II. In addition, free DOX up-regulated MDR 
genes such as MDR1 and MRP, while the conjugates overcame MDR1 and down-regulated 
MRP. Free DOX also activated various cell detoxification mechanisms, while HPMA-DOX 
conjugate down-regulated BCL-2, heat-shock protein 70 (HSP-70), glutathione S-
transferase π (GST-π), bilirubin uridine diphosphate (BUDP) transferases, topoisomerase 
IIα and IIβ, and thymidine kinase 1 (TK1) genes. With the exposure of HPMA-DOX 
conjugate, cell apoptosis, lipid peroxidation, and DNA damage were significantly higher 
compared to free DOX. For more details on design, efficacy, safety, and mechanisms of 
action of HPMA-DOX conjugates, please refer to references [80-85]. 
Omelyanenko et al. [86] synthesized targetable HPMA-DOX conjugates containing N-
acylated galactosamine (GalN) or monoclonal OV-TL 16 antibodies (OV-TL 16 Ab). 
Fluorescence confocal microscopy studies demonstrated that both of the targeted 
conjugates had a similar fate when incubated with the cells, where the conjugates were 
recognized and internalized into the cells, localized in the lysosomes and then DOX was 
released from the polymer and eventually diffused from the cytoplasma into the nucleus. 
Šťastný et al. [87] designed HPMA-DOX conjugates with different targeting moieties, 
including anti-CD71, antithymocyte globulin, anti-CD4, and transferrin, and compared their 
ability to reverse MDR in CEM/VLB cells. Anti-CD4 targeted HPMA-DOX conjugate 
demonstrated the weakest ability to overcome resistance and this was probably due to the 
poor internalization of anti-CD4 molecule. It was hypothesized that receptor-mediated 
endocytosis was a very important factor for the MDR reversal effect of HPMA-DOX targeted 
conjugates and this effect was targeting moiety dependent. Nan et al. [88] prepared targeted 
HPMA-DOX conjugates containing a peptide sequence of WHYPWFQNWAMA, to bind 
surface-specific receptor of Hsp47/CBP2 which was over-expressed in human squamous 
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cell carcinoma of head and neck (SCCHN). Interestingly, both targeted and non-targeted 
conjugates demonstrated the less cellular uptake and lower cytotoxicity than free DOX in 
sensitive SCCHN cells. This indicated the endocytosis process of the conjugates was slower 
than the rapid passive diffusion of free DOX in sensitive SCCHN cells. In contrast, both 
targeted and non-targeted conjugates exhibited significantly higher cellular uptake and more 
potent than free DOX in resistant SCCHN cells. Moreover, targeted conjugates showed 
higher cellular uptake than non-targeted conjugates. Taken together, all the studies 
suggested the targeted HPMA-DOX conjugates had the potential to treat the resistant head 
and neck cancer. Bidwell et al. [89] developed a thermally targeted elastin-like polypeptide 
(ELP) DOX conjugate to overcome MDR in resistant MES-SA/Dx5 and NCI/ADR-RES cells. 
This DOX conjugate contained four functional domains: 1) an anticancer agent of DOX; 2) 
GFLG, a tetrapeptide linker, which could facilitate DOX release from lysosomes; 3) TAT, a 
cell penetrating peptide; 4) ELP, a thermal-responsive polypeptide as the vehicle for DOX. It 
was found to be beneficial to use ELP as a drug carrier compared to HPMA in PK1, based 
on the fact that ELP macromolecules accumulated in tumors and this accumulation may be 
further enhanced by thermal targeting. 
In addition to HPMA-DOX conjugate, Kono et al. [90] conjugated DOX to PEG 
modified poly(amidoamine) dendrimers with either an amide or hydrazone linkage. The 
results demonstrated the acid-labile hydrazone linkage was very important to exhibit the 
antitumor efficacy in resistant cells. It was hypothesized the DOX-dendrimer conjugate was 
taken up into cells via endocytosis and entrapped into subcellular acidic compartments of 
endosomes and lysosomes. The endosomes was ruptured by DOX-dendrimer via proton 
sponge effect, and the hydrazone linkage was broken in acidic environment and then DOX 
was released from the dendrimer to exert its pharmacological action. 
The Fong group [91-93] applied a Schiff base covalent bond formation strategy to 
synthesize dextran-DOX conjugates. Both free DOX and the conjugate were localized 
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mainly in cytoplasmic compartments in resistant KB-V1 cells but for different reasons. Free 
DOX was difficult to diffuse into the nucleus due to the P-gp efflux, while the dextran-DOX 
conjugate was excluded from nucleus due to its large size. The P-gp seemed to be only 
effective on the molecular weight of drug molecules and conjugates less than 70 kDa, but 
not effective against macromolecules larger than 70 kDa. This was consisted with the 
findings that the central pore size of P-gp was 5 nm, while the effective size of 70 kDa 
dextran was ~5 nm [94]. Therefore, dextran-DOX conjugate larger than 70 kDa was not 
good P-gp substrate and had better accumulation in the nucleus. Furthermore, the critical 
size of dextran for DOX accumulation was calculated as 103 kDa based on the relative 
cytotoxicity of dextran-DOX conjugate in sensitive and resistant KB cells. The DOX coupled 
to 70 kDa dextran, i.e. dextran-DOX conjugate (AD-70, DOX-OXD), was tested in a phase I 
clinical trial and the MTD of the conjugate was found to be 40 mg DOX/m2 [95].  
1.2.5    Peptide/Protein Conjugates 
Liang et al. [96] synthesized a TAT-DOX conjugate and evaluated its cellular uptake 
and intracellular distribution in MCF-7 cells. Both the conjugate and free DOX were 
transported into the cells but with different intracellular distribution, where free DOX was 
mainly in the nucleus while the most of the conjugate was located in the perinuclear and 
cytoplasmic regions. On the other hand, the cytotoxicity of the conjugate and free DOX was 
comparable. This suggested DOX also have activity in cytoplasma. The research [97] 
supported that the activity of DOX was not only due to its inhibition of DNA synthesis, but 
also due to its interaction with cytoplasmic components to cause cell apoptosis. Importantly, 
the cytotoxicity of the conjugate was about 8-10-fold higher than free DOX in both resistant 
MCF-7/ADR and AT3B-1 cells. To understand the mechanisms of TAT-DOX conjugate to 
overcome MDR, the intracellular DOX concentration was measured in sensitive and 
resistant MCF-7 cells. About 90% of the free DOX accumulated in sensitive cells but 
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dropped to only 5% in resistant cells, indicating a strong P-gp efflux in resistant cells. In 
contrast, the conjugate had 58.6% retention in resistant cells. In addition, neither the mixture 
of DOX and TAT nor verapamil (a P-gp inhibitor) affected the cytotoxic properties of the 
TAT-DOX conjugate, which suggested the MDR reversal of the conjugate was bypassed but 
not inhibited. Aroui and colleagues [98-100] designed three DOX-cell penetrating peptide 
(CPP) conjugates, namely maurocalcine, penetratin, and TAT, and compared the 
cytotoxicity to free DOX in different sensitive and resistant cells. All three conjugates 
displayed similar efficacy which was about 5-fold more cytotoxic than free DOX in resistant 
cells. Generally, CPPs are used as cell impermeable compounds, while the benefits of 
CPPs applied to the cell membrane permeable compound DOX may be due to improved 
stability, facilitated cell compartment targeting and DNA binding, alteration efflux pathways 
and detoxification reactions of DOX. To understand the mechanisms, BCL-2 and BCL-XL 
protein expressions were determined in the cells treated with DOX conjugates or free DOX 
since anti-apoptotic BCL-2 family was known to control mitochondria membrane 
permeability. However, the results showed no difference between the conjugate and free 
DOX. To determine if other apoptotic pathways were responsible for mitochondrial 
permeabilization, the DOX-CPP conjugates were studied in MDA-MB-231 cells over-
expressing of BCL-2. It was found that the DOX conjugate was 5-fold more toxic than free 
DOX in resistant MDA-MB-231/BCL-2 cells, which indicated that the DOX-CPP conjugate 
activated multiple apoptotic pathways other than mitochondrial events. It should be noted 
that free DOX was mainly localized in the nucleus and the DOX conjugate was localized in 
the cytosol. The alteration of intracellular distribution of DOX conjugate may contribute the 
mitochondrial independent apoptotic pathways. Meyer-Losic et al. [101] conjugated DOX to 
another CPP, Vectocell, via different linkers. This peptide originated from human protein 
with 15-23 amino acid residues, and the studies showed it was internalized by different 
mechanisms [102]. When chemically stable bonds were utilized to the conjugate with 
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Vectocell, e.g. at C14 position of thioether or C3’ position of amide of DOX, the in-vivo activity 
was minimal, which was probably due to inhibition of the interaction between DOX and DNA 
caused by Vectocell. The best linker was found to be at the C14 position of DOX with an 
ester bond, and this Vectocell-DOX conjugate had significantly greater antitumor efficacy 
compared to free DOX both in-vitro and in-vivo in colon and breast tumor models. The 
mechanism of the improved therapeutic index of Vectocell-DOX conjugate was not clear. 
However, because the conjugate had lower charge-to-mass ratio, it seemed to be different 
than other CPPs, such as TAT.  
Mazel et al. [103] coupled DOX to two different peptides, namely penetratin and 
SynB1, respectively, to obtain DOX-peptide conjugates. The results demonstrated the IC50 
value of the conjugates was about 20-fold less than free DOX in resistant K652/ADR cells, 
and the conjugates had similar cellular uptake in both sensitive and resistant cells. All of 
above results suggested that conjugate entered the resistant cells in a way not recognized 
by P-gp, although the mechanism was unknown. It was known that the amino group on DOX 
was an important substrate group for P-gp recognition and since the coupling of DOX to 
peptide was taken place at this amino position. Therefore, the conjugate may enter the 
resistant cells bypass of P-gp efflux. Interestingly, the cytotoxicity of the conjugate was less 
than that of free DOX in sensitive cells, indicating some loss of DOX activity which was 
probably due to the covalent binding between DOX and peptide. It should be noted that the 
conjugates in the studies were not susceptible to hydrolysis because succinate and 
thioether were used as the linkers for SynB1 and penetratin, respectively. When substituted 
succinate linker to disulfide, DOX-SynB1 conjugate was more potent. The DNA binding 
studies showed that the conjugate intercalated with DNA. Other mechanisms, such as 
interaction between conjugate and cell membrane, may be involved in the induction of the 
cell apoptosis by the conjugate. 
21 
 
Fritzer et al. [104, 105] synthesized transferrin-DOX conjugate and demonstrated that 
it was much more potent than free DOX in resistant K562/ADR, HL-60/ADR, KB-C1 and KB-
V1 cells. Since a Schiff based coupling strategy was utilized to prepare transferrin-DOX 
conjugate, the conjugate did not undergo hydrolysis at acidic pH in the endocytic 
compartment. It was stable at least for 2 weeks at 37°C at pH 3.0 without detectable free 
DOX. The fluorescent microscope studies showed that the cell membrane, but not DNA, 
was the target of the conjugate. The mechanisms of transferrin-DOX conjugate were 
proposed where the conjugate slowly dissociated and released DOX in a sustained manner 
after binding to cell membrane, which prolonged the effect of DOX on cell membrane and 
caused membrane damage. In this way, P-gp was unable to circumvent the function of 
transferrin-DOX conjugate. In contrast, Lai et al. [106] suggested a different mechanism of 
transferrin-DOX conjugate where the conjugate entered the cells and mainly localized in the 
cytoplasma. It was pointed out that the discrepancy may be due to the different fluorescent 
labeling, where DOX fluorescence was quantified in the studies while fluorescence-labeled 
transferrin was used for Fritzer’s study. The increased cytotoxicity of transferrin-DOX 
conjugate over that of free DOX was partly explained by the conjugate bio-reductive 
processes and ROS generation in cytoplasma. The ability of the transferrin-DOX conjugate 
to overcome MDR was further confirmed by Łubgan [107], where the conjugate was 4- and 
200-fold more cytotoxic than free DOX in sensitive HL-60 and resistant HL-60/ADR leukemia 
cells, respectively. Interestingly, when Munns et al. [108] investigated transferrin-DOX 
conjugate in sensitive MGH-U1 and resistant MGH-U1R bladder cancer cell lines, it was 
found that the conjugate did not overcome resistance. It is worthy to mention that the mass 
spectrometry data demonstrated that the conjugate did not dissociate at all. To understand 
whether the integral conjugate form was active or not, transferrin-negative TRVb and 
transferrin-positive TRVb-1 cells were utilized as the controls. The results showed 
comparable cytotoxicity for the transferrin-DOX conjugate and free DOX, indicating that both 
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of the DOX forms were equally active. It is known that the lipid composition and fluidity of 
cell membrane are different between resistant and sensitive cells [109, 110], and this 
membrane acquired drug resistance may explain the transferrin-DOX conjugate failing to 
overcome resistance in MGH-U1R bladder cancer cells.  
Guillemard et al. [111] linked DOX to a mAb specifically recognizing the type 1 insulin-
like growth factor receptor (IGF-1R). This IGF-1R-DOX conjugate had more than a 200-fold 
enhanced therapeutic index compared to free DOX in-vitro in resistant KB-V cells, and 
significantly reduced the tumor burden in-vivo in a KB-V xenograft mouse model. Unlike the 
transferrin-DOX conjugate, IGF-1R-DOX conjugate was internalized into cells via receptor-
mediated endocytosis and DOX was released into the perinuclear and cytoplasmic regions 
farther away from the P-gp pump and therefore reducing the likehood for efflux. Again, the 
amino group on DOX was used to couple with mAb. Therefore, this conjugate was able to 
escape P-gp recognition. Based on the fact that the luteinizing hormone-releasing hormone 
receptor (LHRH-R) is found in > 50% of human breast cancers, Bajo et al. [112] chemically 
coupled DOX to [D-Lys6]LHRH to generate a cytotoxic conjugate, called AN-152. The AN-
152 demonstrated significantly antitumor efficacy in-vivo compared to other controls in a 
DOX-resistant MX-1 xenograft mouse model. The following mechanisms of AN-152 were 
proposed to overcome resistance in MX-1 tumors: 1) AN-152 could significantly reduced 
HER2 and HER3 levels but not EGFR, while free DOX had no effect on these receptors; 
therefore, down-regulation of ErbB/HER receptor family members may contribute to 
circumvent MDR; 2) the receptor-mediated endocytosis pathway of the conjugate via 
targeting to LHRH-R may not be the reason of its escape from the efflux pump because the 
resistance of DOX in MX-1 tumors is known to be not mediated by the transport system 
[113]; 3) AN-152 significantly decreased mRNA levels of Gα11 and Gα12 but free DOX did not. 
Both of the above G-proteins are known to couple to LHRH-R and regulate cell growth [114]. 
The disruption in G-protein signaling by AN-152 also contributed to circumvent MDR.  
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Ren et al. [115, 116] conjugated DOX to an antisense oligodeoxynucleotide (AS ODN, 
5’-TCCTCCATTGCGGTCCCCTT-3’) on its 3’-phosphate group. The conjugate significantly 
enhanced the stability of both DOX and AS ODN in biological fluid in-vitro, and increased 
binding affinity of AS ODN to its complementary sequence. The intracellular accumulation of 
AS ODN was much higher in the conjugate form compared to free AS ODN, which was 
mainly due to the improved lipophilicity of AS ODN in conjugate. This AS ODN-DOX 
conjugate demonstrated significantly improved antitumor efficacy, and markedly inhibited P-
gp expression and mRNA levels compared to AS ODN or DOX alone both in-vitro and in-
vivo in a resistant KB-A-1 cell model. 
Ohkawa group [117-120] developed a bovine serum albumin (BSA)-DOX conjugate 
and investigated the conjugate both in-vitro and in-vivo in sensitive AH66P and resistant 
AH66DR cells. The results demonstrated the BSA-DOX conjugate had similar cytotoxicity in-
vitro in both AH66P and AH66DR cells, which indicated the complete reversal of MDR (free 
DOX resistant index: 200). It was also found that DOX concentration in the cell remained 
relatively high even after 36 h. The treatment of BSA-DOX conjugate in rats in a resistant 
AH66DR model led to significantly prolonged survival compared to free DOX. All the results 
indicated this BSA-DOX conjugate had the potential to overcome MDR and it was 
suggested the conjugate entered the cells via endocytosis pathway and the drug was then 
slowly released from lysosomes. Furthermore, both of the drug concentration and molecular 
mass (Mr) of the internalized BSA-[C14]DOX conjugate in different subcellular compartments 
(lysosomes, cytosol, nucleus, and mitochondria) were measured by a liquid scintillation 
counter and HPLC gel filtration, respectively. Interestingly, the accumulation of the 
conjugate markedly increased in lysosomes in resistant AH66DR cells as a function of time 
up to 24 h, while significantly enhanced accumulation in mitochondria but moderate increase 
in lysosomes and nucleus was observed in sensitive AH66P cells. In both of the cell lines, a 
total of three peaks with Mr from 3-70 kDa were identified in lysosomes, one peak with Mr < 
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2 kDa was in nucleus and mitochondria, two peaks with one < 2 kDa and the other one > 
500 kDa were determined in cytosol. No free DOX was found in any compartments. The two 
peaks in the cytosol suggested that the smaller one (< 2 kDa) may be the conjugate 
degradation product released from lysosomes, and the larger one (> 500 kDa) may be the 
complex of the BSA-DOX conjugate or its degradation product with tubulin or other unknown 
proteins. It should be noted that the smaller peaks < 2 kDa were found in nucleus, 
mitochondria and cytosol. In addition, based on the fact that the accumulation of the DOX 
BSA-[C14]DOX conjugate increased in lysosomes in AH66DR cells, all of which indicated the 
BSA-DOX conjugate degraded in lysosomes and resultant active adducts < 2 kDa were 
responsible for the antitumor efficacy in resistant AH66DR cells. To confirm the lysosomal 
degradation products from the conjugate exhibited cytotoxic effect, poly-D-lysine-DOX and 
poly-L-lysine-DOX conjugates were tested. The cellular uptake of both conjugate was 
similar, but only poly-L-lysine-DOX conjugate showed the cytotoxicity because poly-L-lysine 
was digested by lysosomal enzymes but poly-D-lysine did not [121]. Later on, four DOX-
peptide conjugates with Mr < 2 kDa, namely glycylglycine (diGly), glycylglycylglycine (triGly), 
reduced glutathione (GSH), and oxidized glutathione (GSSG), were synthesized and 
evaluated the cytotoxicy effect in both AH66P and AH66DR cells. diGly-DOX and triGly-
DOX demonstrated the same cytotoxicity as free DOX in both of the cell lines, GSSG-DOX 
had the same cytotoxicity as BSA-DOX conjugate in both cells, and GSH-DOX showed 9- 
and 7.5-fold more cytotoxic activity than BSA-DOX conjugate against AH66P and AH66DR 
cells, respectively. The highest cytotoxicity of GSH-DOX among all DOX conjugates was 
due to the rapid uptake and high accumulation in resistant AH66DR cells. 
1.2.6   Solid Lipid Nanoparticles 
Kang et al. [122, 123] developed DOX-loaded solid lipid NPs (SLNs) with glyceryl 
caprate (Capmul MCM C10) as the lipid core, polyethylene glycol 660 hydroxystearate 
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(Solutol HS15) as the surfactant, and curdlan as the shell forming material. The DOX SLNs 
enhanced the cellular uptake to 17.1- and 21.6-fold at 1 and 2 h, respectively, and increased 
apoptotic cell death determined by crystal violet staining assay, when compared to free DOX 
in resistant MCF-7/ADR cells. In addition, the SLNs did not induce hemolytic activity in 
human erythrocytes which indicated the safety of the formulation. It was concluded that the 
DOX SLNs had the potential to overcome MDR. Our laboratory successfully prepared DOX 
and IDA SLNs from warm microemulsion precursors using emulsifying wax as the oil phase, 
and polyoxyl 20-stearyl ether (Brij 78) and TPGS as the co-surfactants [124]. Anionic ion-
paring agents of sodium taurodeoxycholate (STDC) and sodium tetradecyl sulfate (STS) 
were applied to neutralize the cationic anthracyclines and enhance the drug entrapment in 
SLNs. The DOX SLNs had significantly improved antitumor efficacy than free DOX both in-
vitro and in-vivo in a resistant P388/ADR cell model, but IDA SLNs did not demonstrate any 
benefit compared to free IDA, which may be due to the more lipophilic property of IDA. The 
mechanisms of the DOX SLNs overcoming MDR were investigated and it was concluded 
that the MDR reversal of SLNs may due to the P-gp inhibition by Brij 78 and TPGS, and ATP 
depletion by Brij 78 [125]. It is known that SLNs have some potential limitations, such as low 
drug loading capacity, burst drug release behavior, and potential drug expulsion upon 
storage. To avoid above limits, the incorporation of liquid lipid to solid lipid, a second 
generation of SLN – nanostructured lipid carriers (NLC), was developed and found to 
enhance imperfections of SLNs and achieved more space for drug molecules, thus 
improved drug loading [126]. Zhang et al. [127] applied monostearin as the solid lipid and 
oleic acid as the liquid lipid to construct DOX NLC. This DOX NLC exhibited greater in-vitro 
cytotoxicity compared to free DOX in both resistant MCF-7/ADR and SKOV3-TR30 cells. 
The high affinity between lipids or NLC and the cell membrane, competitive inhibition of P-
gp, all of above contributed the increased intracellular drug concentration and overcame 
MDR. 
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Wong et al. [128] developed a novel polymer-lipid hybrid DOX SLN system which was 
composed of hydrolyzed polymer of epoxidized soybean oil (HPESO), stearic acid, pluronic 
F68, and DOX. HPESO was applied not only to achieve more uniform and spherical 
particles, but also to enhance DOX partition in the SLN thereby increasing drug loading 
capacity. The cytotoxicity of DOX SLNs was evaluated in resistant MDA435/LCC6/MDR1 
cells, and the results showed SLNs were significantly more potent than free DOX. The 
mechanisms of DOX SLNs were investigated and proposed as the follows: 1) DOX is 
released from DOX SLNs outside the cells but the cytotoxicity is increased; 2) DOX-SLNs 
enter into the cells and then DOX is released from SLNs inside the cells, resulting in higher 
cytotoxicity. In the meanwhile, the following mechanisms were ruled out: 1) blank SLNs 
and/or excipients inhibit or bypass the MDR proteins based on the fact that the combination 
of blank SLNs and DOX or DOX-HPESO complex did not show significant cytotoxic effect in 
MDR cells; 2) the lipid components in the SLNs alter permeability of cell membrane. These 
two findings are quite different compared to nanomedicine systems discussed previously, 
which suggested the reversal of MDR activities was diversified and carrier dependent. Later, 
endocytosis inhibition and fluorescent image studies of SLNs were performed to better 
understand the mechanisms of the cellular drug uptake [129]. The results suggested the 
phagocytosis pathway was involved in SLN internalization and DOX associated with SLN 
bypassed the P-gp efflux in resistant cells. It was proposed that the DOX in SLNs probably 
entered the cells with the combination of simple passive diffusion of released drug from the 
carrier outside of cells and phagocytosis. The released drug outside of cells may in part be 
effluxed by P-gp, however, DOX that entered cells via phagocytosis would be entrapped in 
cells and difficult to be pumped out by P-gp. In another study, the co-delivery of DOX and 
GG918 (Elacridar, a lipophilic and non-ionic P-gp inhibitor) in the SLNs showed enhanced 
DOX cellular uptake than any forms of DOX/GG918 combination [130]. Shuhendler [131] et 
al. developed polymer-lipid hybrid SLN with myristic acid, HPESO, pluronic F68, 
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PEG100SA, PEG40SA, and both DOX and mitomycin C were simultaneously loaded in the 
SLNs. The SLNs demonstrated to be 20-30-fold more toxic in resistant MB435/LCC6/MDR1 
cells compared to free DOX. 
1.2.7   Magnetic Nanoparticles 
Chen et al. [132] investigated how Fe3O4 magnetic NPs facilitated DNR to overcome 
MDR in-vitro in sensitive and resistant K562 cells. To increase the interaction between NPs 
and lipid portion of cell membrane, tetraheptylammonium (THA) was coated on the NPs. 
Confocal fluorescence, atomic force microscope (AFM), and electrochemical studies were 
performed to evaluate the synergistic effects of NPs on the uptake of DNR in K562 cells. 
The observations confirmed the THA-coated Fe3O4 NPs interacted with cell membrane and 
significantly enhanced the uptake of DNR in resistant K562 cells. The similar size of THA 
capped Ni magnetic NPs were applied as a control, but the NPs showed much less efficacy 
in terms of DNR cellular uptake in both sensitive and resistant cells, indicating the unique 
property of THA capped Fe3O4 NPs to facilitate the DNR uptake. The following mechanisms 
were proposed for THA capped Fe3O4 NPs to overcome MDR: 1) Fe3O4 NPs may function 
as the inhibitor or competitive substrate for MDR associated proteins (e.g. P-gp); 2) the 
interaction between THA capped Fe3O4 NPs and cell membrane. Later on, both DOX and 
tetrandrine (Tet, a P-gp inhibitor) were loaded in Fe3O4 magnetic NPs and the results 
suggested the synergetic reversal effect in resistant K562/A02 cells [133]. Interestingly, Tet-
Fe3O4 NPs were able to decrease by 100-fold the MDR1 mRNA level but could not reduce 
the total amount of P-gp, indicating P-gp function was blocked. The activity of a modified 
Tet, 5-bromotetrandrine (BrTet), was also evaluated and it was demonstrated to have better 
efficacy than Tet in resistant K562/A02 cells both in-vitro and in-vivo [134-137]. The BrTet-
Fe3O4 NPs demonstrated the ability to down-regulate MDR1 mRNA level and P-gp 
expression. The combination of DNR and BrTet-Fe3O4 NPs also had significantly greater 
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antitumor efficacy than any controls in-vitro in resistant K562/A02 cells and in-vivo in 
xenograft nude mice. It was confirmed this NP system inhibited BCL-2 expression, up-
regulated BCL-2-associated X protein (BAX), p53 and caspase-3 proteins in resistant 
K562/A02 xenograft tumors, all of which contributed to synergetic effect of the NPs to 
overcome MDR. Furthermore, short hairpin RNA (shRNA) targeted the sequences of 3491-
3509, 1539-1557, and 3103-3121 nucleotide of MDR1 mRNA was constructed [138]. The in-
vitro data suggested the combination of MDR1 shRNA and Fe3O4 magnetic NPs was more 
efficient to reverse MDR and less toxic in resistant K562/A02 cells. Similarly, DNR-loaded 
ZnO NPs were shown to have greater cytotoxicity compared to free DNR in resistant 
K562/A02 cells [139].  
Kievit et al. [140] developed a complex DOX NP formulation, where polyethylenimine 
(PEI)-DOX was first constructed via a pH-sensitive hydrazone linkage and this PEI-DOX 
was then conjugated to PEG-coated superparamagnetic iron oxide NPs. PEI was used to 
serve as a docking molecule for DOX to achieve high drug loading and help it escape from 
endosomes. The results showed the complex NPs were rapidly taken up in both sensitive 
and resistant rat glioma C6 cells, and significantly enhanced drug retention and greater 
cytotoxicity compared to free DOX in resistant C6 cells. In addition, DOX had the fastest 
release profile at acidic pH, which indicated the cleavage of hydrazone linkage. Taken 
together, this DOX complex NPs overcame MDR in-vitro.  
1.2.8   Gold Nanoparticles 
Gold NPs (Au NPs) have been widely used as biomedical imaging and biosensors 
[141]. Because they are biocompatible, small size, high stability and tissue permeability, Au 
NPs are also served as effective drug delivery carriers and drugs could be associated on the 
NPs by physical adsorption, ionic bonding, and/or covalent bonding [142, 143]. Gu et al. 
[144] conjugated DOX onto PEGylated Au NPs via a disulfide bond (Au-PEG-SS-DOX), and 
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the NPs showed the greater intracellular drug uptake than free DOX in resistant HepG2-R 
cells, which was confirmed by both confocal images and inductively coupled plasma mass 
spectrometry (ICP-MS). Interestingly, the DOX was released from lysosomes and reached 
the cytoplasma but not the nucleus, which implied that the cytotoxic function of Au-PEG-SS-
DOX was not through its interaction with nuclear DNA. It was suggested the ability of NPs to 
overcome MDR may be related to the cell membrane properties, and NPs may dysregulate 
mitochondrial function in cytoplasma thus inducing the cell apoptosis. Zhang et al. [145] 
linked DOX onto Au NPs via an amide bond to form DOX-Au NPs with ultrasmall particle 
size of 2.7 nm. The DOX-Au NPs were observed to be non-toxic and expected to be cleared 
by kidney within hours. The DOX-Au NPs were internalized into the cells and even entered 
into nucleus as seen by confocal and electron microscopy, which was probably due to its 
small size. The NPs were demonstrated to have about 20- and 6-fold greater cytotoxicity 
and faster action than free DOX, respectively, in resistant B16 melanoma cells. The DOX-Au 
NPs were also sensitive to resistant HeLa cells over-expressing BCL-2, which was probably 
due to the entry of NPs into nucleus and DNA damage caused by released DOX. Fu group 
[146, 147] developed 3-mercaptopropionic acid capped Au NPs (MPA-capped Au NPs), and 
the NPs significantly facilitated DNR uptake compared to free DNR in resistant K562/ADM 
cells and the enhanced intracellular DNR fluorescence was mainly located on cell 
membrane. Interestingly, the Au NPs without MPA functional group did not show facilitated 
effect, suggesting this functional group played an important role in the enhanced DNR 
accumulation on cell membrane. It was suggested that MPA-capped Au NPs and free DNR 
formed a complex via electrostatic interaction thus facilitating drug penetration into the cells 
by simple diffusion and phagocytosis. Au NPs may also interact with proteins or other 
components on the cell membrane and circumvent MDR. Wang et al. [148] conjugated DOX 
onto Au NPs via an acid-labile hydrazone linker (DOX-Au Hyd NPs) and NPs were 
confirmed to enter the cells via energy-dependent endocytosis, specifically, both caveolae- 
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and clathrin-mediated endocytosis, and then DOX was released from the NPs to cytoplasma 
and nucleus. The DOX-Au Hyd NPs had significantly enhanced intracellular drug uptake and 
less efflux, and dramatically increased cytotoxicity compared to free DOX in resistant MCF-
7/ADR cells. DOX-Au NPs with a carbamate linker was prepared as a control (DOX-Au Cbm 
NPs) and the linkage was stable so that DOX was not released. In contrast, DOX-Au Cbm 
NPs demonstrated similar cytotoxicity as free DOX in MCF-7/ADR cells, indicating that the 
drug release from NPs was important to exert activity.  
1.2.9   Silica Nanoparticles 
Huang et al. [149] covalently conjugated DOX onto mesoporous silica nanoparticles 
(MNSP) via hydrazone linkage (DOX Hyd MNSP). The DOX Hyd MNSP demonstrated 
significantly induced apoptosis both in-vitro and in-vivo in resistant MES-SA/Dx-5 cells 
compared to the controls. It was suggested the MNSP entered the cells via endocytosis and 
bypassed P-gp efflux pump. It was also claimed that this was the first report that MNSP 
overcame MDR in-vivo. Meng et al. [150] engineered MNSP to simultaneously deliver DOX 
and MDR1 siRNA. The surface of MNSP was functionalized with a phosphonate group 
which allowed DOX binding inside the MNSP via electrostatic action and this functional 
group coated with the cationic polymer of PEI which was further complexed with anionic 
MDR1 siRNA. The dual delivery of DOX and MDR1 siRNA with MNSP significantly 
enhanced intracellular and intranuclear DOX concentration compared to free DOX or DOX 
MNSP without siRNA in resistant KB-V1 cells. It was suggested that the DOX was released 
from lysosomes via proton sponge mechanism which was supported by the findings that the 
addition of NH4Cl inhibited DOX release and entry into nucleus. Shen et al. [151] loaded 
DOX in MNSP and this DOX MNSP showed 8-fold more potent and dramatically enhanced 
drug intracellular uptake and nuclear accumulation than free DOX in resistant MCF-7/ADR 
cells in-vitro. The DOX concentration of DOX MNSP was 6.12- and 5.11-fold greater than 
31 
 
that of free DOX at 0.5 and 2 h, respectively, in xenograft MCF-7/ADR tumor-bearing nude 
mice. It was the first report that the MNSP itself inhibited P-gp expression based on its ability 
to down-regulate P-gp levels. The mechanism of MNSP entry into the cells was through 
micropinocytosis pathway and once the NPs internalized into the cell, MNSP may bypass P-
gp because it was too large to be effluxed. All of the above probably contributed to the 
MNSP ability to overcome MDR. Chen et al. [152] co-delivered DOX and BCL-2 siRNA in 
MNSP, where DOX was entrapped inside the pore of the MNSP and BCL-2 siRNA was 
complexed with MNSP modified polyamidoamine dendrimers. The results demonstrated that 
the MNSPs enhanced drug cytotoxicity by up to 132-fold greater than that of free DOX in 
resistant A2780/AD human ovarian cancer cells, and that the significantly increased 
antitumor efficacy was probably due to the suppression of BCL-2 mRNA and perinuclear 
localization of DOX via MNSP delivery carrier. 
1.2.10  Carbon Nanotubes 
Li et al. [153] coupled P-gp antibody on the functionalized carbon nanotubes via a 
diimide-activated amidation reaction for targeting purpose and loaded DOX on the remaining 
surface of carbon nanotubes via physical adsorption. The physical adsorption between DOX 
and nanotubes maximally preserved the molecule integrity because of the chemical bond 
avoidance. In addition, the release of DOX from nanotubes improved in a controlled manner 
upon exposure of DOX nanotubes under near-infrared radiation. It was proposed that the 
controllable and sustained release of DOX by near-infrared radiation and specific P-gp 
targeting were the main reasons that the nanotube overcame MDR in resistant human 
leukemia K562R cells. It was also suggested that the P-gp antibody conjugated on the 
nanotubes provided huge stereohindrance for P-gp recognition of DOX thus suppressed the 
efflux of DOX by P-gp.  
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1.2.11  Cyclodextrin Nanoparticles 
Qiu and co-workers [154] designed a delivery system of novel β-CD-centered star-
shaped amphiphilic polymers (sPEL/CD) for DOX. To construct the sPEL/CD complex, 
mPEG and PLA were reacted to form linear mPEG-PLA (mPEL) as the arms, and then β-
CD was served as the core to obtain sPEL/CD by an arm-first method. The drug loading of 
DOX was as high as 18% with an entrapment efficiency of 84%, which was probably due to 
the presence of PLA to increase hydrophobic interaction between polymer and drug as well 
as enlarge β-CD interspaces to accommodate more DOX. The DOX-loaded sPEL/CD had 
3-fold decreased IC50 compared to free DOX in resistant MCF-7/ADR cells. Because it was 
reported that pluronic block copolymers were able to prevent MDR in cancer cells [155], it 
was hypothesized the mPEG-PLA block segment in sPEL/CD complex had similar effect 
due to its structural similarity to pluronic. The interaction between polymer and P-gp may be 
another explanation of sPEL/CD system to reverse MDR. 
1.3    Conclusion and Future Perspective 
Anthracyclines are very effective chemotherapeutic drugs to treat various cancers; 
however, the severe cardiotoxicity and the development of MDR are the major limitations for 
the application of anthracyclines in clinic.  
 Nanoparticle delivery systems have emerged as possible novel cancer therapeutics 
to overcome some of the limitations of anthracyclines. With the optimal particle sizes and 
surface properties, NPs may be able to passively target anthracyclines into the tumor 
tissues via the EPR effect, escape from RES recognition, prolong circulation time in blood, 
and improve the drug distribution in the body. Doxil, a DOX PEGylated liposome formulation 
was developed and approved in 1995. This formulation demonstrated slower plasma 
clearance, enhanced circulation and half-life, decreased cardiotoxicity compared to free 
DOX; however, it did not address MDR issue. To date, ma
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been developed and reported, such as liposome formulations, polymeric NPs, solid lipid 
NPs, mesoporous silica NPs, magnetic NPs, polymer-drug conjugates, to effectively 
circumvent MDR both in-vitro and in-vivo. Some of these systems have even been 
advanced to clinical trials, for example the HPMA-DOX conjugate. However, MDR is very 
complicated and multifactorial. In addition, the MDR mechanisms are not fully understood. 
Therefore, it is better to address different MDR pathways in the NP delivery systems. For a 
given particular NP system, ideally it not only inhibits or bypasses efflux pump resistance, 
such as P-gp, BCRP and MRP1, but also circumvents non-pump resistance, such as BCL-2, 
p53. Moreover, in addition to the passively targeting, the active targeting using ligands may 
further improve the anticancer efficacy in resistant tumors while decrease the toxicity in 
normal tissues. 
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Table 1.1 Physicochemical properties of DOX, DNR, and IDA. 
 
 
 
DOX DNR IDA 
Formula C27H29NO11 C27H29NO10 C26H27NO9 
Molecular Weight (g/mol) 543.52 527.52 497.49 
Water Solubility (mg/mL) 92.8 39.2 35.6 
Log P 1.27 1.68 2.10 
pKa ~8.4 10.3 8.5 
Melting Point (°C) 204-205 208-209 173-174 
Half-life (h) 55 18.5 22 
Protein Binding (%) 70 97 97 
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Table 1.2 Summary of the proposed mechanisms of anthracycline NPs to overcome MDR. 
Platform Composition Mechanism Status Ref. 
Liposome 
CL, PC, CHOL interact with P-gp 
modify plasma membrane in-vitro [23, 24] 
CL, PC, CHOL increase drug accumulation  intracellular drug redistribution in-vitro [22] 
DSPE-PEG, 
CHOL, DPPC, 
DPPG 
direct inhibit ATPase 
alter raft lipid composition 
reduce lipid raft-associated Pgp 
in-vitro [26] 
DSPC, CHOL PSC 833 (P-gp inhibitor) in-vivo [27] 
EPC, CHOL, 
PEG-DSPE verapamil (P-gp inhibitor) in-vitro [28] 
EPC, CHOL, 
mPEG-DSPE, 
MAL-PEG-DSPE 
verapamil (P-gp inhibitor) 
transferrin (targeting) in-vitro [29] 
EPC, CHOL, 
DSPE-PEG, 
DPPC 
MDR1 ASO 
BCL-2 ASO 
endocytosis 
membrane fusion 
in-vivo [30] 
DOTAP MRP1 siRNA BCL-2  siRNA in-vitro [32] 
DSAA, DOTAP, 
DOPA, CHOL, 
DSPE-PEG, 
DSPE-PEG-AA 
DSAA (induce ROS, inhibit MDR transporters, 
enhance drug uptake) 
VEGF siRNA (increase drug uptake and 
targeting) 
c-Myc siRNA (improve therapeutic effect and 
down-regulate MDR) 
in-vivo [33] 
Polymeric 
NP 
PIBCA 
PIBCA and its degradation products change or 
modify cell membrane 
massive drug diffusion from NPs saturates P-gp  
NPs do not enter the cells 
in-vitro [35] 
PACA 
NP-cell interaction on cell surface 
form drug-polycyanoacrylic acid ion-pair complex  
cyclosporine A (P-gp inhibitor) 
in-vitro [36, 41, 42] 
PIHCA bypass but not direct inhibit P-gp in-vitro [38, 39] 
AOT-alginate methylene bule (inhibit P-gp and generate ROS) in-vitro [44, 45] 
PPLA porphyrin (photosensitizer) TPGS (P-gp inhibitor) in-vitro [49] 
stearyl-modified 
dextran bypass P-gp in-vitro [43] 
PLGA curcumin (increase drug retention in nucleus, down-regulate P-gp and BCL-2) in-vitro [47] 
PLGA receptor-mediated endocytosis (HER2) in-vitro [48] 
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Table 1.2 (continued) 
 
Platform Composition Mechanism Status Ref. 
Polymeric 
Micelles 
pluronic P85 
interact with P-gp 
change cell membrane structure  
induce cell membrane permeability 
in-vitro [50] 
PEO-PPO-PEO endocytosis 
sensitize cells in-vitro [51] 
PLA-TPGS 
inhibit P-gp 
enhance drug cellular uptake 
promote drug to translocate into nucleus 
in-vitro [52] 
PLGA-PEG-folate TPGS (P-gp inhibitor) in-vitro [53] 
PEG- 
polyphosphazene 
endocytosis 
pH-sensitive polymer (disrupt endosomes by 
proton-sponge effect and/or interact between 
polymer and endosome membrane) 
in-vitro [58] 
CSO-FA 
interact with cell membrane 
alkyl side chain on chitosan introduces 
perturbation effect 
fatty acids form hydrophobic microdomains 
near shell surface 
in-vitro [59-61] 
polyHis/PEG 
(or polyHis/PEG-
folate), 
pLLA/PEG-folate 
receptor-mediated endocytosis (folate) 
trigger drug release at low pH (pH-sensitive) 
interact between polyHis group of the micelle 
and endosome membrane 
in-vivo [62-65] 
PEO-b-PCL 
RGD4C (targeting) 
TAT (cell-penetration peptide) 
MDR1 siRNA 
in-vivo [73] 
PEG-PDLLA 
drug released to plasma membrane and then 
internalized into cells 
PEG-induced fusion to cell membrane 
in-vitro [75] 
PCL-PEO endocytosis in-vitro [76, 77] 
pluronic L61 
facilitate drug to nucleus 
increase drug cellular uptake 
inhibit drug efflux 
in-vitro [78] 
Polymer 
Conjugate 
HPMA 
inhibit P-gp and β2m 
lysosomally degradable linker (GFLG) 
endocytosis 
down-regulate P-gp, MRP, BCL-2, HSP-70 
in-vivo [79-85] 
dextran endocytosis bypass P-gp in-vivo [91-93] 
PEG-modified 
dendrimer 
endocytosis 
rupture endosomes (proton-sponge effect) in-vitro [90] 
Magnetic 
NP Fe3O4, ZnO 
P-gp inhibitor or competitive P-gp substrate 
(Fe3O4) 
interact between NPs and cell membrane 
tetrandrine (P-gp inhibitor) 
up-regulate BAX, p53, caspase-3 
inhibit BCL-2, down-regulate P-gp 
shRNA (targeting) 
in-vivo [132-139] 
Carbon 
Nanotube ― 
controllable and sustained drug release 
P-gp antibody (targeting) in-vitro [153] 
CD NP ― interaction between polymer and P-gp inhibit P-gp in-vitro [154] 
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Table 1.2 (continued) 
 
Platform Composition Mechanism Status Ref. 
Peptide/ 
Protein 
Conjugate 
TAT bypass but not inhibit P-gp in-vitro [96, 97] 
maurocalcine, 
penetratin, TAT 
active mitochondrial independent apoptotic 
pathways in-vitro [98-100] 
Vectocell internalization in-vitro [101, 102] 
penetratin, 
SynB1 
bypass P-gp 
interact between conjugate and cell membrane in-vitro [103] 
transferrin 
bypass P-gp (conjugate slowly dissociates after 
binding to cell membrane)  
receptor-mediated endocytosis 
interact between conjugate and DNA 
in-vitro [104, 105] 
IGF-1R mAb receptor-mediated endocytosis 
escape P-gp recognition in-vivo [111] 
[D-Lys6]LHRH 
not by receptor-mediated endocytosis 
down-regulate ErbB/HER receptors 
disrupt G-protein signaling 
in-vivo [112-114] 
AS-ODN high drug accumulation inhibit P-gp (AS-ODN) in-vivo [115, 116] 
BSA endocytosis 
conjugate degrades in lysosomes in-vivo [117-119] 
diGly, triGly, 
GSH, GSSG 
rapid drug uptake 
high drug accumulation in-vitro [120] 
poly-D-Lysine, 
poly-L-Lysine 
endocytosis 
poly-L-Lysine digested by lysosomes in-vitro [121] 
SLNs 
emulsifying wax, 
Brij 78, TPGS 
inhibit P-gp, deplete ATP, increase drug 
retention  in-vivo [124, 125] 
monostearin, 
oleic acid 
inhibit P-gp 
high affinity between lipids or NLC and cell 
membrane 
in-vitro [127] 
stearic acid, 
Pluronic F68, 
HPESO 
not inhibit or bypass P-gp 
not alter cell membrane permeability 
drug released from outside of cell and then 
simple passive diffusion 
phagocytosis 
GG918 (P-gp inhibitor) 
in-vitro [128-130] 
Gold NP 
― 
change or modify cell membrane properties 
dysregulate mitochondrial function in-vitro [144] 
― 
internalization 
NPs even enter the nucleus in-vitro [145] 
― 
drug-NP complex formation 
phagocytosis 
simple diffusion 
in-vitro [146, 147] 
Silica NP 
― 
endocytosis 
bypass P-gp in-vivo [149] 
― 
PEI (proton sponge effect) 
P-gp siRNA in-vitro [150] 
― 
inhibit P-gp 
micropinocytosis in-vivo [151] 
― 
perinuclear localization 
BCL-2 siRNA in-vitro [152] 
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Figure 1.1 Chemical structures of DOX, DNR and IDA. 
 
 
 Figure 1.2 Schematic summary of different anthracycline NPs 
MDR. 
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Chapter II 
 
Paclitaxel Nano-Delivery Systems for Cancer Therapy 
 
2.1    Paclitaxel and Its Limitations 
Paclitaxel (PX), isolated from the bark of Pacific Yew (Taxus brevifolia), is a white 
crystalline powder with the melting point of ~210°C ( Figure 2.1). It is one of the most 
effective chemotherapeutic drugs and is mainly used to treat lung, ovarian, and breast 
cancer [156]. The mechanism of action of PX is to promote and stabilize microtubules and 
inhibit late G2 or M phases of cell cycle, thereby causing the cell death. The major limitation 
of PX is its low water solubility (~0.4 µg/mL); thus, it is formulated in organic solvents of 
polyoxyethylated castor oil (Cremophor EL) and dehydrated ethanol (50/50, v/v) under the 
trademark ‘Taxol’. However, Cremophor EL is known to cause serious side effects, such as 
hypersensitivity reactions [157]. As a result, prolonged infusion times and pretreatments are 
required. Moreover, the presence of Cremophor EL alters the pharmacokinetic profile of PX 
in-vivo which was described as unpredictable non-linear plasma pharmacokinetics when PX 
was formulated in Cremophor EL [158]. In addition, PX is a substrate of P-glycoprotein (P-
gp), which actively pumps PX out of the cells and induces drug resistance [159]. To 
overcome this problem, several P-gp inhibitors, such as verapamil [160] and PSC 833 [161], 
were co-administered with Taxol but the results were disappointing due to their toxicity 
and/or alteration of PX pharmacokinetics and biodistribution. 
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Nano-delivery systems are promising vehicles in drug delivery because they improve 
solubility of hydrophobic drugs, such as PX, and generally have low toxicity as well. 
Abraxane®, a PX albumin-bound NP formulation with the particle size of ~130 nm, was 
approved by the FDA in 2005 for the treatment of metastatic breast cancer. This formulation 
had demonstrated some advantages in terms of reduced toxicity compared to Taxol. In 
addition, the total dose can be administered within 30 min without pretreatment. However, 
whether Abraxane® could improve survival and address P-gp-mediated drug resistance is 
still unclear. Therefore, the alternative PX formulations are still in demand. In this review, 
various NP systems for the delivery of PX will be addressed, such as polymeric NPs, lipid-
based formulations, polymer conjugate, inorganic NPs, and nanocrystals.  
2.2    Polymeric Nanoparticles 
2.2.1   Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles 
PLGA is one of the most widely used biodegradable copolymers for the development 
of nano-delivery systems because it undergoes hydrolysis in the body and produces 
biocompatible degradants lactic acid and glycolic acid. Since the body effectively deals with 
both degradants, the systemic toxicity associated with PLGA is minimal. 
PX-loaded PLGA NPs have been engineered by different methods, such as o/w 
emulsion-solvent evaporation [162, 163], nanoprecipitation [164] and interfacial deposition 
methods [165]. In most cases, PX was released from PLGA NPs in a biphasic pattern with a 
fast initial release during the first 1-3 days followed by a slow and continuous release [162, 
163, 165-167]. PX-encapsulated PLGA NPs demonstrated enhanced in-vitro cytotoxicity as 
compared to free PX in various cancer cell lines, such as glioma C6 cells [166], NCI-H69 
human small cell lung cancer cells [165], MCF-7 [167] and HeLa cells [164, 167]. 
Furthermore, in-vivo PX-loaded PLGA NPs showed significantly better tumor growth 
inhibition effect with transplantable liver tumors [164].  
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The surface of PLGA NPs was modified for improved drug delivery. Chitosan-coated 
PLGA NPs exhibited slower in-vitro drug release compared to non-coated PLGA NPs and 
significantly changed the zeta potential from the negative charge of -30.1 mV for PLGA NPs 
alone to the positive charge of 26 mV, which facilitated drug cell uptake than uncoated NPs 
[168]. Chakravarthi et al. [169] showed a 4-10-fold increase in cellular association of PX and 
enhanced cytotoxicity when applied chitosan-modified PLGA NPs. A cationic surfactant, 
didodecyldimethylammonium bromide (DMAB), was absorbed on the surface of PX-loaded 
NPs by electrostatic attraction. Upon the addition of DMAB, the negatively-charged NPs 
shifted to become positively-charged [170]. This DMAB modified PX-incorporated PLGA 
NPs completely inhibited intimal proliferation in a rabbit vascular injury model [171]. 
PLGA NPs were also optimized using different emulsifiers. It is known that the 
employed emulsifiers/stabilizers could have strong influence on the properties of produced 
NPs, such as morphology, particle size, drug entrapment efficiency, in-vitro release 
behavior, cellular uptake, in-vitro cytotoxicity, pharmacokinetics and biodistribution, and as a 
consequence therapeutic efficacy [172]. Poly(vinyl alcohol) (PVA) is the most commonly 
used emulsifier. When d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was 
utilized in PX-loaded PLGA NPs as the surfactant emulsifier, the PLGA/TPGS NPs could 
achieve drug encapsulation efficiency of 100% [173], better controlled drug release kinetics 
[174], and enhanced cellular uptake and cytotoxicity [175] compared to that of PVA-
emulsified PLGA NPs. The TPGS-emulsified PLGA NPs achieved 10-fold greater 
bioavailability than Taxol after oral administration [176]. Phospholipids were also applied as 
natural emulsifiers in PLGA NPs, such as 1,2-dilauroylphosphatidylcholine (DLPC) [177] and 
dipalmitoyl-phosphatidylcholine (DPPC) [178]. Both of the emulsifiers demonstrated greater 
benefits compared to PVA. Montmorillonite (MMT) was also incorporated into PX-loaded 
PLGA NPs as both of matrix component and co-emulsifier. The addition of MMT did not 
change particle size, drug entrapment efficiency, or the in-vitro drug release from PLGA 
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NPs. Importantly, the PX-loaded PLGA/MMT NPs enhanced drug cellular uptake over that 
of pure PLGA NPs by 57-177% and 11-55% in Caco-2 and HT-29 cells, respectively [179]. 
The PX-loaded PLGA/MMT NPs were further decorated with human epidermal growth factor 
receptor 2 (HER2) antibody for targeting purposes, and these targeted NPs exhibited a 
12.7-fold enhanced cytotoxicity compared to non-targeted NPs in SK-BR-3 cells [180]. Other 
targeting ligands, such as RGD [181] and transferrin [182-184], have also been conjugated 
to PX-encapsulated PLGA NPs for better antitumor efficacy. For example, PX-incorporated 
PLGA NPs with transferrin ligand showed 5-fold enhanced cytotoxicity over that of non-
targeted NPs or Taxol. The mice treated with targeted NPs demonstrated complete tumor 
inhibition and significantly prolonged survival compared to all controls after intratumoral 
injection in a PC3 prostate cancer mouse model [183]. 
2.2.2    Poly(lactide) (PLA) Nanoparticles 
PLA is another widely used matrix material for polymeric NP preparation because of 
its biocompatibility and biodegradability properties. Methoxy poly(ethylene glycol)-
poly(lactide) copolymer (mPEG-PLA) was synthesized and incorporated into the NPs to 
provide long circulating properties. The in-vitro cytotoxicity of these NPs increased by 33.3-
fold over that of Taxol after 24 h in MCF-7 cells. In-vivo pharmacokinetic studies 
demonstrated the AUC and half-life of PX mPEG-PLA NPs in rat plasma were 3.1- and 2.8-
fold greater than that of Taxol, respectively [185, 186]. PX-loaded NPs with PLA and mPEG-
PLA at various ratios of 100/0, 75/25, 50/50, 25/75, and 0/100 were evaluated. It was found 
that as the mPEG-PLA component in the blend increased, the particle size of NPs and the 
glass transition temperature of PLA decreased, while the zeta potential of NPs and in-vitro 
drug release increased [187]. Copolymers of PLA/Tween 80 were synthesized and PX-
loaded PLA/Tween 80 NPs were shown to be about 3-fold more toxic than PX-loaded PLGA 
NPs in glioma C6 cells [188]. TPGS was also utilized as an emulsifier in PLA NPs. Feng 
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group [189] synthesized PLA-TPGS copolymers using a ring-opening polymerization 
method. Compared to PX-loaded NPs, the PLA/TPGS NPs showed 1.8- and 1.4-fold 
enhanced cellular uptake of PX in HT-29 and Caco-2 cells, respectively. The IC50 value of 
PLA/TPGS NPs was also found to be 40% lower than that of Taxol in HT-29 cells [190]. In-
vivo this PX-loaded PLA/TPGS NP formulation achieved a 27.4- and 1.6-fold greater half-life 
and AUC, respectively, in a xenograft tumor model [191]. PX-loaded PLA/TPGS NPs with 
various ratios of PLA and TPGS were evaluated, and the results demonstrated that the 
PLA/TPGS ratio had little effect on particle size. However, PLA/TPGS NPs with PLA/TPGS 
ratio of 89/11 were the optimized formulation in terms of drug entrapment efficiency, cellular 
uptake, and in-vitro cytotoxicity [192]. Folate-decorated PX-loaded PLA-TPGS NPs were 
further formulated to achieve even better therapeutic effect [193, 194]. Other targeted PX-
loaded PLA NPs, such as HER2 [195], biotin and folic acid [196], were also reported to 
greatly improve efficacy both in-vitro and in-vivo.  
PLA co-polymer micelles have also been reported for PX delivery [197-202]. For 
example, PX-loaded PEG-b-PLA micelles were prepared and the mechanism of action was 
investigated. It was found that the micelles first interacted with cell membranes and then the 
loaded PX was released. After that, PX was internalized into the cells by lipid/raft/caveolae-
mediated endocytosis pathway. In this way, PEG-b-PLA micelles were able to overcome 
MDR which was confirmed by the increased cellular uptake of PX in resistant A2780/T cells. 
The results also suggested PEG-b-PLA micelles could inhibit P-gp efflux [198]. Paxceed® is 
a polymeric micelle formulation where PX is encapsulated in PLA-b-mPEG diblock 
copolymers. The micellar formulation was found to be more efficacious than Taxol at the 
MTD upon intraperitoneal injection in an MV-522 lung tumor-bearing mouse model [203]. 
Currently, Paxceed® is in phase II clinical trials [204]. Genexol-PM remains the most 
successful PX micellar formulation to date, and is composed of PLA-b-PEG diblock 
copolymers [205]. A preclinical in-vivo study with Genexol-PM was found to have 3-fold 
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increased MTD and 2-3-fold higher drug concentration in various tissues and more 
importantly in tumors, compared to Taxol in nude mice. The in-vivo antitumor efficacy of 
Genexol-PM was also significantly improved [206]. In phase I clinical studies, the MTD dose 
was determined to be 180 mg/m2. The plasma AUC and Cmax increased by 3- and 4-fold, 
respectively, when the dose increased from 80 to 200 mg/m2 [207], which suggested the 
pharmacokinetics of Genexol-PM were dose-proportional. In phase II clinical studies, 
Genexol-PM was found to be safe and effective in patients with metastatic breast or 
advanced pancreatic cancer [208, 209]. Phase III clinical studies are currently in process. 
Triblock copolymers of PLA-PEG-PLA and PEG-PLA-PEG were synthesized as 
carriers for PX. The results demonstrated that the drug release from PEG-PLA-PEG 
micelles was slower than from PLA-PEG-PLA micelles, and PEG contents in micelles 
influenced the stealth properties of the micelles. Both of micelles showed 4-fold decreased 
monocyte cell uptake compared to PLA micelles [201, 202]. In another study, a four-armed 
(star-branched) copolymer of PLA and PEO was synthesized. Compared to di-and tri-block 
copolymers, the star-branched micelles exhibited better controlled and more complete 
release manner over 2 weeks. Furthermore, the star-shaped micelles had smaller particle 
size which had the potential to take more advantages of the EPR effect in cancer therapy 
[197]. 
In addition to PEG-modified PLGA micelles, PX-incorporated PVP-b-PLA micelles 
were prepared by Gaucher et al. [199] by an o/w emulsion solvent evaporation method. The 
cryoprotectant property of PVP allowed the same particle size upon reconstitution after 
lyophilization, while PEG-modified PEG-b-PLA micelles did not. For targeting purposes, a 
galactosamine targeted PX-loaded micelle formulation composed of poly(γ-glutamic acid) 
and PLA was developed. The targeted NP formulation showed the most significant 
antitumor efficacy compared to other controls and importantly more drug accumulation in 
tumors was observed in a hepatoma tumor-bearing nude mice [200].  
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2.2.3    Poly(ε-caprolactone) (PCL) Nanoparticles 
The Amiji group [210] developed poly(ethylene oxide)-modified poly(ε-caprolactone) 
(PEO-PCL) NPs for co-delivery of PX and C6-ceramide (an apoptotic signaling molecule) to 
overcome MDR. The prepared PEO-PCL NPs had high drug entrapment efficiency of > 95% 
with PX and C6-ceramide drug loading of 10% (w/w). The particle size of the NPs was ~270 
nm in diameter. In resistant human ovarian cancer SKOV3TR cells, PX and C6-ceramide 
loaded PEO-PCL NPs showed 100-fold enhanced cytotoxicity compared to free PX [211]. 
In-vivo PEO-PCL NPs demonstrated remarkably tumor growth inhibition in both wild-type 
SKOV3 and resistant SKOV3TR xenograft mouse models compared to all the controls. The 
results indicated the combination of PX and C6-ceramide incorporated into PEO-PCL NPs 
overcame MDR in ovarian cancer [212]. The combination of PX and tamoxifen loaded PEO-
PCL NPs was also evaluated both in-vitro and in-vivo. In-vitro this formulation lowered IC50 
by 10- and 3-fold in SKOV3 and SKOV3TR cells, respectively, when compared to free PX. In-
vivo the PEO-PCL NPs significantly enhanced antitumor efficacy and no acute toxicity was 
observed [213]. Later, polymeric NP systems for the co-delivery of both PX and P-gp 
silencing siRNA were developed. In order to do that, poly(ethylene oxide)-modified poly(β-
amino ester) (PEO-PbAE) and PEO-PCL NPs were formulated to encapsulate P-gp 
silencing siRNA and PX, respectively. The co-administration of P-gp silencing siRNA-loaded 
PEO-PbAE NPs and PX-loaded PEO-PCL NPs completely reversed the MDR based on the 
fact that the similar cytotoxic activity of NPs in both sensitive SKOV3 and resistant SKOV3TR 
cells [214]. 
Similarly, PEG-PCL polymeric micelles were prepared by a co-solvent extraction 
technique. A series of PX prodrugs were synthesized and encapsulated into micelles and it 
turned out that 7’-hexonoate PX loaded PEG-PCL NPs demonstrated improved 
pharmacokinetic profile compared to Taxol [215]. Xin et al. [216] prepared mPEG-PCL NPs 
to encapsulate PX by an emulsion-solvent evaporation method. In-vitro PX-loaded mPEG-
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PCL NPs showed higher cytotoxicity than Taxol and PCL NPs. Importantly, mPEG-PCL NPs 
increased the mean survival time to 28 days versus 20 and 23 days for Taxol and PCL NPs, 
respectively, in a C6 tumor-bearing mouse model. Angiopep, a peptide, was further 
conjugated on mPEG-PCL NPs to target the low-density lipoprotein receptor-related 
proteins over-expressed on blood-brain barrier (BBB) and facilitate chemotherapeutic agent 
of PX across BBB [217]. Similarly, Wang and co-workers [218] developed PX-loaded 
mPEG-PCL NPs by solid dispersion method without the use of organic solvents. The NPs 
achieved drug loading of 25.6% (w/w) and an entrapment efficiency of 98%. The MTD of 
NPs was 2.6-fold greater than Taxol in BALB/c mice after bolus intravenous injection. The 
tissue distribution of PX in NPs was different from that of Taxol and significantly greater 
tumor concentrations were observed. Chen [219] prepared more complicated PEG-PCL NPs 
where a PEG-PCL di-block copolymer was hyperbranched aliphatic polyester Boltorn H40, 
and then folic acid was further coated on the surface of the NPs. The PX-loaded NPs 
demonstrated increased cytotoxicity in-vitro. 
In addition to PEG-modified PCL NPs, a PX-loaded PCL/pluronic F68 NP (PCL/F68) 
formulation was prepared using a solvent evaporation method. The incorporation of pluronic 
F68 into PCL NPs formed pores and thus expedited drug release from NPs. The PX-loaded 
PCL/F68 NPs had increased cellular uptake and enhanced toxicity as compared to PCL 
NPs and Taxol in resistant MCF-7/TAX cells [220]. In-vivo the PCL/F68 NPs demonstrated 
the improved tumor inhibitory activity after a single intratumoral injection compared to 
multiple intraperitoneal injections of Taxol in a murine breast cancer model [221]. DMAB was 
further adsorbed on PCL/pluronic F68 NPs via charge-charge interaction to enhance NPs 
internalized into the arterial wall in animal angioplasty models [171].  
Other PX-loaded PCL-based NPs have also been reported. For example, PVP-b-PCL 
NPs demonstrated significantly superior antitumor efficacy to Taxol in hepatic H22 tumor-
bearing mice [222]. PCL grafted PVA (PCL-g-PVA) NPs were engineered and PX-loaded 
48 
 
PCL-g-PVA NPs were characterized and exhibited reduced drug release rate profiles [223]. 
PX-loaded poly(2-ethyl-2-oxazoline) (PEtOz)-PCL NPs [224], galactosamine targeted 
poly(ethyl ethylene phosphate) (PEEP)-PCL NPs [225], and mPEG-PCL-poly(2-aminoethyl 
ethylene phosphate) (mPEG-PCL-PPEEA) NPs [226] were reported to have better antitumor 
activity than Taxol in-vitro and/or in-vivo.  
2.2.4    Chitosan Nanoparticles 
Kim et al. [227] synthesized PX-loaded cholanic acid-modified chitosan NPs using a 
simple dialysis method with drug loading of 10% (w/w). This NP formulation showed faster 
cellular uptake and better therapeutic efficacy in SCC7 tumor-bearing mice compared to 
Taxol. Hydrotropic oligomer-glycol chitosan (HO-GC) was synthesized to enhance the 
aqueous solubility of PX in NPs, and achieved a higher drug loading up to 20% and 
maximum entrapment efficiency of 97%. The PX-encapsulated HO-GC NPs demonstrated a 
sustained in-vitro release profile, and importantly PX predominantly accumulated in tumor 
site in-vivo [228]. Glyceryl monooleate-modified chitosan NPs loaded with PX was reported 
to increase by 4- and 1,000-fold the cellular uptake and cytotoxicity, respectively, in MDA-
MB-231 cells as compared to free PX [229]. A more complex chitosan derivative modified 
with mPEG and cholesterol (CHO) was synthesized for PX delivery. The mPEG-CHO-
Chitosan NPs showed similar cytotoxicity as free PX in-vitro, but significantly slower tumor 
growth rate and improved life span compared to free PX at the dose of 10 mg/kg in a tumor-
bearing mouse model [230]. A pH-sensitive self-assembled modified chitosan NP 
formulation was developed based on the fact that hydrophobic acetyl histidine modified 
chitosan could self-assemble NPs at neutral pH but dissemble at slightly acidic environment 
due to the protonation of its imidazole group. The PX-loaded modified NPs were then 
confirmed to endocytose into cells and release drug in acidic endosomes [231]. In another 
study, the hydrophobic fatty acid of stearic acid was grafted to chitosan oligosaccharide and 
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the micelles were self-assembled. Glutaraldehyde was then crosslinked to the shells of NPs 
to further increase the stability of the micelles. The PX-loaded glutaraldehyde-crosslinked 
chitosan oligosaccharide micelles were found to enhance PX solubility, and have less burst 
release and slower drug release compared to non-crosslinked NPs [232].  
2.2.5    Albumin Nanoparticles 
Albumin is a versatile natural protein carrier for targeted drug delivery. Human serum 
albumin (HSA) is the most abundant plasma protein in the human blood with a half-life of 19 
days. It can reversibly bind hydrophobic drug substances, transport them in the body and 
release drugs at cell surface [233]. In addition, albumin is actively transported into tumors 
via a selective over-expression of a 60 kDa glycoprotein (gp60) receptor (albondin) [234]. 
Albumin-bound PX NPs (Abraxane®) was approved by US FDA in 2005 for the treatment of 
metastatic breast cancer in patients who fail other chemotherapy or relapse. The albumin-
bound PX NPs have an average particle size of about 130 nm. Since this NP formulation 
completely eliminates Cremophor EL and ethanol in Taxol, it is administered in a shorter 
period of 30 min with no need for premedication. For more details about Abraxane® product, 
please refer to the review articles of [235-238]. Interestingly, targeted Abraxane formulations 
with two peptides of CREKA and LyP-1 (CGNKRTRGC), respectively, were developed and 
LyP-1-Abraxane demonstrated significantly improved antitumor efficacy compared to 
untargeted Abraxane in an MDA-MB-435 xenograft mouse model [239]. In addition to 
human albumin, Zhao et al. [240] prepared PX-loaded bovine serum albumin (BSA) NPs 
using a desolvation method, and subsequently coated NPs by folic acid for targeting. The 
folate-decorated NPs exhibited high stability and desired surface properties which 
specifically targeted to human prostate cancer PC3 cells. In another study, a novel octyl-
modified bovine serum albumin (OSA) was synthesized to improve the lipophilicity of 
albumin and facilitate to form PX-loaded core-shell nanomicelles. The OSA NPs had smaller 
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particle size, higher drug entrapment efficiency, and greater stability compared to 
unmodified NPs [241]. 
2.2.6   Hyaluronic acid (HA) Nanoparticles 
HA is a natural biocompatible and biodegradable polysaccharide. Recently, it has 
been widely used as a targeting carrier since most malignant solid tumors over-express HA 
receptors, such as CD44 and hyaluronan-mediated motility receptor (RHAMM) [242]. PX-
loaded HA NPs were reported by Al-Ghananeem [243]. Although the in-vitro cytotoxicity of 
NPs was comparable to free PX in both MDA-MB-231 and ZR-75-1 breast cancer cells, PX 
NPs showed superior antitumor efficacy to free PX when intratumorally injected into 7,12-
dimethylbenz[a]anthracene-induced breast cancer tumor-bearing rats. A modified HA was 
synthesized with an amine-terminated hydrotropic oligmer, which enhanced PX solubility 
and achieved the drug loading up to 20.7%. The NPs were found to selectively target SCC-7 
cells which over-expressed CD44, and exhibited enhanced cytotoxicity in this cell line than 
normal fibroblast CV-1 cells [244].  
2.2.7  Poly(butyl cyanoacrylate) (PBCA) Nanoparticles 
Biodegradable poly(alkyl cyanoacrylate) (PACA) NPs have been widely used for the 
delivery of various active pharmaceutical ingredients during recent 10 years. Among all 
different kinds of PACA NPs, poly(butyl cyanoacrylate) (PBCA) is the most widely used as a 
carrier because it interacts with a variety of drugs [245]. Huang et al. [246] developed PX-
loaded PBCA NPs with the addition of pluronic F127 as the surfactant using a miniemulsion 
method. It was found that the drug loading and entrapment efficiency of pluronic F127 
modified NPs were significantly increased. The PBCA NPs prepared from the miniemulsions 
showed a gradual drug release up to 80% within 96 h. Hyaluronic acid (HA)-coated PBCA 
NPs encapsulated with PX were reported to reduce the initial burst release of the drug and 
decrease the cytotoxicity of placebo HA-PBCA NPs compared to non-HA coated PBCA 
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NPs. Importantly, PX-loaded HA-PBCA NPs enhanced by 9.5-fold the cellular uptake in 
Sarcoma-180 cells and showed more potent antitumor inhibition activity versus non-HA 
coated PX PBCA NPs when i.v. injected into Sarcoma-180 tumor-bearing mice [247]. Mitra 
et al. [248] studied the effect of surfactants on PX-encapsulated PBCA NPs. The surfactants 
of dextran 70, cholesterol, PVA, and lecithin were utilized and the results demonstrated that 
the NPs incorporated with surfactants were better than without surfactants in terms of 
particle size and stability. Among the four surfactants, the natural lipids of cholesterol and 
lecithin were superior to the other two in terms of producing NPs with smaller particle size, 
higher zeta potential and drug entrapment efficiency, and better controlled drug release 
profiles.  
2.2.8  Hyperbranched Polyglycerol (HPG) Nanoparticles 
HPG is a water-soluble, highly biocompatible polymer with minimal toxicity. It is one of 
a few hyperbranched polymers that can be synthesized in a controlled manner [249]. 
Mugabe et al. [250] loaded PX into two types of modified HPG NPs (HPG-C10-PEG and 
PEI-C18-HPG) using a solvent evaporation method. The particle size of both NPs was less 
than 20 nm. The PX was released up to 80% from HPG-C10-PEG while only 40% from PEI-
C18-HPG. PX-loaded HPG-C10-PEG NP formulation was better tolerated and exhibited 
significantly improved antitumor efficacy in-vivo as compared to Taxol, although the in-vitro 
cytotoxicity was slightly decreased compared to Taxol.  
2.2.9  Poly(ethylene glycol)-phosphatidyl ethanolamine (PEG-PE) Nanoparticles 
The Torchilin group [251, 252] developed polymeric micelles composed of PEG and 
diacyllipids, such as phosphatidyl ethanolamine (PE) for PX delivery. The presence of two 
hydrocarbon chains of PE increased hydrophobic interactions and therefore provided better 
stability of the micelles. The PX-loaded micelles had similar size to the placebo micelles. An 
immunomicelle formulation was prepared by attaching mAb 2C5 to the surface of the 
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micelles, and it showed better antitumor activity both in-vitro and in-vivo compared to Taxol 
or non-targeted micelles in a Lewis lung carcinoma mouse model. Later, PX-loaded mixed 
micelles were developed by the mixture of PEG-PE and egg phosphatidylcholine, or the 
mixture of PEG-PE, solid triglycerides, and cationic Lipofectin lipids. The mixed polymeric 
micelles further improved antitumor efficacy [253, 254]. The Rubinstein laboratory prepared 
sterically stabilized mixed micelles (SSMM) consisting of polyethylene glycol-
distearoylphosphatidylethanolamine (PEG-DSPE) and egg phosphatidylcholine. PX loading 
in SSMM was 1.5-fold higher than that of PEG-DSPE micelles at the same lipid 
concentration. PX-loaded SSMM, PEG-DSPE micelles, and free PX had comparable 
cytotoxicity in MCF-7 cells [255]. Actively targeted vasoactive intestinal peptide (VIP)-grafted 
SSMM (SSMM-VIP) was further engineered for the targeting purpose. The PX-loaded 
SSMM-VIP was significantly more potent than PX-loaded SSMM and free PX in drug 
resistant BC19/3 cells [256]. 
2.2.10   Gelatin Nanoparticles 
Lu et al. [257-260] developed PX-loaded gelatin NPs using a desolvation method. The 
IC50 value of NPs was nearly identical to that of free PX in RT4 bladder transitional cancer 
cells. The pharmacokinetic and biodistribution studies indicated that the NP formulation 
altered drug plasma concentration, clearance and tissue distribution in mice. The PX-loaded 
gelatin NPs showed significantly improved antitumor activity compared to free PX in 
intravesical bladder cancer therapy in dogs. 
2.2.11   NK 105 
NK 105 is a micellar NP formulation which is constructed by copolymers of PEG and 
polyaspartate followed by the incorporation of PX into the core of the micelles via 
hydrophobic interaction [261]. The drug loading was up to 23% (w/w) with the particle size of 
85 nm. In preclinical studies, NK 105 exhibited 90- and 25-fold greater plasma and tumor 
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AUCs compared to free PX, respectively, and significantly better antitumor efficacy than free 
PX in a human colorectal cancer HT-29 xenograft mouse model. In addition, the 
neurotoxicity of NK 105 was dramatically lower than that of free PX [262]. In phase I clinical 
studies, the MTD of NK 105 was determined to be 180 mg/m2 and the plasma AUC was 15-
fold higher than Taxol at the dose of 150 mg/m2 [263]. Currently, NK 105 is in phase II 
clinical studies. 
2.3    Lipid-Based Nanoparticles 
2.3.1   Liposomes 
Liposomes are a mature and versatile drug delivery system for both lipophilic and 
hydrophilic compounds. Zhang et al. [264] developed a novel lyophilized liposome-based PX 
formulation using phosphatidylcholine, cholesterol, and cardiolipin. The particle size did not 
change upon reconstitution after lyophilization. In addition, the formulation was physically 
and chemically stable at either 2-8ºC or 25ºC for at least 12 months. The in-vitro drug 
release from liposome formulations was slow with less than 6% of PX released after 120 h. 
Yoshizawa and co-workers [265] formulated PX into liposomes composed of hydrogenated 
soybean phosphatidylcholine (HSPC), cholesterol, and PEG-DSPE2000. The plasma AUC 
of PEGylated liposomes was 3.6-fold higher than non-PEGylated liposome formulation in 
normal rats. In colon-26 solid tumor-bearing mice, the PX-PEGylated liposome had 
significantly better antitumor efficacy and greater tumor uptake of PX compared to non-
PEGylated liposomes. PX-loaded multilamellar liposomes were developed by Fetterly et al. 
[266] which were composed of phosphatidylglycerol and phosphatidylcholine. 
Pharmacokinetic and biodistribution studies of PX liposomes were performed. The results 
showed that the AUC values in blood were comparable to Taxol, but tissue biodistribution 
was different. In general, the AUCs were significantly higher for Taxol in bone marrow, skin, 
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kidney, brain, adipose, and muscles, indicating the reduced toxicity of liposome 
formulations.  
EndoTAG-1, PX-loaded cationic liposome formulations developed by MediGene, had 
the potential to treat cancer. EndoTAG-1 consisted of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethyl-ammonium methylsulfate (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC), which bound to negatively charged endothelial cells in tumor blood vessels. In a 
prostate cancer mouse model, the mice treated with EndoTAG-1 had significantly smaller 
tumor volumes compared to the other controls [267]. In a different orthotopic pancreatic 
cancer model, the combination of EndoTAG-1 and gemcitabine inhibited the pancreatic 
metastasis [268]. Currently, EndoTAG-1 is in phase II clinical trials. 
2.3.2   Solid Lipid Nanoparticles (SLNs) 
Serpe et al. [269] developed PX-loaded SLNs composed of tripalmitin as the oil 
phase, Epikuron 20 as the surfactant, and Na-taurocholate, butanol, and cholesteryl 
hemisuccinate as the co-surfactants. Although the in-vitro cytotoxicity of the SLNs was 
comparable to that of Taxol in HT-29 colorectal cancer cells, the combination of PX and 
DOX loaded SLNs exerted a synergistic effect which was more potent than the mixture of 
Taxol and free DOX. Chen et al. [270] prepared two types of SLNs using Brij 78, or pluronic 
F68 and PEG-DSPE as the surfactants. Both of PX-incorporated SLNs were proved to have 
prolonged circulation compared to Taxol in KM mice. Lee and co-workers [271, 272] 
prepared PX-loaded SLNs with the oil phase of trimyristin using a hot homogenization 
method. The in-vitro cytotoxicity of NPs was similar to Taxol in both OVCAR-3 and MCF-7 
cells. In-vivo pharmacokinetic and biodistribution studies demonstrated the SLN formulation 
provided the comparable circulation when compared to Taxol after intravenous injection in 
Sprague-Dawley rats. Therefore, PX SLNs served as alternative formulations of Taxol. 
Pandita [273] prepared PX-encapsulated SLNs using a modified solvent injection method 
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with stearylamine as the lipid. After oral administration of NPs in mice, the AUCs increased 
by 10- and 2-fold in plasma and most tissues, respectively, as compared to free PX solution. 
Yuan et al. [274] evaluated PX-containing SLNs with different lipids, namely, monostearin, 
stearic acid, glycerol tristearate, and ATO 888. Cellular uptake studies of NPs were 
performed in A549 cells, resulting in uptake in the order of glycerol tristearate > monostearin 
> stearic acid > ATO 888. Since the drug entrapment efficiency was low for glycerol 
tristearate SLNs, the monostearin SLNs were the optimized formulations for PX delivery. 
The Murthy laboratory [275, 276] used either glyceryl palmitostearate or glyceryl 
monostearate as the lipid matrix, and poloxamer 407 as the surfactant to encapsulate PX. 
Yegin et al. [277] developed PX-loaded SLNs with phospholipids and sucrose fatty acid 
esters using either solvent or ultrasound emulsification method.  
The Mumper laboratory [278, 279] developed PX-encapsulated SLNs using 
emulsifying wax as the oil phase, and Brij 78 as the surfactant. The drug loading achieved 
150 µg/mL final PX concentration with entrapment efficiency about 50%. The NPs showed 
significantly enhanced toxicity in P-gp resistant HCT-15 cells, and also increased brain 
uptake using an in-situ rat brain perfusion model. The in-vivo antitumor efficacy of PX-
loaded NPs was conducted in a resistant HCT-15 xenograft mouse model and NPs 
demonstrated slower tumor growth rate compared to Taxol. Taken together, this PX-loaded 
NP formulation had the potential to overcome P-gp-mediated MDR both in-vitro and in-vivo. 
Later, novel SLNs were developed using glyceryl tridodecanoate as the core lipid. 
Compared to previous emulsifying wax-based SLNs, the novel PX-loaded NPs had higher 
drug entrapment efficiency of 85%, superior physical stability, slower and sustained release 
profile and even elimination of initial drug burst release [125, 280]. 
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2.3.3   Lipid Nanocapsules 
Benoit and colleagues [281-283] developed PX-loaded lipid nanocapsules, which were 
composed of Labrafac® (triglycerides), Lipoïd® S75-3 (soybean lecithin), and Solutol® HS15 
(polyethylene glycol 660 12-hydroxystearate), sodium chloride, and water. The NP 
formulations demonstrated longer circulation time in blood, and slower distribution and 
elimination in Wistar rats. Furthermore, the PX-loaded NPs could significantly increase the 
life span as compared to all controls. Captex® 8000 (glyceryl tricaprylate) was utilized 
instead of Labrafac® to engineer another version of lipid nanocapsule formulation, which 
also showed benefits over that of Taxol in-vivo and potentially overcame P-gp-mediated 
drug resistance [284-287].  
The Mumper laboratory [125, 280] developed PX-loaded nanocapsules using a warm 
microemulsion precursor method, which consisted of Miglyol 812 as the oil phase, and Brij 
78 and TPGS as the surfactants. This lipid-based nanocapsule system overcame P-gp-
mediated drug resistance both in-vitro and in-vivo, and the mechanisms were investigated 
which included 1) increase drug cell uptake and retention; 2) inhibit P-gp; 3) deplete ATP. 
Ho et al. [288, 289] prepared a complex self-assembled immuno-nanocapsule formulation. 
First, the PLGA polymeric core was formed to encapsulate PX with the aid of lecithin and 
DSPE-PEG2000. Another lipid layer with DSPC and DSPE-PEG2000 was further coated on 
the PLGA core to load a second drug of combretastatin A4 (a vascular disrupting agent). 
Moreover, a RGD peptide targeting ligand was conjugated on the surface of the lipid layer. 
This dual-drug loaded nanocapsule delivery system was shown to be promising in cancer 
therapy. Bae et al. [290] designed PX-loaded  PEO-PPO-PEO/PEG nanocapsules with a 
targeting ligand of folic acid and a lipid of Lipiodol (an iodized ethyl ester of fatty acid). In 
order to do so, Lipiodol, PEO-PPO-PEO copolymer, and amine functionalized six-arm-
branched PEG were first formed Lipiodol-encapsulated PEO-PPO-PEO/PEG nanocapsules 
using emulsion-solvent evaporation method. PX was then loaded into the nanocapsules and 
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the targeting ligand of folic acid was conjugated on the surface of NPs. PX loading capacity 
in the NPs was about 5-fold higher than without the oil phase of Lipiodol. This polymeric 
nanocapsule formulation with an oil core was served as a novel platform for water-insoluble 
drug delivery. Another novel folate-mediated solid-liquid lipid NP formulation was designed 
and developed to deliver PX. The idea was from that the combination of solid lipids and 
liquid oils could increase drug loading and entrapment efficiency [291]. The NPs 
demonstrated prolonged and sustained in-vitro release and exhibited better antitumor 
efficacy compared to Taxol in S-180 tumor-bearing mice [291]. 
2.3.4   PX Fatty Acid-Prodrug Lipid-Based Nanoparticles 
Although PX is a poorly water-soluble compound, its solubility in many lipids is also 
limited. Therefore, PX has the tendency to aggregate or crystallize from lipid-based NPs. To 
overcome the problem, modification of PX to a prodrug is a potential approach. Fatty acids 
could be used to conjugate to PX, improve the lipophilicity of PX and facilitate its retention in 
the core of lipid-based NPs.  
Ansell et al. [292] synthesized series of PX prodrugs formulated in lipophilic NPs. 
Succinic acid and diglycolic acid were used as linkers. The diglycolic linkage offered a 
higher hydrolysis rate compared to succinate analogues. In In-vitro cytotoxicity studies, 
succinate-linked prodrugs were 3-10-fold and 30-90-fold less potent than diglycolic linked 
prodrugs and free PX, respectively, in A2780 and MCF-7 cells. This was consistent with the 
fact that diglycolic linkage was more susceptible to hydrolysis. To evaluate the partition 
behavior of the prodrug NP formulations in-vivo, NP plasma elimination studies were 
performed. The results showed that prodrugs in the NPs released first and then esterases 
cleaved the ester bond to form active PX form in their lipid NP formulations. Furthermore, 
the partitioning half-lives of diglycolate prodrugs from particles were increased as the 
aliphatic chain length increased, which indicated that the release rate of the prodrug from 
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NPs could be adjusted by the length of aliphatic chains. Interestingly, succinate prodrug-
contaning NPs showed ineffective in-vivo in an HT29 human colon carcinoma tumor 
xenograft mouse model, which was probably due to the low hydrolysis rate and the slowly 
released PX was not sufficient to achieve needed efficacy. In contrast, diglycolate prodrug-
loaded NPs showed tumor growth inhibition and the antitumor activity was correlated with 
the partitioning half-lives of these prodrugs, where longer aliphatic chain length with longer 
partitioning half-life led to improved efficacy. 
Lundberg et al. [293] synthesized a PX-oleate conjugate and incorporated it into a lipid 
emulsion formulation with the mean particle size of 50 nm. The formulated PX-oleate was 
much more lipophilic than PX and had water solubility of 34 nM and Ko/w of 8,074 versus PX 
water solubility of 12.8 µM and Ko/w of 311 at 20ºC. This highly lipophilic PX-oleate conjugate 
in the NP formulation showed significantly greater AUC, higher Cmax, lower systemic 
clearance compared to PX formulated in Cremophor EL/Ethanol in rabbits. Perkins et al. 
[294] attached a 16-carbon acyl chain to PX and this 2’-2-bro-mohexadecanoyl PX (BrC16-
PX) conjugate was further incorporated into lipid-coated particles termed ‘lipocores’. The 
particle size of BrC16-PX-containing lipocores was 50-100 nm. In an in-vivo study, the 
lipocores demonstrated antitumor activity in an ovarian carcinoma SCID mice model after 
intraperitoneal or intravenous administration, and was far less toxic than Taxol. Lee et al. 
[295] synthesized a PX-2’-carbonyl-cholesterol (PX-Chol) conjugate to increase lipophilicity 
of PX and formulated it into a lipid NP formulation. The % entrapment of PX-Chol was 
greater than 90% at a drug/lipid ratio of 1:20, which significantly improved drug loading 
efficiency compared to the previous PX-loaded lipid NPs with the loading efficiency of 70%. 
In addition, the PX-Chol-incorporated NPs exhibited excellent colloidal stability. The most 
successful PX-fatty acid prodrug is docosahexaenoic acid-PX (DHA-PX) conjugate, which 
currently is in phase III clinical trials [296]. DHA (22 carbon chain) is found in human milk 
and is known to be essential nutrition for brain development. DHA was linked to PX through 
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an ester bond on its C-2’ position. The DHA-PX conjugate did not have microtubule 
assembly activity and was non-toxic. It converted to active PX form when metabolized by 
esterases in the body. Therefore, the conjugate prolonged the exposure of PX and reduced 
the peak concentration, which allowed the administration of 4.4-fold higher doses of DHA-
PX conjugate over that of PX alone in mice. In an M109 mouse tumor model, the tumor 
AUCs of PX from DHA-PX conjugate were 1.71- and 5.79-fold higher than those of PX when 
intravenously injected into mice at equimolar and equitoxic doses, respectively [297, 298]. It 
should be noted that DHA-PX is still formulated in Cremophor EL and ethanol, and this 
DHA-PX conjugate is beyond the scope of this review which is focused on PX nano-
medicine delivery systems. 
2.3.5   Emulsions 
TOCOSOL™ is emulsion formulation consisting of vitamin E, TPGS, and poloxamer 
407. In this formulation, PX was formulated in an o/w microemulsion with the particle size of 
100 nm and high drug loading of 10 mg/mL. TOCOSOL™ completely eliminated Cremophor 
EL and ethanol in Taxol formulation, and without any modification of PX molecular structure. 
In preclinical studies, TOCOSOL™ showed much better tolerance and significantly improved 
antitumor efficacy compared to Taxol in both B16 and HCT-15 tumor-bearing mouse 
models. After intravenous injection of TOCOSOL™ at the dose of 10 mg/kg to mice 
implanted with B16 cells, tumor AUC was 2.2-fold higher than that of Taxol, although plasma 
AUC was comparable. The phase I clinical studies confirmed that TOCOSOL™ was well 
tolerated and less toxic than Taxol [299, 300]. However, all the phase III clinical trials of 
TOCOSOL™ were closed due to its comparable objective response rate to Taxol in women 
with metastatic breast cancer. 
Kan et al. [301] optimized PX in an o/w emulsion with an oil blend (tributyrin, 
tricaproin, and tricaprylin), egg phosphatidylcholine (EPC), Tween 80, and glycerol. The 
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particle size of the NPs was ~150 nm with a drug entrapment efficiency of 95%. This 
emulsion formulation remarkably increased the life span of mice compared to Taxol in an 
intraperitoneal S-180 tumor-bearing mouse model. Nornoo and Chow [302, 303] developed 
two microemulsion systems of LBMW (lecithin:butanol:myvacet:water) and CMW 
(capmul:myvacet:water) as the carriers for PX delivery. Compared to Taxol, the release of 
PX was extended by 25% and 50% in LBMW and CMW formulations, respectively. In in-vivo 
pharmacokinetic studies in Sprague-Dawley rats, LBMW and CMW prolonged by 5- and 2-
fold the circulation time of PX in blood, and 8- and 3-fold higher plasma AUC, respectively, 
over that of Taxol.  
2.4    Drug-Polymer Conjugates 
Poly(amidoamine) (PAMAM) dendrimer-based PX conjugates were designed and 
synthesized. Khandare et al. [304] prepared PAMAM dendrimer-succinic acid-PX conjugate 
and showed that the cytotoxicity of the conjugate was 10-fold higher than that of free 
unconjugated drug in A2780 human ovarian carcinoma cells. Multifunctional PAMAM 
dendrimer was also engineered. The functional molecules of fluorescein isothiocyanate 
(FITC, an imaging agent), folic acid, and PX were conjugated to PAMAM dendrimer. This 
conjugate was evaluated and confirmed to have both targeted chemotherapeutic and 
imaging functions to cancer cells in-vitro [305]. 
Wang et al. [306] synthesized a series heparin-PX conjugates with various single 
amino acid spacers, namely, valine, leucine, and phenylalanine. All the three conjugates 
exhibited greater cytotoxicity than that of free PX in MCF-7 cells. The hydrolysis properties 
of the conjugates in physiological and plasma conditions were different and the fastest 
hydrolysis was observed using leucine as the spacer. This heparin-PX conjugate with 
leucine spacer had similar antitumor efficacy compared to Taxol at a dose of 30 mg PX/kg in 
an SKOV3 mouse model. Similarly, hyaluronic acid was utilized as the carrier to conjugate 
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with PX. Different amino acids as the spacers were applied, such as valine, leucine, and 
phenylalanine. The conjugates exhibited increased cytotoxicity compared to free PX in 
MCF-7 cells [307]. A ternary conjugate of heparin-folic acid-PX was synthesized for further 
targeting purposes. This conjugate proved to selectively recognize folate receptor positive 
KB-3-1 cells and remarkably enhanced tumor inhibitory activity in a subcutaneous KB-3-1 
xenograft model [308]. 
Yu group [309-311] developed a novel poly(L-γ-glutamyl-glutamine)-PX (PGG-PX) 
conjugate. Interestingly, this conjugate self-assembled into NPs with the particle size of 12-
15 nm. The formulation had low toxicity in mice and its in-vivo antitumor activity was superior 
to Abraxane in multiple tumor models. Later, a more complex targeted PGG-PX-PEG-RGD 
conjugate was synthesized to further improve the therapeutic index [312].  
An HPMA-copolymer-PX conjugate (PNU 166945) was developed by covalent 
bonding of PX at its 2’-OH position with an enzymatic degradable tetrapeptide linker of Gly-
Phe-Leu-Gly. The polymer/PX ratio was about 19/1 (w/w). It was the first polymer-PX 
conjugate that entered phase I clinical trials. In the phase I studies, PNU 166945 was 
administered by 1 h infusion every 3 weeks to a small patient cohort of 12 patients. One 
patient had a partial response with advanced breast cancer. However, PNU 166945 
demonstrated neurotoxicity and because of that the clinical studies were discontinued [313].  
The most promising polymer-PX conjugate to date is undoubtedly the poly(L-glutamic 
acid)-PX conjugate (PG-PX, CT-2103), where PG is conjugated to 2’-OH position of PX via 
an ester linkage. The conjugate showed significantly better antitumor efficacy compared to 
Taxol in several tumor-bearing mouse models, and in some cases it completely eliminated 
tumors. In addition, the MTD and tumor uptake of CT-2013 were about 2- and 5-fold higher 
than Taxol, respectively, and prolonged circulation time was also observed in mouse tumor 
models. Currently, CT-2103 is in phase III clinical trials [314, 315]. 
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2.5    Inorganic Nanoparticles 
2.5.1   Gold Nanoparticles 
Gibson et al. [316] covalently attached PX with a hexaethylene glycol linker to phenol-
terminated gold NPs. Thermogravimetric analysis indicated there was about 70 PX 
molecules per 1 gold NP. The NPs were characterized by various traditional analytical 
techniques, such as NMR, TEM, SEC, and concluded that the PX-coated gold NPs were 
able to be engineered in a controlled manner and this offered an alternative platform for PX 
delivery. Oh et al. [317] described a novel PX-loaded Gold/Chitosan/Pluronic NP system. To 
prepare the modified gold NPs, PX was first dissolved in Tween 80 and this PX/Tween 80 
was then dispersed into placebo gold NPs. Next, chitosan was introduced to the mixture to 
form PX-loaded Gold/Chitosan NPs via ionic interaction. The Gold/Chitosan NPs were then 
freeze-dried with Pluronic F127 to obtain powders. The results showed that PX was 
released up to 90% from NPs over a 12-day period with a minimum initial burst release. 
Therefore, PX-loaded gold NPs may serve as an effective nanomedicine for better cancer 
therapy. Heo and co-workers [318] described a complex PX-functionalized gold NP system 
with PEG, biotin, and rhodamine B-linked β-CD. In the system, PEG served as an anti-
fouling shell, biotin as a targeting ligand, rhodamine B as a fluorescent marker, β-CD as the 
carrier for both PX and rhodamine B. The PX-loaded gold NP demonstrated more potent 
cytotoxicity in cancer cell lines of HeLa, A549, and MG63 than the normal NIH3T3 cells, 
which indicated its potential use in cancer treatment. 
2.5.2   Magnetic Nanoparticles (MNPs) 
Hua et al. [319] designed poly[aniline-co-sodium N-(1-one-butyric acid) aniline] 
(SPAnNa) coated Fe3O4 MNPs. PX was immobilized onto the surface of MNPs to form 
SPAnNa/MNPs-bound-PX (bound-PX). The drug loading achieved up to 302.75 µg per mg 
of SPAnNa/MNPs. The bound-PX demonstrated higher stability than free PX at 37°C (half-
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life of 57 vs. 19 h). Importantly, this bound-PX exhibited more potent toxicity compared to 
free PX in both PC3 and CWR22R prostate cancer cells. Moreover, the cell inhibition activity 
was even enhanced when a magnetic field was applied. All together, these results indicated 
that this magnetic delivery system had the potential to treat prostate cancer. Hwu and co-
workers [320] developed PX-containing Fe-MNPs. The aqueous solubility of PX in PX-Fe-
MNPs increased 780-fold (312 vs. 0.4 µg/mL). The beauty of the design was that 
phosphodiester moiety was incorporated as the linker of PX. Since dephosphorylation took 
place easier in tumor cells, PX was able to be released from NPs once the NPs reached the 
tumor site. This was confirmed by the fact that 91% free PX was hydrolyzed and released 
from NPs after 10 days. In-vitro cytotoxicity studies were conducted in both human cancer 
OECM1 cells and human normal HUVEC cells. It was found that PX-Fe-MNPs were 14,050-
fold more toxic in cancer cells than human normal cells (IC50 of 5.03 × 10-7 vs. 3.58 × 10-3 
µg/mL).  
2.6    Others 
2.6.1   Carbon Nanotubes (CNTs) 
Liu et al. [321] conjugated PX to branched PEG on single-walled carbon nanotubes to 
form water-soluble CNTs. This PX-loaded PEG-functionalized CNT exhibited excellent 
stability and PX was released from nanotubes by esterases present in the body. The 
formulation demonstrated significantly improved antitumor activity compared to Taxol at the 
dose of 5 mg/kg in a 4T1 breast cancer mouse model, which was supported by the 
prolonged circulation time in blood and 10-fold enhanced tumor uptake. Similarly, Lay and 
co-workers [322] loaded PX on the surface of PEG-functionalized single- or multiple-walled 
CNTs. The drug loading was 26% and 36% (w/w) for single- and multiple-walled CNTs, 
respectively. In-vitro cytotoxicity studies in HeLa and MCF-7 cells showed both PX-loaded 
CNTs significantly increased cell death compared to free PX while the placebo CNTs were 
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non-toxic. Recently Sobhani et al. [323] functionalized multiple-walled CNTs using 
hyperbranched poly citric acid and conjugated PX on the CNTs. The drug loading was about 
38% (w/w). This formulation was more toxic than Taxol in both A549 and SKOV3 cells while 
the blank CNTs had a negligible effect.  
2.6.2   Nanocrystals 
Huang group [324] developed a PX nanocrystal formulation using TPGS as the sole 
excipient. The utilization of TPGS in the formulation was to stabilize PX nanocrystals as well 
as reverse MDR. The average particle size of nanocrystals was 40 × 150 nm. The 
nanocrystals exhibited slower and sustained release than Taxol, and enhanced in-vitro 
cytotoxicity and in-vivo antitumor efficacy in resistant NCI/ADR-RES tumor models. 
PX/Pluronic F127 nanocrystals were also engineered and reported. The drug loading and 
entrapment efficiency were high and this formulation demonstrated significantly tumor 
growth inhibition activity in both human lung cancer and murine breast cancer mouse 
models [325]. Interestingly, it was found that the micellization of pluronic F127 enhanced at 
elevated temperature, which was because the critical micelle concentration (CMC) of 
pluronic F127 decreased at higher temperature. Therefore, the increased temperature 
during preparation procedure may provide better stability of nanocrystals [326]. 
2.6.3   Cyclodextrin (CD) Nanoparticles 
Zhang et al. [327] synthesized a CD-functionalized hyperbranched polyglycerol (HPG) 
as the carrier for PX delivery. The HPG-g-CD self-assembled micelles in water with the 
particle size of 200-300 nm. PX-loaded HPG-g-CD had high drug loading (~8%, w/w) and 
entrapment efficiency (82-88%), and slow and sustained release profile. A β-CD derivative, 
heptakis (6-O-hexanoyl)cyclomaltoheptaose-β-CD (6-O-CAPRO-β-CD) was synthesized to 
stabilize PX NPs with high drug loading and reduce the burst release. Since the carrier of 6-
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O-CAPRO-β-CD demonstrated low hemolysis and cytotoxicity, it may serve as an 
alternative formulation for current Taxol [328-330]. 
2.6.4   Nanogel 
Lee et al. [331] developed PX-loaded injectable in-situ-forming gel with mPEG-PCL 
diblock copolymer. The formulation was in a liquid state at room temperature but rapidly 
formed gel at body temperature. PX in the gel was released in a sustained manner for more 
than 2 weeks in-vitro. This PX injectable depot had significantly improved antitumor efficacy 
compared to Taxol, saline (control), and placebo gel in a B16F10 tumor-bearing mouse 
model upon intratumoral injection. OncoGel is a PX injectable depot developed by 
MacroMed Inc (Sandy, Utah) for local tumor treatment. The gel was composed of the 
thermosensitive triblock copolymer of PLGA-PEG-PLGA, which transformed to a water-
insoluble hydrogel at body temperature. It had sustained release properties for up to 6 
weeks upon injection. OncoGel was proven to be safe and reduced systemic exposure of 
PX because PX concentration in plasma was negligible after single injection into solid tumor 
site. Currently, it is in phase II clinical trials [332, 333].  
2.6.5   ANG 1005 
ANG 1005 is a PX-peptide conjugate, which consists of three PX molecules coupled 
to one molecule of a novel peptide, Angiopep-2. Angiopep-2 is a 19 amino-acid peptide 
which targets low-density lipoprotein receptor-related protein 1 (LRP1) receptor to facilitate 
PX to across BBB for the treatment of brain disease. In preclinical studies, ANG 1005 
demonstrated better antitumor efficacy and increased survival time in several tumor-bearing 
mouse models. Curently, it is in phase II clinical trials [334, 335].  
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2.7    Conclusion and Future Perspective 
PX is one of the most effective anticancer drugs to ever be developed. It is active 
against a broad range of cancers. However, the current Taxol formulations have issues 
related with Cremophor EL and ethanol. Since nano-delivery systems could improve the 
aqueous solubility of hydrophobic drugs and generally exhibit lower toxicity, they are 
promising carriers to improve the therapeutic index and decrease the side effects of PX. To 
date, the PX albumin-bound NPs (Abraxane®) have been approved by the FDA for the 
treatment of metastatic breast cancer, and there are a number of novel PX NP formulations 
in clinical trials (Table 2.4). Some of them have demonstrated certain advantages in terms of 
toxicity, such as lower incidence of hypersensitivity reactions, myelosuppression. However, 
whether these novel formulations may improve survival is largely unknown.  
It has been established that nano-delivery systems are feasible in cancer therapy due 
to the EPR effect and escape from RES recognition. Since tumor leakage is cancer-type 
dependent, nano-delivery systems with particle sizes below 40 nm are desirable to have 
better chance to be passively targeted into tumors. In the meanwhile, the search for new 
tumor targeting ligands will further improve antitumor efficacy while decreasing toxicity to 
normal tissues. Safety is a major concern of these nano-materials and the long-term toxicity 
in human body must be investigated. In regard to this mandate, biodegradable and 
biocompatible polymers are less toxic and have a better opportunity. Furthermore, nano-
delivery systems should be fully characterized both in-vitro and in-vivo by using traditional or 
emerging advanced analytical techniques. 
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Table 2.1 Summary of PX-loaded polymeric NPs. 
Polymer Modification NP Preparation Method % EE Status Ref. 
PLGA 
― emulsion-solvent evaporation 85 in-vitro [163] 
PLGA , PLGA-PEG, 
PCL-PEG nanoprecipitation 70 in-vivo [164] 
Poloxamer 188 interfacial deposition > 90 in-vitro [165] 
TPGS (emulsifier) emulsion-solvent evaporation 100 in-vitro [173] 
DLPC (emulsifier) emulsion-solvent evaporation 15-56 in-vitro [177] 
DPPC (emulsifier) emulsion-solvent evaporation 34-45 in-vitro [178] 
chitosan emulsion-solvent evaporation 75-79 in-vitro [168] 
DMAB emulsion-solvent evaporation 47 in-vivo [170] 
MMT emulsion-solvent evaporation ~50 in-vitro [179] 
MMT 
HER2 (targeting) emulsion-solvent evaporation ~50 in-vitro [180] 
RGD (targeting) emulsion-solvent evaporation 60-65 in-vivo [181] 
pluronic P85 
transferrin (targeting) nanoprecipitation 70-76 in-vivo [182] 
PCL 
PEO-PCL solvent displacement > 95 in-vivo [212, 213] 
PCL-pluronic F68 emulsion-solvent evaporation 84 in-vivo [221] 
PCL-pluronic F68 
DMAB modified solvent displacement 76-88 in-vivo [336] 
mPEG-PCL 
Angiopep (targeting) emulsion and evaporation 90 in-vivo [216, 217] 
mPEG-PCL solid dispersion  98 in-vivo [218] 
PVP-b-PCL modified nanoprecipitation 85 in-vivo [222] 
PEG-PCL co-solvent extraction ― in-vivo [215] 
PEG-PCL 
folic acid (targeting) dialysis ― in-vitro [219] 
PCL-g-PVA dialysis ― in-vitro [223] 
PEtOz-PCL dialysis 5-76 in-vitro [224] 
PCL-PEEP 
galactosamine 
(targeting) 
dialysis ― in-vitro [225] 
mPEG-PCL-PPEEA emulsion-solvent evaporation > 90 in-vivo [226] 
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Table 2.1 (continued) 
Polymer Modification NP Preparation Method % EE Status Ref. 
PLA 
PLA-PEG (diblock) thin film 65 in-vivo [198] 
PLA-PEO (star-branch) solvent evaporation 6-56 in-vitro [197] 
PVA-PEG solvent evaporation 20-62 in-vitro [199] 
poly(γ-glutamic acid)   
galactosamine 
(targeting) 
solvent evaporation 50-54 in-vivo [200] 
PLA-PEG-PLA 
PEG-PLA-PEG solvent evaporation 14-31 in-vivo [201, 202] 
Chitosan 
cholanic acid dialysis 92 in-vivo [227, 337] 
oligomer dialysis 97 in-vivo [228] 
glyceryl monooleate emulsion-solvent evaporation 98-100 in-vitro [229] 
mPEG, cholesterol dialysis 70 in-vivo [230] 
N-acetyl histidine ― ― In-vitro [231] 
stearic acid, 
glutaraldehyde ultrasonication 94-99 In-vitro [232] 
Gelatin ― desolvation > 80 in-vivo [257-260] 
HA 
― desolvation 90 in-vivo [243] 
oligomer dialysis ― in-vitro [244] 
PBCA 
pluronic F127 miniemulsion 80 in-vitro [246] 
chitosan dialysis 90 in-vivo [247] 
surfactants (dextran 70, 
cholesterol, PVA, and 
lecithin) 
polymerization 60-80 in-vitro [248] 
Albumin 
― 
high-pressure 
homogenization ― approved [236] 
CREKA and LyP-1 
peptides (targeting) ― ― in-vivo [239] 
folic acid (targeting) desolvation 95 in-vitro [240] 
octaldehyde dialysis 90 in-vitro [241] 
HPG PEG, PEI solvent evaporation ― in-vivo [250] 
PEG-PE EPC, solid triglycerides, 
cationic Lipofectin lipids solvent evaporation ~100% in-vivo [251-254] 
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Table 2.2 Summary of PX-loaded lipid-based NPs. 
 
Platform Composition % EE 
Particle 
Size 
(nm)  
Status Ref. 
Liposomes 
phosphatidylcholine, cholesterol, 
cardiolipin > 90 ~150 in-vitro [264] 
HSPC, cholesterol, PEG-DSPE ― ~100 in-vivo [265] 
phosphatidylglycerol,  
phosphatidylcholine ―  200, 900 in-vivo [266] 
Solid Lipid 
Nanoparticles 
tripalmitin, Epikuron 20, butanol, 
Na-taurocholate, cholesteryl 
hemisuccinate 
― 160 in-vitro [269] 
stearic acid, lecithin, Brij 78  
(or pluronic F68 and DSPE-PEG) 58-75 100-220 in-vivo [270] 
trimyristin, EPC, PEG2000-PE 72-89 200-250 in-vivo [271, 272] 
glyceryl palmitostearate (or glyceryl 
monostearate), poloxamer 407 55-90 ~200 in-vitro [275, 276] 
Lipoid S 100  
sucrose fatty acid esters 89-92 150-190 in-vitro [277] 
stearylamine, soya lecithin, 
poloxamer 188 75 70-130 in-vivo [273] 
monostearin, stearic acid,  
glycerol tristearate, ATO 888 36-76 160-260 in-vitro [274] 
emulsifying wax, Brij 78 ~50 < 100 in-vivo [278, 279] 
glyceryl tridodecanoate, Brij 78 > 85 170 in-vitro [125, 280] 
Lipid 
Nanocapsules 
Labrafac®, Lipoïd® S75-3,  
Solutol® HS15 ― ~50 in-vivo [281-283] 
Captex® 8000, Lipoïd® S75-3, 
Solutol® HS15 93 ~50 in-vivo [284-287] 
Miglyol 812, Brij 78, TPGS 85-97 ~200 in-vivo [125, 280] 
PLGA, lecithin, DSPE-PEG2000, 
DSPC, RGD (targeting)   82 68 in-vivo [288, 289] 
Lipiodol, PEO-PPO-PEO, 
functionalized PEG,  
folic acid (targeting) 
46 110 in-vivo [290] 
lecithin, Dynasan 118, Miglyol 812, 
folate-PEG-PE, Span 60 (or PEG-PE) 98 207 in-vivo [291] 
Emulsions 
vitamin E, TPGS, poloxamer 407 ― 100 phase I/II [299] 
oil blend, EPC, Tween 80, glycerol > 95 150 in-vivo [301] 
lecithin, butanol, myvacet 
(or capmul, myvacet) ― ~110 in-vivo [302, 303] 
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Table 2.3 Summary of PX-polymer conjugates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymer Linker/Spacer Status Ref. 
PAMAM 
ester/succinic acid in-vitro [304] 
ester/FITC-folic acid in-vitro [305] 
Heparin 
ester/valine, leucine, phenylalanine in-vivo [306] 
ester/folic acid in-vivo [308] 
PGG 
ester in-vivo [309-311] 
ester/PEG-RGD in-vitro [312] 
HA ester/valine, leucine, phenylalanine in-vitro [307] 
HPMA ester/Gly-Phe-Leu-Gly phase I/discontinued [313] 
PG ester phase III [314, 315] 
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Table 2.4 Summary of PX-loaded NPs in clinical development. 
   
 
 
Name Delivery Strategy Company Clinical Stage 
NK 105 polymeric micelle NanoCarrier phase II 
CT-2103 polymeric conjugate Cell Therapeutics phase III 
Abraxane protein-bound particle Abraxis Bioscience (now Celgene) approved 
Genexol-PM polymeric micelle Samyang phase III 
ANG 1005 peptide-bound conjugate Angiochem phase II 
EndoTag cationic liposome MediGene phase II 
PNU166945 polymeric conjugate Pfizer phase I/discontinued 
Tocosol emulsion Sonus Pharmaceuticals phase III/discontinued 
Paxceed polymeric micelle Angiotech Pharmaceuticals phase II 
LEP-ETU liposome NeoPharm phase I 
OncoGel gel Protherics phase II 
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Figure 2.1 Chemical structure of PX. 
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Figure 2.2 Schematic summary of different 
 
CD: cyclodextrin; CNT: carbon 
hyperbranched polyglycerol; 
nanoparticle; NC: nanocapsule; 
poly(butyl cyanoacrylate); PCL: 
poly(L-γ-glutamyl-glutamine)
solid lipid nanoparticle. 
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investigated PX nano-delivery systems.
nanotubes; FA: fatty acid; HA: hyaluronic acid
HPMA: N-(2-hydroxypropyl)methacrylamide; MNP: 
NP: nanoparticle; PAMAM: poly(amidoamine); PBCA: 
poly(ε-caprolactone); PG: poly(L-glutamic acid)
; PLA: poly(lactide); PLGA: poly(lactic-co-glycolic acid); 
 
; HPG: 
magnetic 
; PGG: 
SLN: 
  
Chapter III 
 
Development of Idarubicin and Doxorubicin Solid Lipid Nanoparticle Formulations 
to Overcome P-gp-Mediated Resistance in Leukemia 
 
3.1    Summary 
The objectives of these studies were to investigate and compare solid lipid 
nanoparticles (SLNs) of two anthracyclines, idarubicin (IDA) and doxorubicin (DOX), against 
P-gp-mediated multiple drug resistance (MDR) in-vitro and in-vivo using different human and 
murine cancer cell models. IDA and DOX SLNs were developed from warm microemulsion 
precursors comprising emulsifying wax as the oil phase, and polyoxyl 20-stearyl ether (Brij 
78) and D-alpha-tocopheryl polyethylene glycol succinate (TPGS) as the surfactants. 
Anionic ion-pairing agents, sodium taurodeoxycholate (STDC) and sodium tetradecyl sulfate 
(STS), were used to neutralize the charges of the cationic anthracyclines and enhance 
entrapment of the drugs in the SLN. The in-vitro cytotoxicity results showed that the IC50 
value of DOX NPs was 9-fold lower than that of free DOX solution in resistant P388/ADR 
cell line. In contrast, free IDA had comparable IC50 values as IDA NPs in P-gp-
overexpressing P388/ADR and HCT-15 cells. In the in-vivo P388/ADR leukemia mouse 
model, the median survival time of DOX NPs was significantly greater than that of free DOX 
and controls. In contrast, free IDA was equally as effective as IDA NPs in P388 and P-gp- 
 
P. Ma, X. Dong, C.L. Swadley, A. Gupte, M. Leggas, H.C. Ledebur, and R.J. Mumper, 
“Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-
mediated multiple drug resistance in leukemia.” Journal of Biomedical Nanotechnology, 
2009 5(2):151-161. 
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overexpressing HCT-15 mouse tumor models. The cell uptake of IDA formulated as free IDA 
and IDA NPs was comparable in P-gp-overexpressing cells. In conclusion, DOX NPs could 
overcome P-gp-mediated MDR both in-vitro in P388/ADR leukemia cells and in-vivo in the 
murine leukemia mouse model. The present study suggests that the SLNs may offer 
potential to deliver anticancer drugs for the treatment of P-gp-mediated MDR in leukemia; 
however, selection of target drug may be very important. 
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3.2    Introduction 
Anthracyclines rank among the most effective anticancer drugs ever developed [5]. 
The cytotoxicity of anthracyclines is generally due to their ability to diffuse across the cell 
membrane, intercalate between DNA base pairs, and target topoisomerase II [7]. 
Doxorubicin (DOX, Figure 1.1) is one of the oldest anthracyclines and is commonly used to 
treat leukemia, Hodgkin’s lymphoma, bladder and breast cancers. Idarubicin (IDA, 4-
demethoxydaunorubicin, Figure 1.1), a synthetic analog of daunorubicin (DNR), was 
approved by the US FDA in 1990. It is mainly used to treat acute myelogenous leukemia 
(AML) and chronic lymphocytic leukemia (CLL) [338]. The absence of the methoxy group at 
position 4 of IDA results in significantly enhanced lipophilicity [339], which results in faster 
cellular uptake, superior DNA-binding capacity, and consequently greater cytotoxicity 
compared to DOX and DNR. 
After initial treatment with anthracyclines, many patients achieve a complete 
remission; however, about 70% of the patients eventually experience a relapse of the 
disease. A major cause of treatment failure in patients with leukemia is the development of 
multiple drug resistance (MDR). Different MDR mechanisms have been characterized [340]. 
P-glycoprotein (P-gp), a membrane transporter encoded by the MDR1 gene, is responsible 
for the efflux of anthracyclines used in the treatment of leukemia. Goasguen et al. [341] 
reported the correlation of complete remission, relapse rate and lymphoblast P-gp 
expression in a study involving 23 adult patients with acute lymphoblastic leukemia (ALL). In 
this study, complete remission was achieved in 5/9 P-gp+ patients compared to 13/14 of P-
gp- patients (56 vs. 93%). During the follow-up period, relapse occurred in all P-gp+ patients 
that had initially shown complete remission compared to 6/13 P-gp- patients (100 vs. 46%), 
which indicated that the presence of a critical level of functional P-gp in leukemic 
lymphoblasts was potentially an important determinant of response to chemotherapy 
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treatment. To overcome P-gp-mediated MDR in leukemia, various P-gp inhibitors, such as 
quinine, cyclosporine A, and PSC 833, have been developed and co-administered with 
anticancer agents [342-344]. This approach resulted in significant improvement in 
anthracycline tumor therapy. However, the co-administration of P-gp inhibitors with 
anticancer drugs often results in enhanced drug toxicity due to the non-specific inhibition of 
P-gp that leads to alteration of drug elimination pathways, e.g. in liver or kidney [279]. 
The use of small particle delivery systems, such as liposomes and nanoparticles 
(NPs), has been shown experimentally to improve cancer treatment as carriers of 
conventional chemotherapeutic agents [345]. The utility of nano-scale delivery systems is 
based on their potential to enhance drug delivery into tumor tissues (e.g. EPR effect), while 
minimizing systemic exposure and thus enhancing drug efficacy and reducing non-specific 
toxicity. These colloidal delivery systems have also been shown to increase the circulation 
time of drugs in the blood, thereby increasing the ability of drugs to reach their sites of 
action. The efficacy of these systems has been reported utilizing numerous anticancer drugs 
including paclitaxel [346], tamoxifen [347], and anthracyclines [348]. For example, Gian and 
colleagues [349] developed IDA SLNs and determined the pharmacokinetics after duodenal 
administration in rats. The authors found that duodenally administered SLNs significantly 
increased IDA exposure, where the area under the curve (AUC) of concentration versus 
time profiles and the elimination half-life of IDA SLNs was 21- and 30-fold higher, 
respectively, as compared to a solution of free IDA. 
SLNs have attracted increasing attention during recent years. The major advantages 
of these SLNs include high drug loading and entrapment efficiency, improved drug stability, 
and potential biocompatibility since the SLNs use lipids [350]. Due to the fact that many 
anthracyclines have cationic moieties, counter-ions have been employed to facilitate the 
entrapment of the drug in SLNs. The Gasco group [351] showed that either decyl phosphate 
or hexadecyl phosphate could form ion-pairs with DOX or IDA in SLNs containing stearic 
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acid and egg lecithin. The resulting ion-pair complexes increased the lipophilicity of IDA and 
DOX, which resulted in an increase in the apparent partition coefficient between stearic acid 
and water. SLNs containing these lipophilic ion-pairs carried payloads of DOX and IDA at up 
to 7% and 8.4% (w/w), respectively. Similarly, an anionic hydrolyzed polymer of epoxidized 
soybean oil (HPESO) was used by Wong and co-workers [128] to complex with cationic 
DOX. The resulting complex was then dispersed together with a lipid to form DOX SLNs. 
The overall goals of the present studies were: 1) to investigate and compare IDA 
SLNs and DOX SLNs against P-gp-mediated MDR in-vitro and in-vivo; and 2) to test the 
feasibility of the SLNs as potential drug carriers for MDR-related cancer therapy. Based on 
previous research work in our laboratory and literature search, it was hypothesized that: 1) 
negatively charged lipids and/or polymers could form ion-pair complex with IDA and DOX, 
where they not only neutralize cationic charge of drugs but also increase drug lipophilicity; 2) 
The ion-pair complex could be encapsulated in our lipid-based NPs and should be stable; 3) 
IDA and DOX lipid-based NP formulations will overcome P-gp-mediated resistance both in-
vitro and in-vivo. To evaluate the above hypotheses, different counter-ions were employed 
to ion-pair with IDA or DOX and together incorporated into SLN formulations. IDA and DOX 
SLNs were then engineered from warm microemulsion precursors. The SLN formulations 
versus free drug solutions were tested in different mouse and human sensitive and P-gp-
overexpressing cell lines in-vitro, as well as in-vivo in NCr-nu/nu and CD2F1 mouse models. 
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3.3    Materials and Methods 
Materials 
Idarubicin hydrochloride was obtained from Synbias Pharma Ltd (Donetsk, Ukraine). 
Doxorubicin hydrochloride, sodium taurodeoxycholate (STDC, > 97% pure), dextran sulfate 
sodium (DS, MWs approx. 5,000 and 8,000), and protease inhibitor cocktail were purchased 
from Sigma (St. Louis, MO, USA). Emulsifying wax (E-wax), and sodium tetradecyl sulfate 
(STS) were from Spectrum Chemicals (New Brunswick, NJ, USA). Polyoxyl 20-stearyl ether 
(Brij 78) was obtained from Uniqema (Wilmington, DE, USA). DSPE-PEG3000 (25 mg/mL in 
chloroform) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). RIPA buffer 
(containing 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS), and the bicinchoninic acid protein assay kit were from Thermo Scientific 
(Rockford, IL, USA). Mouse monoclonal antibody Mdr-1 (D-11), β-actin mouse monoclonal 
antibody, and goat anti-mouse IgG-HRP were bought from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). TPGS was generously provided by Eastman Chemical Co. 
(Kingsport, TN, USA). Dextran sulfate sodium (MW approx. 2,500) was obtained from ABCR 
GmbH & Co. (Karlsruhe, Germany).  
Human colorectal carcinoma cell line HCT-15, human breast cancer cell line MDA-
MB-468, and human promyelocytic leukemia cell line HL-60 were purchased from ATCC 
(Manassas, VA, USA). The resistant cell lines of HL-60/VCR and HL-60/ADR were kindly 
provided by Dr. Maria R. Baer (Roswell Park Cancer Institute, Buffalo, NY, USA). Murine 
leukemia P388 and P388/ADR cell lines were obtained from the NCI (Frederick, MD, USA). 
The MDA-MB-468 cell line was maintained in DMEM and all the other cell lines were 
cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine 
serum (FBS) (ATCC, Manassas, VA, USA) and antibiotics at 37°C in 5% CO 2 humidified 
atmosphere. 
80 
 
Preparation of IDA or DOX Ion-Pair Complex 
To neutralize the charges of cationic anthracyclines and enhance drug entrapment, an 
ion-pair complex was prepared using a co-precipitation method. STDC, dextran sulfate 
sodium (MWs approx. 2,500, 5,000, and 8,000), and STS were investigated as potential 
counter-ions. The amount of IDA or DOX used was calculated as the base form throughout 
the experiments. One hundred (100) µL of 1 mg/mL IDA or DOX in water was aliquoted into 
a series of 1.5 mL centrifuge tubes, and then 100 µL of different concentrations of ion-
pairing aqueous solution was added to the tubes. The tubes were shaken for 5 min with the 
speed of 40 rpm, and centrifuged for another 5 min with the speed of 1,530 g. The 
concentrations of IDA or DOX in the supernatant were determined using Beckman DU 800 
UV/Visible spectrophotometer based on the standard calibration curves (Figure 3.1). The 
percentage of the drug ion-paired with counter-ions was calculated as follows: 
% of the drug ion-paired with counter-ions = [100% - (% drug in supernatant)] (w/w)     
(Equation 3.1) 
Preparation of NPs from Microemulsion Precursors 
Microemulsion precursors were prepared as reported by Mumper et al. [352]. Briefly, 2 
mg of E-wax as the oil phase, 2.3 mg of Brij 78, and 3.0 mg of TPGS as the surfactants 
were accurately weighed out into a 7 mL glass vial. The vial was heated to 65oC to melt the 
oil and surfactants while stirring. The IDA or DOX ion-pair complex precipitate was dissolved 
in ethanol and transferred to the vial containing the oil and surfactant mixture. Residual 
ethanol was evaporated under a stream of nitrogen gas, and then preheated deionized 
water was added to obtain a final volume of 1 mL. Oil-in-water microemulsions formed 
spontaneously at this elevated temperature. Upon direct cooling of the warm 
microemulsions to room temperature, clear SLN suspensions were formed. Polyethylene 
glycol coated NPs (PEG NPs) were also engineered as described above, except that 16 µL 
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of a DSPE-PEG3000 stock solution in water (10 mg/mL) was added to the vial 5 min before 
cooling. Blank NPs were prepared in the same manner except that the IDA or DOX, and ion-
pairing agents were omitted. 
Characterization of NP Formulations  
Photon Correlation Spectroscopy 
The average particle size and polydispersity index (PI) of IDA or DOX NPs were 
determined by photon correlation spectroscopy (PCS) using a Coulter N5 Plus Sub-Micron 
Particle Sizer (Beckman Coulter, Miami, FL, USA) at a fixed angle of 90º and a temperature 
of 25ºC. Prior to size determination, NP suspensions were diluted in deionized water to 
ensure light scattering intensity within the required range of the instrument (5 × 104 to 1 × 
106 counts/s). Each sample was analyzed in triplicate. 
Zeta Potential Determination 
To determine the zeta potential, NP samples were diluted 1:100 (v/v) with 10 mM PBS 
(pH 7.4) and placed in the dip cell of Zetasizer Nano Z (Malvern Instruments, Westborough, 
MA, USA). Each sample was analyzed in quintuplicate. 
% Entrapment of NPs 
To determine % entrapment of IDA or DOX in the NPs, Microcon Ultracel YM-100 
Centrifugal Filtration Devices (MW cut-off 100 kDa) (Millipore, Billerica, MA, USA) were 
used. A fixed volume (300 µL) of the drug NP formulations was added to a Microcon tube 
and spun at 14,000 g at 25oC for 30 min. The collected filtrate in the tube was labeled as 
‘free drug filtrate’. Then the filter apparatus was removed, inverted, and transferred to a new 
Microcon tube. Drug NPs were spun at 6,000 g at 25oC for 4 min and collected in this tube 
labeled as ‘drug in NPs’. Concentrations of IDA or DOX were determined using a Synergy 2 
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Multi-Detection Microplate Reader (BioTek, Winooski, VT, USA) at the wavelengths of 483 
and 487 nm, respectively. The % entrapment was calculated as follows:  
% entrapment = [(mass of drug in NPs) / (mass of drug added into NP formulations)] 
                              × 100% (w/w)                                                                  (Equation 3.2) 
Short-Term Stability of IDA NPs 
A short-term stability study of IDA-STDC and blank NPs was carried out for a 
continuous 15 days, and IDA-STS NPs for 7 days. All the NP formulations were stored at 
4ºC and the samples were taken out for particle size measurement at various time points. 
To mimic the physiological conditions, IDA-STDC and IDA-STS NPs were also incubated at 
37ºC in a water bath up to 50 h. The average particle size and PI were determined by PCS 
at different time points. 
Lyophilization of IDA NPs 
IDA-STS NPs were lyophilized using an AdVantage Freeze Dryer 2.0 liter XL (VirTis, 
Gardiner, NY, USA). Before lyophilization, IDA-STS NPs were prepared in 10% lactose 
solution, then dispensed into 5 mL amber glass vials and frozen at -80ºC for 1 h. The 
samples were lyophilized at 100 mTorr with the primary drying at -10°C for 7.5 h and the 
second drying at 25°C for another 7.5 h. After lyophi lization, the vials were sealed, wrapped 
with aluminum foil, and stored at 4ºC. Upon reconstitution, the resultant lyophilized products 
were reconstituted in 1.5 mL of deionized water and swirled to dissolve. The particle sizes, 
zeta potentials, pH values, osmotic pressures, and drug entrapment of IDA-STS NPs were 
measured and compared before and after lyophilization.  
Western Blot Analysis 
Cellular content of the Mdr-1/P-gp transporter molecule was detected by western blot 
analysis in P388, P388/ADR, and HCT-15 cell lines. Briefly, 107 cells were lysed in 0.3 mL 
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RIPA buffer, including protease inhibitor cocktail. The quantification of the protein content 
was performed with the bicinchoninic acid (BCA) protein assay kit. For immunoblotting, 40-
60 µg of total protein extract was mixed with Laemmli sample buffer (Bio-Rad Laboratories, 
Hercules, CA, USA) and transferred to a 10% polyacrylamide gel. Gel electrophoresis was 
performed with a Mini Protean® 3 Cell (Bio-Rad Laboratories, Hercules, CA, USA) applying 
100 V for 100 min. After electrophoresis, proteins were blotted to a PVDF membrane (100 V 
for 1 h) using a Mini Trans-Blot® Cell (Bio-Rad Laboratories, Hercules, CA, USA). The 
membrane was blocked for 1 h with PBS-T (phosphate buffered saline containing 0.05% 
Tween 20) with 5% nonfat milk. After washing three times with PBS-T, the membrane was 
incubated at 4ºC overnight with the primary mouse monoclonal antibody Mdr-1, diluted 
1:200 (v/v) in PBS-T with 5% nonfat milk. β-actin was used as a loading control by staining 
with β-actin mouse monoclonal antibody at a dilution of 1:2000 (v/v). After incubation with 
the first antibody, the membrane was washed with PBS-T three times and then incubated 
with the secondary goat anti-mouse IgG-HRP diluted 1:2000 (v/v) for 1 h at room 
temperature. The membrane was then washed, and P-gp and β-actin detection were 
performed with the ECL Detection VersaDoc™ Imaging System (Bio-Rad Laboratories, 
Hercules, CA, USA). The molecular weight was identified using the Precision Plus Protein™ 
Standard Dual Color (Bio-Rad Laboratories, Hercules, CA, USA). 
In-Vitro Cytotoxicity Assay 
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay was 
utilized to assess cytotoxicity of the NPs [348]. Viable cells were counted by trypan blue 
staining (> 90% cell viability for experiments) and seeded in 96-well plates at 8,000 cells/100 
µL growth medium. Serial dilutions of DOX or IDA formulations were added to the plate (100 
µL/well) at 37°C in 5% CO 2 for 48 h. The cells were then incubated with MTT stock solution 
(5 mg/mL in PBS; pH 7.4) at 37ºC for 4 h. Cell suspensions were spun down for 10 min at 
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1,000 g (this step was not required for adherent cell lines). The medium was then removed 
and the converted dye was solubilized with the addition of DMSO. The absorbance was 
measured using the Synergy 2 Multi-Detection Microplate Reader at 570 nm, and the 
concentration of drug that inhibited cell survival by 50% (IC50) was determined from cell 
survival plots. 
Cellular Uptake of Free IDA and IDA NPs  
Cellular uptake of free IDA and IDA NPs were performed in HL-60 and HL-60/VCR cell 
lines. Different dilutions of each test article were added to a 12-well plate (7.5 × 105 
cells/well). After 4 h incubation at 37°C in 5% CO 2, cells were transferred to 15 mL 
graduated tubes and centrifuged. The medium was then aspirated and replaced with fresh 
medium. Cell-associated fluorescence was read using the Synergy 2 Multi-Detection 
Microplate Reader at the excitation and emission wavelengths of 485 ± 20 and 545 ± 10 nm, 
respectively. 
Visualizing Cellular Uptake of IDA and DOX NPs 
MDA-MB-468 cells were first plated onto glass slides, then aliquots of free DOX or 
IDA, and their NPs (10 µL) were dispersed on glass slides and covered with coverslips. The 
cellular uptake of free drug and drug NPs was visualized with CytoViva Microscope System 
(Auburn, AL, USA) at room temperature. 
In-Vivo Animal Efficacy Studies 
Five-week-old male CD2F1 or six-week-old male athymic NCr-nu/nu mice from NCI-
Frederick Animal Production Area (Frederick, MD, USA) were used for the studies. All mice 
were on a 12-h light/dark cycle and sterilized rodent diet (Harlan-Teklad TD8656) ad libitum. 
The animal experiments complied with the rules set forth in the NIH Guide for the Care and 
85 
 
Use of Laboratory Animals. In total, three separate in-vivo studies were performed: the first 
two studies using IDA formulations and the third study using DOX formulations. 
Study 1: HCT-15 Human Colon Tumor Cells Implanted Subcutaneously to Treat with 
Free IDA and IDA-STS PEG NPs 
Male athymic nude mice subcutaneously (s.c.) implanted with 107 HCT-15 human 
colon tumor cells were treated with free IDA and IDA-STS PEG NPs. Study 1 consisted of a 
vehicle-treated control group (saline) having 10 mice, and 9 treatment groups with 10 mice 
each for a total of 100 mice. Free IDA and IDA-STS PEG NPs were administered 
intravenously (i.v.) at doses of 2.25, 1.5, 1.0, and 0.67 mg/kg/injection on a q4d × 3 
treatment schedule. Free DOX at the dose of 8.0 mg/kg/injection was applied as another 
treatment group. The mice weight and tumor sizes were measured twice per week starting 
from the first day of treatment. Tumor volume was measured by caliper and calculated as 
the following formula:  [½ × (tumor width)2 × (tumor length)] (Equation 3.3). This formula was 
also used to calculate tumor weight, assuming unit density of 1 mm3 equals 1 mg. 
Study 2: P388 Murine Leukemia Intravenously Implanted to Treat with Free IDA, IDA-
STS NPs, and IDA-STS PEG NPs 
Male CD2F1 mice intravenously (i.v.) implanted with 105 P388 murine leukemia cells 
were treated with free IDA, IDA-STS NPs and IDA-STS PEG NPs. The day of tumor cell 
inoculation was designated as Day 0 and the treatment started from Day 1 on a q4d × 3 
treatment schedule. Study 2 consisted of a vehicle-treated control group (saline) having 10 
mice, and 12 treatment groups with 6 mice each for a total of 82 mice. Free IDA, IDA-STS 
NPs and IDA-STS PEG NPs were each i.v. injected at doses of 2.25, 1.5, 1.0, and 0.67 
mg/kg/injection. The number of 36-day survivors, median day of death, and increase in life-
span (ILS) based on median day of death were recorded. The percentage of ILS was 
calculated as follows: 
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% ILS = [(median death day of a treatment group – median death day of the control group) /                     
(median death day of the control group)] × 100%                               (Equation 3.4)   
Study 3: P388/ADR Murine Leukemia Intraperitoneally Implanted to Treat with Free 
DOX, DOX-STS NPs, DOX-STS PEG NPs, and Blank NPs 
Male CD2F1 mice intraperitoneally (i.p) implanted 105 of P388/ADR murine leukemia 
cells were treated with free DOX, DOX-STS NPs, DOX-STS PEG NPs, and blank NPs. The 
day of tumor cell inoculation was designated as Day 0. The animals were randomly 
assigned to the various treatment groups on Day 1 after tumor implantation. The experiment 
consisted of a vehicle-treated control (saline) having 10 mice, and 12 treatment groups with 
6 mice each for a total of 82 mice at the start of treatment on Day 1. Free DOX, DOX NPs, 
DOX PEG NPs, and blank NPs were each injected i.p. at doses of 8.0, 5.3, and 3.5 
mg/kg/injection on a q4d × 3 treatment schedule. Doses were administered by exact body 
weight using an injection volume of 0.1 mL/10 g of body weight. The number of 25-day 
survivors, median day of death, and ILS based on median day of death were calculated.  
Statistical Analysis 
For the animal efficacy studies, statistical analysis was conducted using a life table 
analysis (stratified Kaplan-Meier estimation followed by the Mantel-Haenszel log-rank test). 
A life table analysis allowed the data between groups using the animals that did not reach 
the endpoint to be compared by censoring them. When appropriate, the data sets were 
analyzed using Student’s t-test. Differences were considered significant if p < 0.05. 
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3.4    Results 
Preparation of IDA or DOX Ion-Pair Complex 
To facilitate the entrapment of positively charged IDA or DOX in the oil phase, several 
negatively charged ion-pairing agents were identified and tested, such as STDC, DS2500, 
DS5000, DS8000, and STS. Figure 3.2 shows the % IDA ion-paired with STS at different 
IDA/STS molar ratios in aqueous solution. At IDA and STS molar ratios of 1:2, 1:1.75, 1:1.5, 
and 1:1.25, greater than 95% of IDA was ion-paired with STS. As more or less STS were 
added, the % IDA formed in ion-pair complex decreased as indicated by the bell-shaped 
curve. The optimal IDA/STS molar ratio was 1:1.25, at which 98.0 ± 0.1% of IDA ion-paired 
with STS. Therefore, this IDA/STS molar ratio was used for future IDA-STS NP 
preparations. Figure 3.3 displays the structure of the IDA-STS or DOX-STS complex. The 
negatively charged sulfate group on STS attracts the positively charged amino sugar moiety 
on IDA or DOX in roughly a 1:1 molar ratio. Furthermore, the long alkyl chain on STS 
increases the lipophilicity of the complex thereby facilitating the entrapment of IDA or DOX 
in the oil phase. The optimal weight ratios of IDA/DS2500, IDA/DS5000, IDA/D8000 were 
2.94:1, 3.48:1, 2.49:1, respctively, at which more than 90% IDA ion-paired with all various 
DS counter-ions. However, probably due to the large size of the DS molecule and its relative 
hydrophilicity, the loading of the IDA-DS or DOX-DS ion-pair complex in the oil phase was 
low. The optimal IDA/STDC molar ratio was 1:1. Therefore, STDC and STS were selected 
as ion-pairing agents in our studies. The optimal molar ratio of DOX and STS was 1:1.25 
(data not shown).  
Characterization of NP Formulations  
Table 3.1 reports the average particle size, PI, % entrapment, and zeta potential 
values for IDA and DOX NPs. The average particle size of either IDA NPs or DOX NPs was 
less than or around 100 nm. PI values were small (< 0.3) indicating uniform and mono-
88 
 
disperse NP suspensions. Entrapment efficiencies were also high (> 80%) and zeta 
potential ranged from -5 to -15 mV. 
More concentrated IDA-STDC NPs, from 240 µg up to 600 µg IDA/mL, were also 
successfully engineered by simply decreasing the volume of aqueous phase in the warm 
o/w microemulsion while keeping the composition of oil phase (oil + surfactant + drug) 
constant (Figure 3.4). No significant changes of particle size and PI values were observed 
between different concentrated NP formulations. This provides a very convenient method for 
preparing concentrated NP preparations by simply adding less water during the formation of 
the warm oil-in-water microemulsions. In a similar manner, DOX-STS NPs could also be 
prepared from 200 µg up to 800 µg DOX/mL without significant change in particle size and 
PI values (data not shown). 
Short-Term Stability of IDA NPs 
Figure 3.5 demonstrates the particle size of IDA-STDC and blank NPs over time 
stored at 4ºC. The original particle size of IDA-STDC NPs was ~20 nm smaller than its blank 
NPs (88 vs. 105 nm). In general, the particle size of IDA-STDC NPs increased faster than 
that of blank NPs where blank NPs increased 20 nm over 15 days while IDA-STDC NPs 
increased 20 nm only in 7 days, ~30 nm over 15 days, and 60 nm over 44 days (data not 
shown). Figure 3.6 shows the particle size of IDA-STS NPs over time stored at 4ºC. The 
particle size of IDA-STS NPs increased ~20 nm over 7 days, which was comparable with 
IDA-STDC NP formulation. The PI values of all the formulations were kept consistent during 
the 15- or 7-day storage at 4ºC. 
In order to better understand in-vivo stability of the NPs, IDA-STDC and IDA-STS NPs 
were also incubated at 37ºC in a water bath up to 50 h (Figure 3.7). The particle size of both 
IDA NP formulations increased over time. Particle size of IDA-STDC formulations increased 
faster than that of IDA-STS formulation. Within 4 h incubation, particle size of IDA-STDC 
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NPs increased 30 nm, while IDA-STS NPs only increased 20 nm. After 50 h, the particle 
size of IDA-STDC NPs reached to 320 nm, while IDA-STS NPs to 270 nm. The PI and % 
entrapment values were also measured during the incubation. The results showed there 
was no significant change in PI and % entrapment during the 50-h incubation for both of the 
formulations (data not shown).  
Lyophilization of IDA NPs 
IDA-STS NPs were lyophilized by AdVantage Freeze Dryer 2.0 liter XL as described in 
the session of Material and Methods. The lyophilization cycle of IDA-STS NPs was listed in 
Table 3.2. After lyophilization, the lyophilized cake was in light orange color with shiny 
surface. Upon reconstitution with deionized water, the samples turned to orange color and 
became clear. The % entrapment of reconstituted IDA-STS NPs was 94.5% and this was 
kept the same as before lyophilization. However, the reconstituted IDA-STS NPs 
demonstrated variable particle size results. Most of them showed multiple particle size 
distributions and all resulted in a larger particle size than the original pre-lyophilized 
formulation (87 vs. 151 nm), and even had some very large particles since % dust increased 
from 0 to 19% after lyophilization (particle size larger than 3 µm is generally recognized as 
dust). After lyophilization, pH values of IDA-STS NPs increased and osmotic pressure 
decreased a little bit, which may be due to omission of the volume effect of lyophilized cake 
during lyophilization process (Table 3.3). 
Western Blot Analysis 
Expression of P-gp levels in P388, P388/ADR, and HCT-15 cell lines was detected 
using western blot analysis. As shown in Figure 3.8, P388/ADR and HCT-15 cell lines over-
expressed P-gp, while P388 cells did not demonstrate any P-gp-specific signal. This was 
consistent with the documented information on P-gp expression level for these cell lines. β-
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actin was used as the loading control. The P-gp expressions of P388/ADR and HCT-15 cells 
were comparable when normalized to β-actin. 
In-Vitro Cytotoxicity Assay 
In-vitro cytotoxicity of free IDA or free DOX, IDA NPs or DOX NPs, and blank NPs 
were conducted in various sensitive and resistant cell lines. The IC50 values of different IDA 
or DOX formulations are listed in Table 3.4. IDA NPs showed comparable cytotoxicity with 
free IDA in most of the cell lines tested. In some resistant cell lines (e.g. P388/ADR), 
although the difference in IC50 values was statistically significant, the cytotoxicity of IDA NPs 
was only 1-2-fold lower than that of free IDA. In contrast, the IC50 values of DOX NPs were 
almost 10-fold lower than that of free DOX in P388/ADR cell line. In the sensitive cell line 
P388, DOX NPs showed equivalent cytotoxicity to free DOX as expected (p = 0.13). Blank 
NPs were shown to be cytotoxic when the drug equivalent NP concentration was about 
1000 nM. 
Cellular Uptake of Free IDA and IDA NPs  
Cellular uptake of free IDA and IDA NPs were performed in both sensitive HL-60 and 
resistant HL-60/VCR cell lines. After a period of 4 h incubation, a concentration dependent 
increase in the cell-associated fluorescence intensity was observed for both free IDA and 
IDA NPs in both cell lines (Figure 3.9). There was little or no difference between free IDA 
and IDA NPs within each cell line. More notably, there was no or little statistical difference in 
the cell-associated fluorescence for free IDA and IDA NPs between the HL-60 (Figure 3.9A) 
and HL-60/VCR (Figure 3.9B). For example, at an IDA concentration of 25 nM, the cell-
associated fluorescence intensity of free IDA and IDA NPs was 75 ± 5 and 115 ± 42 in HL-
60, respectively, and 98 ± 7 and 180 ± 32 in HL-60/VCR, respectively. These data suggest 
that free IDA may not be strongly effluxed from the P-gp-overexpressing HL-60/VCR cell 
line. This is in sharp contrast to our previous studies in P-gp-overexpressing human ovarian 
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carcinoma NCI/ADR-RES cell line, wherein greater than 15-fold DOX remained in the P-gp 
cells for DOX NPs as compared to free DOX after 4 h of efflux [125].  
Visualizing Cellular Uptake of IDA or DOX NPs  
Cell uptake of free IDA and DOX, and their NPs were visualized with the CytoViva 
Microscope System. The uptake rate of free IDA was faster than that of free DOX, which is 
due to its higher lipophilicity. The extent and rate of uptake for both NP formulations was 
high as after 10 min, significant red fluorescence of DOX was seen in most of the nuclei in 
MDA-MB-468 cells. However, and in stark contrast, the fluorescence of IDA was seen 
everywhere in the cell except the nucleus (Figure 3.10). 
In-Vivo Animal Efficacy Studies 
Study 1: HCT-15 Human Colon Tumor Cells Implanted Subcutaneously to Treat with 
Free IDA and IDA-STS PEG NPs 
In the study 1, intravenous administration of both free IDA and IDA-STS PEG NPs 
administered at the higher doses of 2.25 and 1.5 mg/kg/injection on a q4d × 3 treatment 
schedule to mice bearing s.c. implanted HCT-15 human colon tumor cells was toxic, which 
resulted in more than five of ten mice death within Day 27. Treatment with free IDA and IDA-
STS PEG NPs administered i.v. at a lower dose of 1.0 mg/kg/injection resulted in tumor 
growth delays of -0.2 and 1.8 days, respectively. The tumor mass doubling time between 
these two groups was statistically insignificant (p = 0.1019). Treatment with free IDA and 
IDA-STS PEG NPs administered i.v. at the lowest dose of 0.67 mg/kg/injection resulted in 
tumor growth delays of 0.3 and 0.8 day, respectively, and the tumor mass doubling time 
between these two groups was also insignificant (p = 0.5739). Treatment with free DOX 
administered i.v. at the dose of 8.0 mg/kg/injection on a q4d × 3 treatment schedule 
produced a tumor growth delay of 0.9 day (Figure 3.11). 
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Study 2: P388 Murine Leukemia Intravenously Implanted to Treat with Free IDA, IDA-
STS NPs, and IDA-STS PEG NPs 
In the study 2, free IDA and IDA-STS PEG NPs, and free IDA and IDA-STS NPs were 
equally effective against the P388 murine leukemia cells (all the p values > 0.10) in male 
CD2F1 mice when administered i.v. at doses of 1.5 and 1.0 mg/kg/injection on a q4d × 3 
treatment schedule (Figures 3.12-13). At the highest dose of 2.25 mg/kg/injection, there was 
a statistical difference (p = 0.0045) in survival times between free IDA and IDA-STS PEG 
NPs; however, this dose appeared to be toxic for both test agents because the maximum 
losses in average body weight of the mice were 16.1% (3.7 g) and 26.5% (6.3 g), 
respectively. At the lowest dose of 0.67 mg/kg/injection, there was a statistical difference (p 
= 0.0201) in survival times between free IDA and IDA-STS NPs; however, the difference in 
survival times was only one day. 
Study 3: P388/ADR Murine Leukemia Intraperitoneally Implanted to Treat with Free 
DOX, DOX-STS NPs, DOX-STS PEG NPs, and Blank NPs 
In the study 3, the % ILS after i.p. treatment with DOX NPs was found to be 
statistically significant when compared with DOX PEG NPs, blank NPs, and free DOX in the 
P388/ADR murine leukemia model in male CD2F1 mice at dose of 3.5 mg/kg/injection given 
with the treatment schedule of q4d × 3 (Figure 3.14). This treatment resulted in a median 
day of death of 20 days and ILS value of 67% for DOX NPs, 16.5 days and 38% for DOX 
PEG NPs, 14.5 days and 21% for free DOX, and 11 days and -8% for blank NPs, 
respectively. DOX PEG NPs and free DOX were equally effective, and as expected, 
treatment with blank NPs was ineffective. At dose of 5.3 mg/kg/injection, DOX NPs was 
found to be statistically significant when compared with blank NPs (p = 0.0497), or 
approached statistically significant compared with DOX PEG NPs (p= 0.0835); while at dose 
93 
 
of 8.0 mg/kg/injection, there was no survival difference between DOX NPs and the other 
groups, and the median day of death for all groups ranged from 12.5 to 14.5 days.  
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3.5    Discussion 
In the present studies, IDA NPs and DOX NPs were engineered using a 
microemulsion precursor method previously described by the Mumper group [353]. This 
method provides many advantages including formulation adaptability to several different 
excipients, reproducibly engineered and well defined solid NPs (< 100 nm), and no need for 
expensive and/or damaging high-torque mechanical mixing, microfluidization, or 
homogenization. E-wax, Brij 78, TPGS and together with the ion-pairing complex were 
utilized to form a warm oil-in-water microemulsion precursor, which solidified to SLNs upon 
direct cooling. This microemulsion precursor method allowed instantaneous and 
reproducible formation of both IDA and DOX NPs, with exhibited diameters around or below 
100 nm, small PI (< 0.3), high entrapment efficiency (> 80%) and homogenous size 
distribution. The zeta potential of both SLNs was slightly negative, range from -5 to -15 mV. 
A 15-day physical stability test of the IDA NPs at 4ºC was also conducted and no statistical 
difference was found when comparing the particle size over time (Figure 3.5-6). 
Particle size is a very important parameter for characterizing the physicochemical 
properties of SLNs. Since NPs with large size will usually be taken up by liver, spleen and 
other parts of the reticuloendothelial system (RES) in-vivo, particles with size less than 100 
nm in diameter and a uniform size distribution are preferred for tumor targeting [354]. In 
addition to particle size, particle surface properties will also affect particle uptake route [355]. 
Since NPs with more hydrophobic surface will preferentially be taken up by liver, followed by 
spleen and lungs, presentation of a more hydrophilic surface is desired [356]. Therefore, 
insertion of hydrophilic PEG groups on the surface is a common strategy to enhance the 
hydrophilicity of the particle surface [357]. In our study, DOX PEG NPs were prepared to 
enhance in-vivo performance. However, the results showed that DOX PEG NPs were less 
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effective in ILS than non-PEGylated DOX NPs in the P388/ADR CD2F1 mouse model, 
which may be due to reduced cell uptake of the PEGylated formulation (Figure 3.14). 
To neutralize the cationic charge and enhance entrapment of IDA and DOX 
hydrochloride salt forms, counter-ions such as STDC and STS were employed. STDC and 
STS were effective counter-ions for IDA and DOX in our SLN formulations. Titration of an 
aqueous solution of IDA or DOX with aqueous solution of STDC or STS resulted in 
immediate formation of ion-pair complex as red precipitates. During this complexation 
process, more than 95% of the drugs could ion-pair with counter-ions, which was very 
efficient (Figure 3.2). The obtained ion-paired precipitate was isolated by centrifugation and 
was soluble in ethanol. This counter-ion strategy was also employed previously by the 
Gasco group [351]. The Gasco group used decyl phosphate or hexadecyl phosphate to form 
ion-pairs with DOX or IDA hydrochloride and increase the entrapment of these drugs in 
SLNs. Although the group achieved a relatively high loading of IDA and DOX up to 7% and 
8.4% (w/w) and low drug release rate (0.1% in 2 h) when the SLNs were placed in water, 
however, ideally the release study should be performed in PBS instead of water, which is 
biologically more relevant and also provides the necessary pH and ionic strength to test the 
ability of the ion-pairing agent to retain the drug in the SLNs. The IDA and DOX SLNs in the 
present studies had a loading capacity up to 10% (w/w), and the release rate for IDA and 
DOX from NPs made with STDC as the ion-pairing agent was 100% in 6 h in PBS at 37oC. 
In contrast, the release rate for DOX from NPs made with STS as the ion-pairing agent was 
84% in 24 h (data not shown). The slower release rate of drug from NPs made with STS as 
the ion-pairing agent is most likely due to the enhanced stability of the STS ion-pair complex 
in PBS as compared to the STDC ion-pair complex. It should be noted that the ‘burst effect’ 
also occurred in our SLN formulation, which commonly happened during the lipid 
solidification process where the small drug molecules tended diffuse rapidly and 
concentrated near the particle surfaces, resulting drug leak out in the medium [358]. 
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IDA or DOX SLNs have also been formulated to address P-gp-mediated MDR by 
several other research groups. Wong et al. [128] prepared DOX SLNs with a drug 
entrapment efficiency of 60-80% and particle size ranging from 80-350 nm. Treatment of 
MDR cells with their DOX SLNs resulted in an over 8-fold increase in cell death when 
compared to DOX solution treatment at equivalent doses. In comparison, the DOX NPs in 
the present studies had increased entrapment efficiency, smaller and more monodisperse 
particle size, and almost a 10-fold greater cytotoxicity in a P-gp-overexpressing cell line 
P388/ADR (Table 3.4). Furthermore, at the dosage of 3.5 mg/kg/injection to our P388/ADR 
mouse model, the median survival time was 20 days after DOX NP treatment and only 14.5 
days after free DOX treatment, which significantly improved therapeutic effect in this MDR 
mouse model (Figure 3.14). In sharp contrast, IDA NPs showed comparable cytotoxicity with 
free IDA in most of the cell lines tested in-vitro (Table 3.4). IDA NPs were also equally 
effective as free IDA in-vivo in P388 mouse model and ineffective in-vivo in HCT-15 mouse 
model (Figure 3.11-13). The P-gp expression in P388/ADR and HCT-15 cells and lack 
thereof in P388 cells was confirmed by western blot analysis (Figure 3.8). Our findings are in 
agreement with the previous report from Nancy and co-workers [348]. The authors 
formulated IDA liposomes to improve its antitumor activity. However, the results 
demonstrated that neither free IDA nor the IDA liposome formulation was therapeutically 
active in-vivo in resistant P388/ADR or MDA435LCC6/MDR1 models. 
The mechanism responsible for the different cytotoxic activity of IDA NPs and DOX 
NPs versus free drug observed in P-gp-overexpressing cells both in-vitro and in-vivo 
remains to be addressed, although the models applied were different (HCT-15 cell model for 
IDA and P388/ADR cell model for DOX, respectively). The compositions of excipients in 
both NP formulations were the same except for very slight differences in the amount of the 
ion-pairing agent used in the formulations. Both IDA and DOX belong to the anthracycline 
family and have the same amino sugar moiety, daunosamine, with a pKa of 8.4, which bears 
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the positive electrostatic charge localized at the protonated amino nitrogen. Thus, both 
drugs should exhibit similar electrostatic interactions with cell membrane [339]. However, 
IDA has a hydrogen atom in position 14, where DOX has a hydroxyl group attached. 
Furthermore, IDA does not have the methoxy group at position 4 (Figure 1.1), which results 
in significantly increased lipophilicity and cell permeability as compared with DOX [359].  
The molecular mechanism of IDA action does not seem to differ significantly from that 
of DOX. Both drugs accumulate in the nucleus and intercalate into DNA, which seems to be 
the main locus of activity. However, another interesting finding in these studies was the 
difference in the intracellular localization of IDA and DOX in sensitive cells after 10 min. 
Whereas IDA was found largely extra-nuclear after 10 min, DOX was almost entirely 
intranuclear. This observation was supported by Zohreh et al. [360], who found the binding 
affinity of DOX to chromatin was higher than that of IDA; therefore, higher aggregation of 
chromatin with DOX occurred. They also suggested that the weaker interaction of IDA with 
chromatin is possibly attributed to its higher lipophilic nature. 
It should be kept in mind that the activity of a drug depends largely upon its 
intracellular concentration, and specifically for IDA and DOX the nuclear concentration, 
which is basically determined by the kinetics of its influx and efflux of the drug across cell 
membrane. The influx rate is greatly affected by the lipophilicity of the drug, while the efflux 
rate is correlated with P-gp and MRP associated MDR. Marbeuf-Gueye et al. [361] have 
demonstrated that the relative drug resistance of anthracyclines poorly correlated with drug 
efflux kinetics in P-gp-expressing cells, which indicates that the influx rate may be the more 
important contributor to the intracellular concentration for anthracyclines. The IDA cell 
uptake studies in both sensitive HL-60 and resistant HL-60/VCR cell lines demonstrated that 
the cellular uptake of IDA was comparable for both IDA NPs and free IDA. In addition, no 
significant difference in the cellular uptake of IDA was found between the sensitive and 
resistant cell lines (Figure 3.9), which suggests that the increased lipophilicity of IDA may 
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help circumvent MDR by the influx-governed mechanism and thereby enhance its 
chemotherapeutic efficacy.  
Similar results were previously reported by Carole et al. [362]. They demonstrated that 
the uptake rate of IDA was much higher than the efflux rate mediated by P-gp, which may 
be a main factor in the improved IDA cytotoxicity observed in MDR cells in-vitro. Supporting 
evidence was also found by Hargrave and co-workers [363], who reported that IDA did not 
induce P-gp expression in K562 human leukemia cell line whereas other anthracyclines did. 
Laurence group [364] concluded that the efficiency of anthracycline incorporation in bilayer 
membranes depended neither on cationic charge of the drug nor on anionic phospholipids, 
but on the hydrophobicity of the drug molecule. Smeets [365] proposed that reduced 
sensitivity of IDA to MDR mechanisms of P-gp or MRP1 was due to its higher lipophilicity. 
Mariagraziaet et al. [366] showed that mdr-1 gene over-expression was strongly associated 
with the development of a high level of resistance to DNR and DOX, but not to their 
derivative of IDA. Their data suggest that more lipophilic anthracycline derivatives may also 
be active in MDR cell systems. Kazuki [367] reported that the uptake of IDA was greater 
than those of DNR and DOX in both HL60 and human mononuclear cells (MNC) because of 
the higher uptake property of IDA. All of the above studies suggest that IDA, although 
belongs to the family of anthracycline, is probably not a good P-gp substrate due to its high 
lipophilicity. 
In contrast, after treatment of P-gp-overexpressing human ovarian carcinoma cell line 
NCI/ADR-RES with our DOX-STS NPs, greater than 15-fold DOX remained in the P-gp cells 
compared to free DOX [125]. The mechanism responsible for increased cellular uptake of 
our DOX SLNs may be mediated by the endocytosis pathway described earlier [279]. Wong 
et al. [128] also proposed two possible mechanisms of cytotoxicity for DOX SLNs: 1) DOX is 
released from DOX SLNs outside the cells but the cytotoxicity is increased; 2) DOX SLNs 
enter into the cells and then DOX is released from SLNs inside the cells, resulting in higher 
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cytotoxicity. They also suggested that the mechanisms of SLNs responsible for reversal of 
MDR activities are diversified and probably vary from one drug carrier to another. Since P-
gp efflux is an energy dependent process, intracellular ATP levels were also investigated. In 
previously studies by our group, it was found that the surfactants Brij 78 and TPGS inhibited 
P-gp (as evidenced by increased calcein AM influx), but only Brij 78 depleted ATP [125]. 
The cell uptake mechanisms of our DOX and IDA NPs were proposed as shown in Figure 
3.15. It also should be noted that cell nucleus is the major target of anthracyclines, and it 
has been demonstrated that the nuclear membrane also expresses P-gp to prevent drug 
penetration into the cell nuclei [368]. SLNs may be able to overcome this possible source of 
drug resistance as well, although the mechanism is not fully understood. 
 
100 
 
Table 3.1 Characterization of IDA and DOX NPs. Results are expressed as mean ± SD (n = 
3-5). 
 
 
 
 
 
  Particle Size 
(nm) PI 
Zeta Potential 
(mV) 
% 
Entrapment 
 
     
IDA-STDC NPs 79.7 ± 0.2 0.112 ± 0.035 -5.7 ± 0.6 82 ± 3 
     
IDA-STS NPs 94.7 ± 0.2 0.213 ± 0.057 -13.7 ± 2.1 85 ± 5 
     
DOX-STS NPs 104.2 ± 1.1 0.221 ± 0.071 -14.8 ± 1.2 86 ± 6 
     
Blank NPs 94.4 ± 0.2 0.097 ± 0.022 -10.3 ± 1.7 ― 
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Table 3.2 Lyophilization cycle of IDA-STS NPs. 
 
 
Thermal Treatment 
 
              Temp (ºC)             Time (min) 
Step 1            -80             60 
Drying 
 
Temp  
(ºC) 
Time  
(min) 
Vacuum 
(mTorr) 
    
Step 1 -35 10 100 
Step 2 -30 5 100 
Step 3 -25 5 100 
Step 4 -20 5 100 
Step 5 -15 5 100 
Step 6 -10 450 100 
Step 7 -5 5 100 
Step 8 0 5 100 
Step 9 10 5 100 
Step 10 20 5 100 
Step 11 25 450 100 
    
 
102 
 
Table 3.3 Characterization of IDA-STS NPs before and reconstitution after lyophilization. 
Results are expressed as mean ± SD (n = 3-5). 
 
 
 
Before  
Lyophilization 
Reconstitution After 
Lyophilization 
pH 5.440 6.007 
Particle Size (nm) 87.4 ± 2.6 151.0 ± 3.4 
PI 0.302 ± 0.059 0.470 ± 0.030 
% Dust 0 19 
Osmotic Pressure 
(mOsm) 350 313 
Zeta Potential (mV) -13.0 ± 0.89 -18.7 ± 0.72 
% Entrapment 94.4 94.5 
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Table 3.4 IC50 values (nM) of free IDA, DOX and their NP formulations in various cell lines. 
Results are expressed as mean ± SD (n = 4). 
 
 
*p < 0.05, ** p < 0.01  
ND: Not Determined 
†
 The concentrations of blank NPs refer to ‘drug equivalent’ NP concentrations. 
 
   
   
   
   
   
   
   
   
   
   
 
  
   
   
   
   
   
 
 
 
 
  HCT-15 HL-60 HL-60/ADR HL-60/VCR P388 P388/ADR 
 
       
IDA NPs 120 ± 30 23 ± 4 240 ± 36 ** 22 ± 3 ** 6 ± 1 55 ± 2 * 
       
Free IDA 129 ± 38 27 ± 4 558 ± 62 ** 51 ± 6 ** 4 ± 1 82 ± 4 * 
       
DOX NPs ND ND ND ND 27 ± 4 582 ± 144 ** 
       
Free DOX ND ND ND ND 34 ± 5 5,220 ± 794 ** 
       
Blank NPs † > 1,000 ND ND ND > 1,000 > 1,000 
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Figure 3.1 IDA standard calibration curve in deionized water. IDA concentration was in the 
range from 1 to 50 µg/mL and the absorbance was measured using Beckman DU 800 
UV/Visible Spectrophotometer at the wavelength of 483 nm (n = 3). 
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Figure 3.2 IDA-STS ion-pair complex formation upon mixing of IDA and STS aqueous 
solutions. IDA ion-pair complex precipitates were formed upon mixing different molar ratios 
of IDA and STS aqueous solutions. After precipitation, the ion-pair complex was centrifuged, 
and the concentrations of IDA in the supernatants were measured. The % of IDA ion-paired 
with STS was calculated as described in the Materials and Methods section. Results are 
expressed as mean ± SD (n = 3). 
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Figure 3.3 Proposed chemical interaction of IDA- and DOX-STS ion-pair complexes. 
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Figure 3.4 Characterization of concentrated IDA-STDC NPs. IDA-STDC NPs with 
concentrations ranging from 240 µg up to 600 µg IDA/mL were engineered by decreasing 
the volume of aqueous phase in the warm o/w microemulsion while keeping the composition 
of oil phase (oil + surfactant + drug + ion-pairing agent) constant. Particle size, 
polydispersity index (PI), and the total weight of NPs (w/v) were measured. The total weight 
of NPs (w/v) was calculated as follows: The total weight of NPs (w/v) = [mass of the oil 
phase (oil + surfactant + drug + ion-pairing agent), µg] / [volume of NPs, mL]. Results of 
particle size measurement are expressed as mean ± SD (n = 3). 
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Figure 3.5 Short-term stability of IDA-STDC and blank NPs at 4ºC. Both of the NP 
formulations were stored at 4ºC, and the samples were taken out for particle size 
measurement at Day 1, 2, 3, 4, 5, 6, 7, 10, and 15. Results are expressed as mean ± SD (n 
= 3). 
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Figure 3.6 Short-term stability of IDA-STS NPs at 4ºC. The IDA-STS formulation was stored 
at 4ºC, and the samples were taken out for particle size measurement at Day 1, 2, 5, and 7. 
Results are expressed as mean ± SD (n = 3). 
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Figure 3.7 Stability of IDA-STDC and IDA-STS NPs in PBS at 37ºC. Both of the NP 
formulations were incubated at 37ºC in a water bath, and the samples were taken out for 
particle size measurement at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, and 50 h. Results are expressed as 
mean ± SD (n = 3).  
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Figure 3.8 Western blotting detection of P-gp in P388, P388/ADR, and HCT-15 cell lines. 
Forty to sixty micrograms of protein of each cell lysate was isolated using a 10% SDS/PAGE 
gel. Immunoblotting was performed using Mdr-1/P-gp antibody, followed by goat anti-mouse 
IgG-HRP. The images were then developed using enhanced chemiluminescence. β-actin 
was used as the loading control. Lanes 1-3: low protein load; Lanes 4-6: high protein load. 
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Figure 3.9 Cellular uptake of free IDA and IDA NPs in (A) HL-60; (B) HL-60/VCR cell lines. 
Tested articles were added to a 12-well plate (7.5 × 105 cells/well) and incubated at 37°C for 
4 h. Cells were then transferred to 15 mL graduated tubes and centrifuged. The medium 
was then aspirated and replaced with fresh medium. Cell-associated fluorescence was 
measured at the excitation and emission wavelengths of 485 ± 20 and 545 ± 10 nm, 
respectively. Results are expressed as mean ± SD (n = 3). (* p < 0.05, ** p < 0.01) 
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Figure 3.10 Cellular uptake of free IDA or free DOX, and drug NPs in MDA-MB-468 cell line. 
Cells were first plated onto glass slides, and then 10 µL of tested articles were dispersed on 
glass slides and covered with coverslips. After 10 min, cellular uptake pictures were taken 
by CytoViva microscope at room temperature: (A) Free DOX; (B) DOX NPs; (C) Free IDA; 
(D) IDA NPs. 
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Figure 3.11 Antitumor activity of free IDA and IDA-STS PEG NPs in mice bearing HCT-15 
human colon tumor model. Male athymic nude mice were s.c. implanted with 107 HCT-15 
human colon tumor cells and i.v. administered with the following treatment groups at doses 
of 2.25, 1.5, 1.0 and 0.67 mg/kg/injection on a q4d × 3 treatment schedule: (♦) Control; (□) 
Free IDA (1.0 mg/kg/injection); (▲) Free IDA (0.67 mg/kg/injection); (○) IDA-STS PEG NP 
(1.0 mg/kg/injection); (*) IDA-STS PEG NP (0.67 mg/kg/injection); (●) Free DOX (8.0 
mg/kg/injection). Tumor weight was measured twice per week, assuming unit density of 1 
mm3 equals to 1 mg.  
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Figure 3.12 Antitumor activity of free IDA, IDA-STS NPs and IDA-STS PEG NPs in mice 
bearing P388 leukemia model. Survival curves were derived from the following different 
treatment groups in male CD2F1 mice i.v. inoculated with 105 P388 cells and treated 24 h 
later via i.v. administration at the doses of 2.25 and 1.5 mg/kg/injection on a q4d × 3 
treatment schedule: (♦) Control; (▲) Free IDA (2.25 mg/kg/injection); (∆) Free IDA (1.5 
mg/kg/injection); (×) IDA-STS PEG NP (2.25 mg/kg/injection); (*) IDA-STS PEG NP (1.5 
mg/kg/injection); (●) IDA-STS NP (2.25 mg/kg/injection); (○) IDA-STS NP (1.5 
mg/kg/injection).   
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Figure 3.13 Antitumor activity of free IDA, IDA-STS NPs and IDA-STS PEG NPs in mice 
bearing P388 leukemia model. Survival curves were derived from the following different 
treatment groups in male CD2F1 mice i.v. inoculated with 105 P388 cells and treated 24 h 
later via i.v. administration at the doses of 1.0 and 0.67 mg/kg/injection on a q4d × 3 
treatment schedule: (♦) Control; (▲) Free IDA (1.0 mg/kg/injection); (∆) Free IDA (0.67 
mg/kg/injection); (×) IDA-STS PEG NP (1.0 mg/kg/injection); (*) IDA-STS PEG NP (0.67 
mg/kg/injection); (●) IDA-STS NP (1.0 mg/kg/injection); (○) IDA-STS NP (0.67 
mg/kg/injection). 
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Figure 3.14 Antitumor activity of free DOX and DOX NPs in mice bearing P388/ADR 
leukemia model. Survival curves were derived from the following different treatment groups 
in male CD2F1 mice inoculated i.p. with 105 P388/ADR cells and treated 24 h later at the 
dose of 3.5 mg/kg/injection on a q4d × 3 treatment schedule: (♦) Control; (□) DOX NPs; (■) 
DOX PEG NPs; (◊) Blank NPs; (*) Free DOX. The number of 25-day survivors, median day 
of death, and increase in life-span (ILS) based on median day of death were recorded.  
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Figure 3.15 Proposed cell uptake mechanisms of IDA and DOX SLNs. Free DOX diffused 
into cells but eventually was pumped out of the cells by P-gp, while DOX SLNs could be 
endocytosed into the cells thus overcome P-gp-mediated MDR both in-vitro and in-vivo in a 
P-gp-overexpressing leukemia cell model. Unlike free DOX, the cell uptake of free IDA was 
comparable with IDA SLNs in P-gp-overexpressing cells, which is likely due to the more 
lipophilic property of IDA. The present study suggests that the SLNs may offer potential to 
deliver anticancer drugs for the treatment of P-gp-mediated MDR in leukemia; however, 
selection of target drug may be very important. 
  
Chapter IV 
 
Development of 2’-Behenoyl-Paclitaxel Conjugate Nanoparticles 
for the Treatment of Metastatic Breast Cancer 
 
4.1    Summary 
The objective of the current studies was to develop a novel 2’-behenoyl-paclitaxel 
(C22-PX) conjugate nanoparticle (NP) formulation for the treatment of metastatic breast 
cancer. C22-PX conjugate was synthesized to increase the lipophilicity of PX and facilitate 
its retention within the core of lipid-based NPs, and the formation of the conjugate was 
confirmed by NMR, MS, TLC, and HPLC analyses. The solubility of C22-PX in Miglyol 812 
was 25-fold greater than that of PX due to its more lipophilic property. The cytotoxicity of 
C22-PX was much lower than PX where the IC50 value of C22-PX was 282 nM versus 38 
nM of PX in 4T1 cells. C22-PX had some tubulin polymerization activity, but much weaker 
than PX. The C22-PX conjugate NPs were successfully prepared with the drug loading up to 
1 mg/mL. The C22-PX in NP formulation was stable for at least 48 h during 37°C incubation 
in PBS while free C22-PX degraded at this condition, which indicated that NP formulation 
could protect C22-PX from degradation. The MTD of C22-PX NPs increased 6-fold 
compared to Taxol in a 4T1 mouse model, which suggested C22-PX NPs were better 
tolerated and safer than Taxol. The C22-PX NPs at MTD exhibited significantly better in-vivo 
antitumor efficacy than all control groups. The C22-PX NPs demonstrated improved 
pharmacokinetic and tumor uptake profiles than Taxol, where the plasma and
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 tumor AUCs of C22-PX from C22-PX NPs were 186- and 24.4-fold greater than PX from 
Taxol at MTD, respectively. The present studies suggest that the C22-PX NPs may offer the 
potential to treat metastatic breast cancer.  
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4.2    Introduction 
Paclitaxel (PX) is one of the most effective chemotherapeutic drugs, which is mainly 
used to treat lung, ovarian, and breast cancer [156]. Due to its low water solubility, it is 
formulated in a mixture of polyoxyethylated castor oil (Cremophor EL) and dehydrated 
ethanol (50:50, v/v) under the trademark ‘Taxol’. However, Cremophor EL is known to be 
associated with serious side effects, such as hypersensitivity [157]. In addition, PX is known 
as a substrate of P-glycoprotein (P-gp), which could actively pump PX out of the cells and 
induce drug resistance [159]. To overcome these problems, several strategies have been 
applied, mainly including change of current PX formulations [265, 271, 369, 370] and/or 
structure modification of the drug (e.g. PX analogs and prodrugs) [371-373]. 
The primary goal of reformulating the current PX formulation of Taxol is to eliminate 
Cremophor EL/Ethanol with a better tolerated vehicle. In recent years, a lot of research has 
been conducted to formulate PX into different carriers, such as o/w emulsions [369], 
micelles [370], liposomes [265], and solid lipid nanoparticles [271]. These formulations did 
show some benefits compared to Taxol both in-vitro and in-vivo, however, in most cases the 
solubilization capacity of PX in these formulations was limited and PX released rapidly from 
the formulation. Furthermore, most of the formulations lacked the mechanisms to overcome 
P-gp-mediated drug resistance. In contrast, our laboratory has developed a new technology 
to engineer stable PX BTM (Brij 78 and TPGS as the surfactants, and Miglyol 812 as the oil 
phase) nanoparticles (NPs) from oil-in-water microemulsion precursors [280]. The loading 
capacity of the drug was up to 8% (drug/oil, w/w), and the drug only released 50% after 72 h 
in PBS. This PX BTM NP system has shown significantly better anticancer efficacy in nude 
mice bearing resistant NCI/ADR-RES tumors compared to Taxol. The mechanisms of PX 
BTM NPs to overcome P-gp-mediated drug resistance were also investigated which were 
probably via P-gp inhibition and ATP depletion [125]. However, PX BTM NPs demonstrated 
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comparable pharmacokinetic profile and tumor uptake to Taxol in mouse models, which may 
be due to the fast drug release from NPs in blood after intravenous injection.  
To further improve the lipophilicity of PX and facilitate its retention in the lipid core, 
modification of PX to a fatty acid-PX derivative is a potential approach. To date, many PX 
derivatives have been reported to increase its water solubility [373-376], or oppositely 
enhance its lipophilicity in order to encapsulate more drugs into lipid-based formulations 
[292, 293, 295, 298]. The most successful PX derivative is docosahexaenoic acid-PX (DHA-
PX), which currently is in phase III clinical trial [296-298, 377]. DHA is linked to PX through 
an ester bond on its C-2’ position. The DHA-PX conjugate does not have microtubule 
assembly activity and is presumably non-toxic. It converts to active PX form when 
metabolized by esterases in the body. Therefore, the conjugate prolonged the exposure of 
PX and reduced the peak concentration, which allowed 4.4-fold higher maximum tolerated 
dose (MTD) of DHA-PX than PX in mice. In an M109 subcutaneous lung tumor mouse 
model, DHA-PX could completely eliminate measurable tumors while PX did not cause 
neither complete nor partial tumor regression at MTD [298]. Although it is promising, this 
DHA-PX conjugate formulation has some drawbacks, such as formulated in Cremophor 
EL/Ethanol, and remain a P-gp substrate [378].  
In this study, 2’-behenoyl-paclitaxel (C22-PX) conjugate was synthesized and 
formulated into NPs. Based on PX BTM NPs and overall goal of the current research 
project, five hypotheses are proposed as follows: 1) more lipophilic C22-PX could be 
successfully synthesized to have greater solubility in the oil phase of Miglyol 812 and exhibit 
much higher entrapment efficiency in our BTM NPs compared to PX; 2) C22-PX BTM NPs 
will be less toxic and enhance MTD than Taxol due to the elimination of Cremophor 
EL/Ethanol; 3) C22-PX will be slowly released from BTM NPs, and would convert to PX by 
esterases in the body; 4) C22-PX NPs will have long circulation time in blood thus take full 
advantage of EPR effect to preferably accumulate in tumor site; 5) C22-PX conjugate NPs 
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will exert better in-vivo antitumor efficacy, improved pharmacokinetics and tumor uptake 
than Taxol. To evaluate above hypotheses, a series of in-vitro and in-vivo studies were 
performed to compare C22-PX conjugate or C22-PX-loaded NPs to Taxol. 
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4.3    Materials and Methods  
Materials 
PX was purchased from LC Laboratories (Woburn, MA, USA). PX injection was 
bought from Hospira Inc. (Lake Forest, IL, USA). Polyoxyl 20-stearyl ether (Brij 78) was 
obtained from Uniqema (Wilmington, DE, USA). D-alpha tocopheryl polyethylene glycol 
1000 succinate (TPGS) was generously provided by Eastman Chemical Co. (Kingsport, TN, 
USA). Behenoyl chloride, anhydrous dichloromethane (DCM), and 4-
dimethylaminopyridine (DMAP) were purchased from Sigma (St. Louis, MO, USA). The 
tubulin polymerization assay kit was purchased from Cytoskeleton Inc. (Denver, CO, USA). 
4T1 mouse mammary carcinoma cell line was obtained from ATCC (Manassas, VA, USA). 
The cell line was cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) containing 
10% fetal bovine serum (FBS) (ATCC, Manassas, VA, USA) and antibiotics at 37°C in 5% 
CO2 humidified atmosphere.  
Synthesis and Characterization of C22-PX 
A flame-dried round-bottom flask was charged with PX (25 mg, 2.9 × 10-5 mol, 1 equiv) 
and DMAP (7.2 mg, 5.8 × 10-5 mol, 2 equiv) in anhydrous DCM (3 mL) under argon. The 
solution was stirred for 10 min at 0°C. Behenoyl chlori de (11 mg, 3.1 × 10-5 mol, 1.05 equiv) 
was added, and the reaction mixture was stirred for 6 h at 0°C under argon. The reaction 
was monitored by TLC (EtOAc:hexane 3:1 v/v, Rf = 0.74) for completion. After completion, 
the solvent was removed by rotary evaporation in-vacuo and the crude product was 
dissolved in diethyl ether (10 mL) and washed with 5% HCl (3 × 10 mL), and finally with 
brine (10 mL) to remove the salt byproducts. The organic phase was dried over anhydrous 
sodium sulfate, and the solvent was evaporated in-vacuo. The product was purified by silica-
packed column chromatography (EtOAc:hexane 3:1, v/v) to give the desired PX derivative 
as a white solid (29.3 mg, 85%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 0.81 (t, 3H, –
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CH3(CH2)20), 1.06 (s, 6H, –H16,17), 1.18 (m, 18H, –(CH2)7CH2CH3), 1.61 (s, 3H, –H19), 1.72 
(m, 2H, –H6), 1.80 (m, 2H, –H14), 1.87 (s, 3H, –H18), 2.15 (s, 6H, –H22,31), 2.38 (d, 1H, –H3), 
3.41 (q, 2H, –H5,7), 3.74 (s, 1H, –OH7), 3.76 (s, 1H, –OH1), 4.14 (d, 1H, –H20), 4.23 (d, 1H, –
H20), 4,39 (t, 1H, –H13), 4.86 (d, 1H, –H2), 5.22 (s, 1H, –H10), 5.84 (d, 1H, –H2’), 6.81 (d, 1H, 
–H3’), 7.18-7.32 (m, 5H, –Ar-H33-37), 7.32-35 (m, 3H, Ar-H26-28), 7.44 (m, 3H, Ar-H8’-10’), 7.66 
(d, 2H, –Ar-H7’,11’), 8.05 (d, 2H, –Ar-H25,29). 13C NMR (100 MHz, CD3OD): δ (ppm) = 8.58 (–
C19), 13.1 (–CH3(CH2)20), 13.8 (–C18), 19.8 (–C31), 21.1 (–C22), 21.7 (–(CH2)19CH2CH3), 23.7 
(–C16,17), 25.8 (–(CH2)18CH2CH2C1”), 30.9 (–CH3CH2CH2(CH2)18C1”), 32.8 (–C6), 34.5 (–C14), 
42.1 (–C15), 44.6 (–C3), 51.8 (–C3’), 57.5 (–C8), 70.7 (–C13), 71.1 (–C7), 72.8 (–C2), 74.1 (–
C10), 74.6 (–C20),  76.3 (–C6’), 78.2 (–C1), 80.1 (–C4), 83.4 (–C5), 125.5 (–C33,35,37), 126.1 (–
C7’,11’), 127.4-128.2 (–C26,28, –C34,36, –C8’,10’), 129.2 (–C24,25,29), 132.6 (–C27), 131.0 (–C9’), 
131.8 (–C27), 132.6 (–C32), 136.0 (–C11), 141.8 (–C12), 166.1 (–C23), 167.1 (–C5’), 168.8 (–
C21, –C30), 170.2 (–C1’), 171.5 (–C1”), 202.8 (–C9). Mass spectrometry analysis also provided 
evidence for successful preparation of the C22-PX conjugate. The mass of the observed 
molecular ion clearly corresponded to the Na+ adduct of the conjugate, with no observable 
lower molecular weight fragments or starting material. Calc.: [M]+ m/z = 1176.47. Found LC-
MS: [M + Na+] = 1198.13.  
PX and C22-PX Solubilities in Different Miglyols 
Excess PX or C22-PX powder was added into Miglyols of 808, 810, 812, and 818, 
respectively, and kept stirring at room temperature for 24 h. After that, the samples were 
centrifuged at 25°C at the speed of 14,000 g for 20 m in. The supernatant was accurately 
weighted into a 50 mL volumetric flask and dissolved in methanol. The concentration of PX 
or C22-PX in the flask was determined. 
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In-Vitro Cytotoxicity of C22-PX 
The cytotoxicity of C22-PX and PX in 4T1 mouse mammary carcinoma cells was 
determined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay 
[124]. Briefly, the viability of 4T1 cells was determined by trypan blue staining (> 95% cell 
viability for experiments) and the cells were counted and seeded in 96-well plates at 5,000 
cells/100 µL growth medium. Serial dilutions of C22-PX and PX were added to the plate 
(100 µL/well) at 37°C in 5% CO 2 for 48 h. The cells were then incubated with MTT stock 
solution (5 mg/mL in PBS; pH 7.4) at 37ºC for another 4 h. Next, the medium was then 
removed and the converted dye was solubilized with the addition of DMSO. The absorbance 
was measured using the Synergy 2 Multi-Detection Microplate Reader (BioTek, Winooski, 
VT, USA) at 570 nm, and the concentration of drug that inhibited cell survival by 50% (IC50) 
was determined from cell survival plots. 
Tubulin Polymerization Activity of C22-PX 
The tubulin polymerization assay was performed using the kit purchased from 
Cytoskeleton Inc. (Cat# BK006P, Denver, CO, USA). It is based on the principle that the 
light scattered by microtubules to some extent is proportional to the concentration of tubulin 
polymer [379, 380]. The standard (control) polymerization reaction contains 100 µL of 3 
mg/mL tubulin in 80 mM PIPES pH 6.9, 0.5 mM EGTA, 2 mM MgCl2, 1 mM GTP, and 10% 
glycerol. The assay was conducted at 37ºC and the tubulin polymerization reaction was 
monitored by the change of the absorbance at 340 nm with a temperature controlled 
Synergy 2 Multi-Detection Microplate Reader. C22-PX concentrations of 5, 10, and 20 µM 
were applied in the assay. PX (10 µM) was used as the positive control. 
Optimization and Characterization of C22-PX NPs 
Our laboratory has developed ‘nanotemplate engineering’ technology to successfully 
prepare PX BTM NPs with the particle size of 200 nm [280]. Since C22-PX is more lipophilic 
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and to some extent exhibits surfactant property, the current C22-PX BTM NP formulations 
were optimized by decreasing the amount of surfactants of Brij 78 and TPGS used in PX 
BTM formulation. In parallel, C22-PX NPs were also prepared with the same technology but 
different solid oil phases of stearyl alcohol [381] and emulsifying wax [124], respectively. 
C22-PX micelles were prepared in the same manner as the NP formulation but without the 
oil phase of Miglyol 812. The particle sizes of the micelles and NPs were determined by 
photon correlation spectroscopy (PCS) using a Coulter N5 Plus Sub-Micron Particle Sizer 
(Beckman Coulter, Miami, FL, USA) at a fixed angle of 90º and a temperature of 25ºC. The 
optimal NP formulations were defined as the narrow particle size distribution less than 200 
nm, high drug entrapment efficiency, and physical stability upon storage at 4ºC or room 
temperature. The % drug entrapped in the NPs was determined by gel permeation 
chromatography (GPC) method. Briefly, the prepared NPs were passed through a 15 cm 
Sepharose CL-4B GPC column (Sigma, St. Louis, MO, USA) with the elution solvent of 
PBS. The NP fractions of 5-8 (1 mL per fraction) were collected and the total amount of C22-
PX in these fractions was determined. The % entrapment was calculated as follows:  
% entrapment efficiency = [(total mass of drug in NP fractions of 5-8) / (total mass of        
drug added in NPs)] × 100% (w/w)                     (Equation 4.1) 
Stability of Various C22-PX Formulations in PBS at 37ºC  
Different C22-PX formulations, including free C22-PX, C22-PX NPs, and C22-PX 
micelles were incubated in PBS at 37°C in a water bath . At the scheduled time points of 1, 
4, 10, 24, 48 h, respectively, samples were taken out and the concentration of C22-PX was 
determined by HPLC. Free PX was used as the control and the final concentrations of the 
drug in the experiment were 10 µg/mL. 
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C22-PX Conversion to PX in Tumor Homogenates 
To test C22-PX conversion to more active form of PX, C22-PX and C22-PX NPs were 
spiked into fresh 4T1 tumor homogenates at the concentration of 10 µg/g tumor and 
incubated at 37°C in a water bath. At determined tim e points, ~40-50 mg of samples was 
taken out. The concentrations of both C22-PX and PX converted from C22-PX or C22-PX 
NPs were determined. 
Maximum Tolerated Dose (MTD) Studies of C22-PX NPs 
The MTD studies of Taxol, C22-PX NPs, and C22-PX micelles were conducted in 4T1 
tumor-bearing mice. BALB/c female mice from Charles River Laboratories (Wilmington, MA, 
USA) were subcutaneously inoculated of 1 × 106 4T1 cells in the right flank. When the tumor 
sizes reached in the range of 50-150 mm3 (5 days after cell inoculation), the mice were 
intravenously tail vein injected of different formulations with the treatment schedule of q4d × 
3. A total of 7 groups were involved in the study (2-3 mice/group): 30 and 40 mg PX/kg of 
Taxol, 135 and 180 mg PX/kg of C22-PX NPs, 90 and 120 mg PX/kg of C22-PX micelles, 
and an untreated group as the control. Mice body weight change and survival were closely 
monitored on a daily basis for continuous two weeks. The MTD was defined as the 
allowance of body weight loss less than 20% at the highest dose, and neither mice death 
due to toxic effects nor any remarkable changes in general signs observed during the study.  
In-Vivo Antitumor Efficacy Studies at MTD 
In-vivo antitumor efficacy studies of Taxol, C22-PX NPs, and C22-PX micelles at MTD 
were carried out in a 4T1 subcutaneous mouse model. The four- to six-week-old BALB/c 
female mice from Charles River Laboratories were subcutaneously inoculated with 1 × 106 
4T1 cells on Day (-5), and intravenously tail vein injected different formulations starting from 
Day 0 with the treatment schedule of q4d × 4. Mice were divided into a total of 6 groups in 
the study (9-10 mice/group): 25 mg PX/kg of Taxol, 25 and 160 mg PX/kg of C22-PX NPs, 
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25 and 100 mg PX/kg of C22-PX micelles, and an untreated group as the control. The mice 
weight and tumor sizes were measured every other day during the study, and tumor volume 
was calculated as:  [½ × (tumor width)2 × (tumor length)] (Equation 4.2). All the mice were 
sacrificed on Day 18 and upon sacrifice the tumors of all the mice were harvested and 
weighted. 
Pharmacokinetic and Biodistribution Studies 
The pharmacokinetic and biodistribution studies of Taxol and C22-PX NPs were 
conducted in 4T1 tumor-bearing mice. The four- to six-week-old BALB/c female mice were 
subcutaneously injected with 1 × 106 4T1 cells into the right flank. When tumor sizes 
reached 200-300 mm3, the mice were intravenously tail vein injected with Taxol or C22-PX 
NPs as a single bolus. A total of 2 independent studies were performed, one was at the 
same dose of 10 mg PX/kg, and the other one was at MTD (25 mg PX/kg for Taxol and 160 
mg PX/kg for C22-PX NPs). In each study, mice were sacrificed at the determined time 
points (3 mice/time point), and plasma, the tissues of tumor, kidney, lung, heart, liver, and 
spleen were harvested. Tissues were flash-frozen in liquid nitrogen and stored at -80ºC. 
Upon analysis, the frozen tissues were homogenized by Omni Bead Ruptor 24 
Homogenizer (Kennesaw, GA, USA) and the drug was extracted by the solvent of methanol-
acetonitrile (2/1, v/v) (except for PX plasma samples which were extracted by solid phase 
extraction method described below). The plasma concentration versus time data of both 
Taxol and C22-PX NPs were analyzed by noncompartmental analysis using WinNonlin 
(Version 5.3, Pharsight Co., Mountain View, CA, USA).  
Quantitative Analysis of PX and C22-PX 
The concentration of PX was determined by HPLC/MS/MS system. The HPLC system 
comprised a Finnigan Surveyor Autosampler Plus and a Finnigan Surveyor MS Pump Plus 
(Thermo Scientific). Chromatographic separations were achieved by using a SunFire™ C18 
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column (2.1 × 30 mm, 3.5 µm particle size, Waters) at 25ºC. The mobile phase consisted of 
55% methanol and 45% of 0.1% formic acid in deionized water (v/v) for 0.2 min, then linear 
gradients to 70:30 (v/v) in 6 min and went back to 55:45 (v/v) in 8 min. The flow rate was 0.5 
mL/min. Mass spectrometric analysis was performed by Thermo Scientific TSQ Quantum 
Access with positive ionization. The capillary temperature was set up to 390ºC, and the 
spray voltage was 4,000 V. M/z 876.3 → 308.0 for PX and m/z 830.0 → 549.0 for docetaxel 
were used for quantification of analytes. Docetaxel was added as the internal standard. To 
quantify PX concentration in plasma samples, another sample treatment step of solid phase 
extraction was applied before LC/MS assay. Waters Oasis® HLB cartridge (1 cc/10 mg) was 
used and conditioned by 20% methanol in dichloromethane, methanol and water, 
respectively, then the plasma samples were loaded on the cartridge and washed by 5% 
methanol followed by 55% methanol in water. After that, the collection samples were eluted 
by 20% methanol in dichloromethane, then the organic solvent was evaporated and 
residues were dissolved in the mobile phase for LC/MS analysis. 
The concentration of C22-PX was determined by HPLC analysis by using an Inertsil 
ODS-3 column (4.6 × 150 mm, 3 µm particle size, GL Sciences) at the wavelength of 230 
nm. The mobile phase consisted of acetonitrile-water-isopropanol (35/5/60, v/v/v) with the 
flow rate of 1.0 mL/min. For plasma or tissue samples, C22-PX was extracted from the 
samples by single extraction of methanol-acetonitrile (2/1, v/v). The mixtures were then 
centrifuged at 14,000 g for 5 min, and the supernatant was taken out for HPLC analysis. 
Statistical Analysis 
Statistical comparisons were analyzed using unpaired Student’s t-test for two groups, 
and one-way analysis of variance (ANOVA) for multiple groups (Prism, Version 5.01, 
GraphPad Software Inc, La Jolla, CA, USA). Differences were considered statistically 
significant if the value of p < 0.05. 
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4.4    Results 
Synthesis and Characterization of C22-PX 
To increase the retention of PX in the lipid core of the lipid-based NPs, modification of 
PX to a fatty acid-PX derivative is a potential approach to enhance the lipophilicity of PX and 
its solubility in the lipid core of Miglyols. In this study, a novel fatty acid-PX derivative of 2’-
behenoyl-PX conjugate (C22-PX) was successfully synthesized (Figure 4.1) and the fatty 
acid was coupled to C-2’ hydroxyl position of PX, which was confirmed by 1H- and 13C-NMR 
(Figure 4.2), MS (Figure 4.3), TLC (Figure 4.3) and HPLC analyses (Figure 4.4). 
PX and C22-PX Solubilities in Different Miglyols 
The solubilities of PX and C22-PX in different Miglyols at room temperature were 
determined. Due to the introduction of a long carbon chain (C22), the solubilities of C22-PX 
in Miglyols dramatically increased to 15-25-fold than that of PX (51-73 versus 3.2-3.5 µg/mg 
Miglyol for C22-PX and PX, respectively) as shown in Figure 4.5. Among all the tested 
Miglyols (Migloyls of 808, 810, 812, and 818), the solubility of C22-PX in Miglyol 812 was 
the highest (72.5 ± 17.1 µg/mg Miglyol), therefore, Miglyol 812 was chosen as the oil phase 
for further C22-PX NP preparation. It should be noted that because all of the tested Miglyols 
were composed of medium chain triglycerides (C6-C10), there was no significant solubility 
difference within the Migloyls for both C22-PX (p = 0.1878) and PX (p = 0.5083). 
In-Vitro Cytotoxicity of C22-PX 
In-vitro cytotoxicity studies of free C22-PX and PX were conducted in the 4T1 cell line. 
As shown in Figure 4.6, the IC50 value of C22-PX was about 8-fold higher than PX (282 ± 42 
versus 38 ± 1 nM). The results were expected and consistent with other reported 2’-fatty 
acid-PX conjugates [293, 295, 382], where the conjugates were much less toxic compared 
to PX since C-2’ hydroxyl group was essential for PX cytotoxicity and microtubule assembly 
activity. 
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Tubulin Polymerization Activity of C22-PX 
In general, under standard (control) reaction conditions the microtubule polymerization 
curve has three phases: nucleation (Figure 4.7A-I), growth (Figure 4.7A-II), and steady state 
(Figure 4.7A-III). Vmax value (mOD/min) is recommended to determine the ability of ligand (in 
this case is C22-PX) to stabilize tubulin because Vmax is defined to the greatest extent 
change of absorbance over time and this offers the most sensitive indicator of tubulin/ligand 
interaction. 
As shown in Figure 4.7B, the positive control of PX at the concentration of 10 µM even 
eliminated the nucleation phase and had the greatest Vmax value of 45.0 ± 3.6 mOD/min, 
while the standard control had the lowest Vmax value of 25.3 ± 3.2 mOD/min. For C22-PX 
conjugate, the interaction between C22-PX and tubulin was dose dependent and at lower 
concentrations of 5 and 10 µM, C22-PX had no effect on tubulin polymerization (p > 0.05 
compared to control); however, it had some tubulin polymerization activity at higher 
concentration of 20 µM (p < 0.01 compared to control). It should be noted that PX at 10 µM 
was much more active than C22-PX at 20 µM (p < 0.01). 
Optimization and Characterization of C22-PX NPs 
C22-PX NP formulations were engineered using a microemulsion precursor method 
previously described by the Mumper group (Figure 4.8) [124]. The C22-PX BTM NPs were 
optimized in terms of drug entrapment efficiency, particle size and stability of NPs. Since 
C22-PX exhibits some surfactant property due to the presence of both lipophilic and 
hydrophilic moieties within the structure, C22-PX BTM NP formulations were optimized by 
decreasing the amount of surfactants of Brij 78 and TPGS based on PX BTM NPs. A total of 
four BTM NP formulations (Formulations of I-IV in Table 4.1) were investigated, and the 
particle size and drug entrapment in NPs were determined. All the formulations were 
acceptable in terms of particle size except for Formulation I. As shown in Table 4.1, the less 
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surfactant utilized, the more drug content retained in NP fractions. This was expected 
because the Miglyol and surfactants in the system would competitively solubilize C22-PX. 
As less surfactants were utilized, more drug would prefer to be retain in the lipid core of 
Miglyol 812. Although Formulation IV had the highest drug content in NP fractions, the NPs 
precipitated within one week upon the storage at 4ºC. Instead, Formulation III was much 
more stable and its blank NPs were stable at least for 4 months upon the storage even at 
room temperature. Therefore, Formulation III was chosen as the most optimized C22-PX 
BTM formulation. In parallel, the C22-PX NPs were also prepared with the same technology 
but using solid oil phases of stearyl alcohol [381] and emulsifying wax [124]. As expected, 
the drug entrapment in solid lipid NPs was much lower than Miglyol-based oil-filled NPs, 
which was probably because the drug was expelled to the outer layer of NPs upon 
solidification of the solid oil phases. 
Interestingly, although C22-PX NPs showed mono-distribution with low polydispersity 
index by Coulter N5 Particle Sizer, two distinct particle size populations occurred when C22-
PX NPs passed through a Sepharose CL-4B column with the elution solvent of PBS, with 
one at 100-200 nm and the other at ~50 nm (Figure 4.9A). As expected, drug content of 
C22-PX NPs in NP fractions of 5-8 was much higher than PX NPs, which is due to the more 
lipophilic property of C22-PX conjugate (Figure 4.9B). C22-PX micelles with particle size of 
~50 nm were used as the control, which were prepared in the same manner as the NP 
formulation but without the oil phase of Miglyol 812. The compositions in PX NPs, C22-PX 
NPs, and C22-PX micelles were summarized in Table 4.2. C22-PX from C22-PX micelle 
formulation eluted out in the later fractions of 9-16 due to its small size, which confirmed the 
presence of small size population in C22-PX NPs after PBS elution (Figure 4.9C). It should 
be noted that for the fractions 9-14 of C22-PX NPs with the particle size of ~50 nm, it is 
unknown whether they are micelles, smaller lipid-based NPs or the combination of the both.  
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Another interesting phenomenon is that although C22-PX NPs showed two particle 
size populations eluted by PBS, only one population was observed with deionized water 
elution. To better understand the ion effect of the PBS, different concentrations of PBS 
solution (0.1 ×, 0.5 ×, 1 ×, and 2 × PBS) were applied as the elution solvents and all of them 
showed two size populations (Figure 4.10A). To exclude the elution profiles were dependent 
of BTM NP and Sepharose CL-4B column, latex beads with particle size of 200 nm and a 
Sephacryl S-500 GPC column were used as the controls. The results showed that latex 
beads were eluted out only in the void volume of fractions 5-8 by deionized water, but eluted 
out in a wider range of fractions 5-14 by PBS (Figure 4.10B). When Sephacryl S-500 GPC 
column was utilized, there were still two distinct populations occurred with the elution by 
PBS, but one population with deionized water elution (Figure 4.10C). This indicated the 
different elution profile by PBS or deionized water was neither dependent on the type of NPs 
nor the packing column material. Our data were consistent with the findings of Jay group 
[381] where their solid lipid NPs prepared by the same method also demonstrated two 
distinct size populations by elution of PBS but not deionized water. It should be noted that 
both Sepharose CL-4B and Sephacryl S-500 columns exhibit negative charge. Since the 
zeta potential of C22-PX NPs in deionized water is -15.1 ± 0.814 mV (n = 3), all the NPs 
would bypass the column beads and elute out in the void volume due to electrostatic 
repulsion; however, the zeta potential of C22-PX NPs in PBS was neutral at -1.80 ± 0.640 
mV (n = 3), the NPs with smaller particle size of 50 nm will be trapped within the pores of the 
gel (pore sizes of Sepharose CL-4B and Sephacryl S-500 are calculated as 7-60 and 6-60 
nm, respectively, based on the equation R = 0.051 × Mw0.378). Therefore, the smaller 
particles were eluted out from the later fractions as shown in Figure 4.9A and Figure 4.9C. 
This hypothetical elution theory was also supported by using different concentrations of PBS 
solution and latex beads. Since the ion effect in PBS is saturated even with 0.1 × PBS 
where the zeta potential of C22-PX NPs in 0.1 × PBS is close to neutral at -1.94 ± 0.08 mV 
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(n = 3), it explains the GPC elution profile in Figure 4.10A. The latex beads also 
demonstrated the significant different zeta potentials in PBS versus deionized water (-16.5 ± 
0.737 versus -5.29 ± 0.957 mV), which leads the elution profile in Figure 4.10B. To validate 
the hypotheses, the fraction 6 of C22-PX NPs eluted from Sepharose CL-4B by PBS was 
reloaded and passed through the column for the second time by BPS elution and all the 
drugs exclusively eluted out in the void volume of fractions 5-8. C22-PX NPs also passed 
through a Sephadex G-100 (pore size of 2-9 nm) column and all the drugs eluted out in the 
void volume with both of PBS and deionized water elution (data not shown).  
Stability of Various C22-PX Formulations in PBS at 37°C 
The in-vitro stability of free C22-PX, C22-PX NPs, and C22-PX micelles in PBS was 
investigated. Free PX was used as the control. As demonstrated in Figure 4.11, free C22-
PX underwent degradation during PBS incubation at 37ºC as a function of time and there 
was only ~30% retained after 48 h. It should be noted that the degradation behavior of C22-
PX in PBS was very similar to free PX and they are expected to undergo the same 
degradation pathway (Figure 4.12). In contrast, C22-PX NP or micelle formulations were 
very stable with no C22-PX degradation occurring during 48 h incubation in PBS, which 
indicated that the NP or micelle formulations could protect C22-PX from degradation in PBS 
during the incubation period.  
C22-PX Conversion to PX in Tumor Homogenates 
In-vitro C22-PX hydrolysis studies were performed in fresh 4T1 tumor homogenates at 
37ºC to test C22-PX conversion to the active form of PX. As shown in Figure 4.13, there 
was little PX formed from either free C22-PX or C22-PX NPs during the first 10 h. After that, 
PX was gradually detected, and at 48 h the amount of PX derived from free C22-PX or C22-
PX NPs was equal to 5-7% of total C22-PX added in the experiment. This confirmed that a 
part of PX could be converted from C22-PX or from its NP formulations at the tumor site. 
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Maximum Tolerated Dose (MTD) Studies of C22-PX NPs 
The MTD studies of Taxol, C22-PX NPs, and C22-PX micelles were conducted in 4T1 
tumor-bearing BALB/c mice with the treatment schedule of q4d × 3. The results are 
summarized in Table 4.4. The body weight loss in all groups was less than 6% during the 
whole study. Due to toxicity, 2 of 2 mice received 40 mg PX/kg Taxol died immediately upon 
the first injection, and 1 of 3 mice died after the second treatment of C22-PX NPs and C22-
PX micelles at the doses of 180 and 120 mg PX/kg, respectively. Therefore, the MTDs of 
Taxol, C22-PX NPs, and C22-PX micelles were determined as 30-40, 135-180, 90-120 mg 
PX/kg, respectively. It was noted that all the mice in Taxol group at the dose of 30 mg PX/kg 
lost consciousness immediately upon injection but recovered after several minutes, whereas 
mice treated with NP and micelle formulations did not. This is due to the use of Cremophor 
EL and dehydrated ethanol as the vehicles in Taxol formulation. On the basis of the results, 
MTDs of 25, 160, and 100 mg PX/kg for Taxol, C22-PX NPs, and C22-PX micelles, 
respectively, were chosen in the following in-vivo antitumor efficacy study.  
In-Vivo Antitumor Efficacy Studies at MTD 
In-vivo antitumor efficacy of Taxol, C22-PX NPs and C22-PX micelles at MTD were 
evaluated in a 4T1 subcutaneous mouse model. Two dose levels of C22-PX NPs and 
micelles were applied in the study: 25 mg PX/kg at Taxol MTD, and their unique MTDs as 
determined (160 mg PX/kg for C22-PX NPs and 100 mg PX/kg for C22-PX micelles). Mice 
treated with all the formulations at any dose level were well tolerated since their body weight 
was comparable to the untreated mice (Figure 4.14A), indicating no induced toxicity by 
either NP or micelle formulations even at their MTDs. As expected, the tumor growth rate of 
untreated group was the fastest. The C22-PX NPs at MTD exhibited significantly improved 
tumor inhibitory activities than other groups starting from Day 6 (Figure 4.14B). It should be 
pointed out that both of C22-PX NPs and C22-PX micelles had similar antitumor activity with 
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Taxol at the dose of 25 mg PX/kg, and the increase from 25 to 100 mg PX/kg of C22-PX 
micelles did not induce additional improved antitumor efficacy (p > 0.05). The data of the 
tumor weight (Figure 4.14C) were consistent with the tumor size measurement, where the 
tumors of untreated mice were the largest and heaviest, and the tumors treated with C22-PX 
NPs at MTD were the smallest and statistically significant compared to all other groups (p < 
0.05). 
Pharmacokinetic and Biodistribution Studies 
Pharmacokinetic and biodistribution studies of C22-PX NPs and Taxol at 2 dose levels 
of 10 mg PX/kg and their MTDs were conducted (Figures of 4.15-16). As shown in Figures 
of 4.15A, 4.16A and Table 4.5, PX concentration from Taxol dropped rapidly in plasma due 
to its short half-life and its concentration was lower than the detection limit after 8 and 48 h 
at the doses of 10 and 25 mg PX/kg, respectively. In contrast, the concentrations of C22-PX 
and PX derived from C22-PX NPs declined much slower. The plasma AUCs of C22-PX from 
C22-PX NPs were 22- and 186-fold greater than PX from Taxol at the doses of 10 mg PX/kg 
and MTD, respectively. The half-life of C22-PX from C22-PX NPs increased 8-fold (8.57 
versus 1.09 h) compared to PX from Taxol at the dose of 10 mg PX/kg. The clearance rate 
and volume distribution of C22-PX from C22-PX NPs in plasma were also significantly 
decreased. All these results suggested the C22-PX NPs had long circulation time and 
confined in blood stream. The distributions of C22-PX from C22-PX NPs and PX from Taxol 
in various tissues were shown in Figures of 4.15B, 4.15C, 4.16B and 4.16C. In general, PX 
concentration from Taxol decreased as a function of time and PX was widely distributed into 
most tissues of liver, lung, kidney and heart. In contrast, C22-PX from C22-PX NPs reached 
the maximal concentration between 1-4 h after intravenous administration in most of tissues, 
and C22-PX was mainly distributed in liver and spleen. Importantly, tumor AUCs of C22-PX 
from NP formulations were 2.6- and 24.4-fold higher than PX from Taxol at the doses of 10 
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mg PX/kg and MTD, respectively. Tumor AUC of PX derived from C22-PX NPs was 1.5-fold 
greater than PX from Taxol at their MTDs (Figures of 4.15D, 4.16D and Table 4.5).  
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4.5    Discussion 
PX is a very effective anticancer drug; however, due to its low water solubility and lack 
of ionizable functional groups, currently it is formulated in the mixture of Cremophor EL and 
ethanol. Our laboratory developed PX oil-filled NPs which were free of organic solvents, and 
demonstrated promising in-vitro and in-vivo antitumor efficacy [125, 280]. Pharmacokinetics 
and tumor uptake of PX NPs were investigated to better understand the fate of NPs in the 
body. In order to extract PX from biological samples, liquid-liquid extraction, solid phase 
extraction (SPE), and/or the combination are commonly used (Table 4.6). In these studies, 
SPE method was applied and validated using a LC/MS method (Table 4.7 and Figure 4.17-
18). Unfortunately, PX BTM NPs demonstrated superimposable pharmacokinetic and tumor 
uptake profiles with Taxol in mouse models (Table 4.8 and Figure 4.19), which is probably 
due to rapid loss of PX from NPs in the blood upon i.v. injection.  
In order to make better PX NP formulations, more lipophilic PX derivatives were 
developed to enhance drug affinity with lipid core of our lipid-based NPs. PX derivatives are 
generally designed at its C-2’ because the free hydroxyl group at this position is much more 
reactive than the C-7 hydroxyl group, and PX-ester based derivatives can be synthesized 
selectively at C-2’ group of PX without protecting C-7 hydroxyl group. To date, several 
synthesized 2’-fatty acid-PX ester derivatives have been reported, such as 2’-linoleic acid-
PX [383], 2’-carbonylcholesterol-PX [295], 2’-oleate-PX [293], 2’-α-bromohexadecanoyl-PX 
[382], DHA-PX [297, 298], all of which showed some benefits compared to Taxol in-vitro 
and/or in-vivo. For example, the lipophilic 2’-oleate-PX conjugate showed significant greater 
AUC, higher Cmax, lower systemic clearance compared to PX formulated in Cremophor EL 
and ethanol in a rabbit model [293]. Perkins and co-workers [382] synthesized 2’-α-
bromohexadecanoyl-PX conjugate and further incorporated it into lipid-coated particles 
termed ‘lipocores’. In-vivo study, the lipocores showed far less toxic than Taxol after i.p or 
i.v. administration and was active in the ovarian carcinoma SCID mice model. DHA-PX is so 
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far the most promising PX prodrug. In an M109 s.c. mouse model, the tumor AUCs of PX 
from DHA-PX conjugate were 1.71- and 5.79-fold greater than Taxol when i.v. injected into 
mice at equimolar and equitoxic doses, respectively [298]. However, the results from the 
most recent Phase III study to treat metastatic malignant melanoma were disappointing in 
that DHA-PX was not superior to dacarbazine in terms of overall survival, and there were no 
significant differences between the two drugs in patient response rate, duration of response, 
and time to progression on an every 3-week treatment schedule [296].  
In this study, a novel 2’-behenoyl-PX ester derivative (C22-PX) was successfully 
synthesized and its structure was confirmed by 1H- and 13C-NMR, MS, TLC and HPLC 
analyses. Since C-2’ hydroxyl group is essential for PX cytotoxicity and microtubule 
assembly activity, C22-PX conjugate should be much less toxic compared to PX if it does 
not convert to its more active form of PX. This was supported by 1) tubulin polymerization 
assay (Figure 4.7). PX as the positive control which could stabilize microtubule proteins at 
10 µM, however, C22-PX had no microtubule activity at this concentration but did have a 
dose dependent ability to stabilize microtubules. The results were similar to DHA-PX and 2’-
linoleic acid-PX where both of the prodrugs were not able to assemble microtubule at the 
concentration level of 10 µM [298, 383]; 2) in-vitro cytotoxicity study in 4T1 cells (Figure 4.6), 
where the cytotoxicity of C22-PX was much less than its parent PX (IC50: 282 ± 42 versus 38 
± 1 nM) after 48 h incubation in the cell culture medium. These results were consistent with 
other 2’-fatty acid-PX prodrugs. For example, 2’-α-bromohexadecanoyl-PX, and 2’-
diglycolate- and succinate-PX prodrugs were 70- and 10-100-fold, respectively, less potent 
compared to PX against human MCF-7 cells during 72 h incubation [292, 382]. DHA-PX was 
reported to be cytotoxic at µM concentration range, while PX was in nM range for a variety 
of human tumor cell lines [298]. Similarly, the cytotoxicity of 2’-oleate-PX in lipid emulsions 
was much lower than PX but with time dependent manner, where the IC50 values were 
5,500, 500, 150, and 100 nM for 24, 48, 72, and 96 h incubation, respectively, compared to 
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IC50 of 50 nM for Taxol at 48 h in HeLa cells [293]. The difference in IC50 between C22-PX 
conjugate and PX may be due to the limiting hydrolysis rate of C22-PX conversion to PX, 
which is supported by C22-PX hydrolysis in 4T1 tumor homogenates, where there was only 
about 5-7% of C22-PX converted to PX during 48 h incubation for both free C22-PX and 
C22-PX NPs (Figure 4.13). If faster hydrolysis is required, electron-withdrawing substituents 
in the α-position of the fatty acid can be introduced. Currently 2’-α-bromohexadecanoyl-PX 
has been synthesized and is under investigation in our laboratory. 
The C22-PX BTM NP formulations were engineered using a microemulsion precursor 
method previously described by the Mumper group [124, 384]. Miglyol 812 was used as the 
oil phase based on its highest solubilization capacity for C22-PX (Figure 4.5), and because 
C22-PX solubility in the oil phase of Miglyol 812 increased 25-fold compared to PX (72.5 ± 
17.1 versus 3.2 ± 0.1 µg/mg Miglyol), the drug entrapment in our lipid-based NPs improved 
remarkably which was confirmed by the GPC method. When C22-PX NP formulations were 
passed through a Sepharose CL-4B GPC column, 47% of drug was retained in 200 nm NPs 
versus only 10% for PX NPs (Figure 4.9B), which is probably due to more lipophilic property 
of C22-PX. Interestingly, although C22-PX NPs showed mono-distribution with low 
polydispersity index as detected by photon correlation spectroscopy, two distinct particle 
size populations were determined by the GPC method (Figure 4.9A). The results were 
consistent with the findings of the Jay group [381], where their solid lipid NPs containing 
stearyl alcohol with the same NP engineering method showed two distinct size populations 
after GPC elution. Previously, an ultracentrifuge method was applied to determine the drug 
entrapment efficiency and the results may be somehow misleading because drugs may 
precipitate and aggregate during the ultracentrifugation process and drug molecules may 
also bind to filter membrane, while the GPC method is more dynamic and would be 
expected to more accurately predict the in-vivo fate of NPs.  
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The in-vitro stability of free C22-PX and C22-PX NPs was investigated at 37ºC in PBS 
(Figure 4.11). Interestingly, C22-PX degraded in PBS over time and only ~30% of C22-PX 
was retained after 48 h incubation. It was reported that PX hydrolyzed to its main 
degradation products of baccatin III and V, 10-deacetylbaccatin III, and 7-epi-PX in PBS, 
and its degradation kinetics was determined to be the first order for the first 12 h (Figure 
4.12) [385]. In the present studies, free PX was used as the control and the degradation 
behavior of C22-PX in PBS was found to be very similar to that of free PX. Therefore, it was 
hypothesized that C22-PX and PX undergo similar degradation pathways in PBS. In 
contrast, both C22-PX NP and micelle formulations were stable and no C22-PX degradation 
occurred during 48 h incubation in PBS, which indicated that the NP or micelle formulations 
could protect C22-PX from degradation in PBS. 
Since C22-PX BTM NPs were completely free of Cremophor EL and ethanol which 
are the solvents in Taxol, the vehicle associated toxicity should be much less. In fact, this 
was confirmed by the 6-fold greater MTD of C22-PX NPs compared to Taxol (Table 4.4). 
The antitumor efficacy of C22-PX NPs at MTD was then evaluated in a 4T1 s.c. mouse 
model with a q4d × 4 treatment schedule. C22-PX NPs at MTD exhibited non-toxicity based 
on the body weight change comparable to the untreated mice (Figure 4.14A). More 
importantly, C22-PX NPs demonstrated significantly superior antitumor activity compared to 
Taxol and C22-PX micelles at MTD (Figures of 4.14B-C). To better understand the in-vivo 
behavior of C22-PX NPs, a total of two pharmacokinetic and tissue biodistribution studies of 
C22-PX NPs versus Taxol were then conducted at the doses of 10 mg PX/kg and MTD, 
respectively (Figures of 4.15-16). PX concentration from Taxol declined very fast in plasma 
while C22-PX from C22-PX NP formulations had much longer circulation time in blood, 
where the plasma AUCs of C22-PX from C22-PX NPs were 22- and 186-fold greater than 
those of PX from Taxol at the doses of 10 mg PX/kg and MTD, respectively. The prolonged 
circulation time would enable NP formulations to take full advantage of EPR effect thus 
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more of the drug would be expected to accumulate in tumor site. This was confirmed by the 
fact that the tumor AUCs of C22-PX from NP formulations were 2.6- and 24.4-fold greater 
than that of PX from Taxol at the doses of 10 mg PX/kg and MTD, respectively. It should be 
noted that the tumor AUC of PX derived from C22-PX NPs was 1.5-fold greater than PX 
from Taxol at their MTDs. Taken together, there are at least three possible reasons for the 
enhanced antitumor efficacy of C22-PX NPs at MTD: 1) the 6-fold increase of MTD allowed 
much higher dose of the drug to be administered to mice; 2) C22-PX NPs had a remarkably 
improved pharmacokinetic profile and prolonged circulation time in blood, and much higher 
drug accumulation in tumor due to EPR effect, based on the facts that the plasma and tumor 
AUCs of C22-PX from C22-PX NPs were 186- and 24.4-fold greater than PX from Taxol at 
MTD, respectively; 3) Once C22-PX NPs reached the tumor site, PX was converted and 
released from C22-PX in a sustained manner. 
It should be noted that the BTM NPs were able to overcome P-gp mediated MDR both 
in-vitro and in-vivo, and the mechanisms were investigated which included: 1) increase drug 
cell uptake and retention; 2) inhibit P-gp; and 3) deplete ATP [125]. This would be a huge 
advantage in clinic because PX resistance is a significant problem in cancer therapy and the 
BTM NPs may have the potential to overcome this problem. Unfortunately, the 4T1 murine 
cell line in this study is not a resistant one [386]. However, the 4T1 cell line was very 
aggressive based on the facts that 1) the tumor sizes of untreated mice reached ~1,500 cm3 
after 20-25 days of cell injection; 2) the q4d × 4 treatment with Taxol at MTD of 25 mg/kg did 
not show a significantly better antitumor inhibition effect compared to untreated mice (Figure 
4.14B). It is expected that C22-PX BTM NPs would have much better antitumor efficacy if 
resistant and less aggressive mouse models were utilized. In addition, EGFR targeted NPs 
could potentially be engineered for even less side effects and further improved anticancer 
efficacy. 
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Table 4.1 Optimization and characterization of C22-PX BTM NPs. C22-PX BTM NP 
formulations were optimized with Miglyol 812, stearyl alcohol, or emulsifying wax as the oil 
phases, respectively. Formulation III was the optimal C22-PX NP formulation in terms of the 
physical stability and % drug content retained in NP fractions of 5-8 with a Sepharose CL-4B 
column elution.  
 
 
Formulations C22-PX (mg/mL) 
Miglyol 
812 
(mg/mL) 
Stearyl 
Alcohol           
(mg/mL) 
Emulsifying 
Wax 
(mg/mL) 
Brij78 
(mg/mL) 
TPGS 
(mg/mL)
 Polysorbate 
60       
(mg/mL) 
Temp 
(°C) 
Particle 
Size 
(nm) 
% Drug 
in F5-8 
I 0.2 2.5 ― ― 3.5 1.5 ― 70 18 N/Da 
II 0.2 2.5 ― ― 3.5 1.5 ― 65 189 ± 8 37 ± 8 
III 0.2 2.6 ― ― 2.0 1.6 ― 65 192 ± 10 47 ± 9 
IV 0.2 2.5 ― ― 1.6 0.8 ― 65 202 ± 16 60 ± 6 
V 0.2 ― 2.0 ― 4.5 ― 0.5 65 67 32 
VI 0.2 ― ― 2.0 2.0 2.6 ― 65 100 24 
 
a N/D: Not Determined 
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Table 4.2 Comparison of compositions in PX BTM NPs, C22-PX BTM NPs, and C22-PX 
micelles. 
 
Formulations Drug Loading (mg/mL) 
Miglyol 812 
(mg/mL) 
Brij 78 
(mg/mL) 
TPGS 
(mg/mL) 
Particle Size 
(nm) 
PX BTM NPs 0.15 2.5 3.5 1.5 ~200 
C22-PX BTM NPs 1.0 2.6 2.0 1.6 ~200 
C22-PX Micelles 0.8 ― 2.0 1.6 ~50 
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Table 4.3 Extraction of C22-PX from mouse plasma. Various extraction solvents and SPE 
columns were tried and applied to extract C22-PX from mouse plasma samples. The solvent 
of MeOH-ACN (2:1, v/v) was the most effective with > 90% recovery of C22-PX in plasma; 
therefore, this solvent was used for C22-PX extraction in-vivo studies.  
 
 
Extraction Solvents 
MeOHa 
ACNb 
DCMc 
MTBEd 
Hexane 
MeOH-ACN (2:1, v/v) 
SPE Cartridges 
Oasis HLB® Extraction 
Discovery® DSC-8 
Discovery® DSC-18 
Discovery® DSC-CN 
HybridSPE™-Precipitation 
 
 
a MeOH: methanol 
b ACN: acetonitrile 
c DCM: dichloromethane 
d MTBE: methyl tert-butyl ether 
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Table 4.4 The MTDs of Taxol, C22-PX NPs, and C22-PX micelles in 4T1 tumor-bearing 
mice with the treatment schedule of q4d × 3.  
 
Drug Formulation Drug Dose
a
 
(mg/kg) 
Lipid Dose 
(mg/kg) 
Max Wt Lossb 
(%) FRD
c
 
MTDa 
(mg/kg) 
Taxol 30 ― -1.8 0/3 30-40 
40 ― 0.0 2/2 
       C22-PX NPs 135 1155 -2.3 0/3 135-180 
180 1540 -5.7 1/3 
C22-PX Micelles 90 559 -5.0 0/3 90-120 
120 745 -5.9 1/3 
 
       
a
 The doses refer to PX equivalent doses. 
       
b Max Wt Loss: maximum weight loss 
       
c FRD: formulation related death 
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Table 4.5 Summary of important pharmacokinetic parameters of PX from Taxol, PX and 
C22-PX from C22-PX NPs in a 4T1 s.c. mouse model. The pharmacokinetic parameters 
were calculated from the data in Figures of 4.15-16 by non-compartment analysis utilizing 
WinNolin software (Version 5.3, Pharsight Co., Mountain View, CA, USA). 
 
 
Plasma Tumor 
Drug Dose
a
 
(mg/kg) 
  T1/2 
(h) 
MRT 
(h) 
AUC 
(ng/L.h) 
CL 
(L/h/kg) 
Vd 
(L/kg) 
AUC 
(h.µg/g) 
PX from Taxol 10 1.09 0.76 16,464 0.61 0.46 26.81 
C22-PX from C22-PX NPs 10 8.57 11.2 356,583 0.03 0.31 68.51 
PX from C22-PX NPs 10 ― ― 1,223 ― ― 6.256 
PX from Taxol 25 5.20 1.31 73,897 0.33 0.44 148.5 
C22-PX from C22-PX NPs 160 10.95 4.59 13,718,751 0.01 0.05 3,622 
PX from C22-PX NPs 160 ― ― 70,629 ― ― 221.6 
 
a
 The dose refers to PX equivalent dose. 
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Table 4.6 Summary of PX extraction methods from Taxol formulation in plasma and tissue 
samples. In general, liquid-liquid extraction, solid phase extraction, and/or combination of 
the both were applied to extract the drug from biological plasma and tissue samples. 
 
 
Authors Extraction Methods Ref. 
A. Sharma et al. MTBEa [387] 
C. Zhang et al. MTBE [388] 
X. Tong et al. MTBE [389] 
S. Lee et al. MTBE [390] 
H. Yonemoto et al. MTBE [391] 
P.H. Wiernik et al. ACNb [392] 
F. Mohamed et al. ACN [393] 
G.J. Fetterly et al. ACN [394] 
J.L. Eiseman et al. ACN [395] 
A. Elyazigi et al. Ethyl acetate [396] 
S.M. Longnecker et al. Ethyl acetate [397] 
S.C. Kim et al. Ethyl acetate [398] 
Y. Wang et al. Diethyl ether [399] 
F. Coudore et al. Dichloromethane [400] 
A. Sparreboom et al. ACN:n-butylchloride (1:4, v/v) [401] 
L.Z. Lopez et al. ACN:n-butylchloride (1:4, v/v) [402] 
T.A. Willey et al. Cyano bond elut SPE [403] 
M. Suno et al. Sep-Pak C18 cartridge [404] 
W.K. Kelly et al. C18-HS SPE [405] 
A. Sparreboom et al. Diethyl ether + Cyano bond elut SPE [406] 
 
 
a
 MTBE: methyl tert-butyl ether 
b ACN: acetonitrile 
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Table 4.7 % Recovery of free PX and PX BTM NPs from rat plasma and whole blood. Free 
PX and PX BTM NPs were spiked into rat plasma and whole blood at the concentrations of 
10, 100, and 1,000 ng/mL, respectively. PX from both formulations was extracted by SPE 
method, and its concentration was determined by LC/MS described in the Material and 
Method section. % Recovery is expressed as mean ± SD (n = 3). 
 
 
 
Formulations PX Conc. (ng/mL) % Recovery 
Plasma 
Free PX 
10 107.0 ± 4.0 
100 106.0 ± 5.3 
1,000 99.3 ± 0.8 
PX BTM NPs 
10 105.3 ± 3.8 
100 99.1 ± 2.6 
1,000 89.8 ± 4.4 
Whole Blood 
Free PX 
10 111.9 ± 11.6 
100 109.0 ± 3.0 
1,000 102.6 ± 12.8 
PX BTM NPs 
10 127.7 ± 11.9 
100 118.3 ± 6.8 
1,000 119.0 ± 8.7 
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Table 4.8 Summary of important pharmacokinetic parameters of PX from Taxol and PX 
BTM NP formulations. All pharmacokinetic parameters were calculated from the data in 
Figure 4.19 by non-compartment analysis utilizing WinNolin software (Version 5.3, Pharsight 
Co., Mountain View, CA, USA). 
 
 
 
Plasma Tumor 
Drug T1/2 (h) 
MRT 
(h) 
AUC 
(µg/L.h) 
CL 
(L/h/kg) 
Vd 
(L/kg) 
AUC     
(h.ng/g) 
PX from Taxol 1.82 2.28 807 2.79 6.35 1,090 
PX from PX BTM NPs 1.44 1.66 800 2.81 4.67 1,213 
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Figure 4.1 Synthesis of C22-PX conjugate via a one-step esterification reaction of PX and 
behenoyl chloride. The synthesized C22-PX conjugate was confirmed by 1H- and 13C- NMR, 
MS, TLC, and HPLC analyses. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 The 1H- and 13C
of C22-PX; (B) 13C-NMR spectrum of C22
 
(A)
(B)
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Figure 4.3 The mass spectrum and TLC assay of C22-PX conjugate. (A) Mass spectrum of 
C22-PX. The C22-PX conjugate exhibited a strong and sharp peak at m/z of 1198.13, which 
corresponds to [M + Na]+ (C69H93NO15Na+, Calc.: 1198.46); (B) TLC assay of C22-PX. Ethyl 
acetate-hexane (3:1, v/v) was used as the mobile phase. The Rf value of PX was 0.34, while 
the Rf value of C22-PX was 0.74. 
 
T: + c ESI Q1MS [30.000-2000.100]
200 400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
a
tiv
e
 
Ab
u
n
da
n
ce
1198.13
1266.13
685.11
662.65 1334.56786.60 952.20 1058.64 1537.92 1645.25 1786.76640.25481.34235.15160.41 PX C22-PX
(A) (B)
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 HPLC assay of C22-PX conjugate. (A) The representative chromatography of 
C22-PX and C22-PX BTM NPs; (B) C22-PX standard calibration curve validated by HPLC 
analysis. The concentration of C22-PX from 0.1341-26.2 µg/mL was quantified by a Thermo 
Finnigan Surveyer HPLC System plus an Inertsil ODS-3 column (4.6 × 150 mm) coupled 
with an Agilent guard column (Zorbax SB-C18, 4.6 × 12.5 mm). The mobile phase was 
ACN/IPA/Water (35/60/5, v/v/v).  
 
 
 
 
 
 
 
 
 
 
 
Minutes
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
m
AU
-10
0
10
20
30
40
50
60
70
80
m
AU
-10
0
10
20
30
40
50
60
70
80
D etector 1-230nm
C 22-PX NPs 30 uL in  2 mL MeOH  9/2/2010 9:37:19 PM.dat
Retention Time
Area
Detector  1-230nm
MeOH  9/1/2010 11:53:14 PM.dat
Detector  1-230nm
C22-PX 08-18 10.85 ugmL 9/2/2010 4:39:24 AM.dat
C22-PX NPs
C22-PX
MeOH
(A)
y = 92331.861x
R² = 1.000
0.0E+00
5.0E+05
1.0E+06
1.5E+06
2.0E+06
2.5E+06
3.0E+06
0 10 20 30
Ar
ea
C22-PX Conc. (µg/mL)
(B)
156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Solubilities of PX and C22-PX conjugate in different Miglyols. Excess of C22-PX 
and PX were added into the Miglyols and were kept stirred for 24 h at room temperature. 
The mixtures were then centrifuged at 14,000 g for 20 min at 25ºC. After that, the 
supernatant was taken out, accurately weighted, and dissolved in methanol in a 50 mL 
volumetric flask. The concentrations of PX and C22-PX were determined by HPLC analysis. 
Results are expressed as mean ± SD (n = 3).  
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Figure 4.6 The cytotoxicity of free PX and free C22-PX in 4T1 mouse mammary carcinoma 
cells. Serial dilutions of free PX and free C22-PX were incubated at 37°C for 48 h. After that, 
the MTT assay was applied to measure the cell viability normalized to control. The 
concentration of drug that inhibited cell survival by 50% (IC50) was determined from cell 
survival plots. 
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Figure 4.7 Tubulin polymerization assay of C22-PX conjugate. The standard (control) 
polymerization reaction contains 100 µL of 3 mg/mL tubulin in 80 mM PIPES pH 6.9, 0.5 mM 
EGTA, 2 mM MgCl2, 1 mM GTP, and 10% glycerol. The assay was conducted at 37ºC and 
the tubulin polymerization was monitored by the change of the absorbance at 340 nm over a 
60 min period (1 reading per min) with a temperature controlled Microplate Reader. C22-PX 
concentrations of 5, 10, and 20 µM were applied in the assay. PX (10 µM) was used as the 
positive control. (A) Tubulin polymerization curves of the control, PX, and C22-PX; (B) Vmax 
values of the control, PX, and C22-PX. Data are presented as mean ± SD (n = 3). (** p < 
0.01, *** p < 0.001) 
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Figure 4.8 C22-PX BTM NPs were engineered from oil-in-water microemulsion precursors. 
The oil and surfactants were melted at 65°C, C22-PX in ethanol stock solution was then 
transferred to the vial containing the oil and surfactant mixture. Residual ethanol was 
evaporated under a stream of nitrogen gas, and then preheated deionized water was added 
into the vial. Oil-in-water microemulsions formed spontaneously at this elevated 
temperature. Upon direct cooling of the warm microemulsions to room temperature, NP 
suspensions were formed. The average particle size was measured by photon correlation 
spectroscopy with a Coulter N5 Plus Sub-Micron Particle Sizer at a fixed angle of 90º and a 
temperature of 25°C. 
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Figure 4.9 Gel permeation chromatography elution profiles with a Sepharose CL-4B 
column. A total of 20 fractions were collected (1 mL/fraction) with the elution solvent of PBS. 
(A) Particle size (♦) and intensity (■) of each fraction of C22-PX BTM NPs; (B) % drug 
retention in each fraction of PX (■) and C22-PX BTM NPs (□). Results are expressed as 
mean ± SD (n = 3); (C) % C22-PX retention in each fraction of C22-PX BTM NPs (♦) and 
C22-PX micelles (■). % drug retention was calculated as: [(total mass of drug in each 
fraction) / (total mass of drug loaded into the column)] × 100% (w/w) 
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Figure 4.10 Gel permeation chromatography elution profiles. A total of 20 fractions were 
collected (1 mL/fraction), and particle size or % drug retention of each fraction was 
determined. (A) C22-PX NPs passed through a Sepharose CL-4B column with different 
elution solvents: (♦) 0.1 × PBS; (─) 0.5 × PBS; (●) 1 × PBS; (▲) 2 × PBS; (■) deionized 
water; (B) Latex beads with particle size of 200 nm passed through a Sepharose CL-4B 
column with either (♦) 1 × PBS or (▲) deionized water as the elution solvent; (C) C22-PX 
NPs passed through a Sephacryl S-500 column with either (♦) 1 × PBS or (▲) deionized 
water as the elution solvent. 
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Figure 4.11 Various C22-PX formulations incubated in PBS at 37°C i n a water bath. At 
determined time points, samples were taken out and the concentration of C22-PX was 
determined by HPLC. Free PX was used as the control. The final drug concentrations in the 
experiment were equal to 10 µg/mL. Results are expressed as mean ± SD (n = 3). 
 
 
 
0 10 20 30 40 50
0
20
40
60
80
100
120 Free C22-PXFree PX
C22-PX NPs
C22-PX Micelles
Time (h)
%
 
D
ru
g 
Re
ta
in
e
d
163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Major PX degradation products after incubation in PBS at 37°C (Ref: [385]).   
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Figure 4.13 C22-PX and C22-PX NPs incubated in tumor homogenates at 37°C.  C22-PX 
and C22-PX NPs were spiked into fresh 4T1 tumor homogenates at the concentration of 10 
µg/g tumor and incubated at 37°C in a water bath. At  determined time points, ~40-50 mg of 
samples was taken out. The concentrations of both C22-PX and PX converted from C22-PX 
or C22-PX NPs were determined.  
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Figure 4.14 In-vivo antitumor efficacy studies of Taxol, C22-PX NPs, and C22-PX micelles 
in a 4T1 mammary carcinoma mouse model. The BALB/c female mice (n = 9-10 per group) 
were s.c. injected with 1 x 106 4T1 cells on Day (-5), and i.v. tail vein injected different 
formulations starting from Day 0 with the treatment schedule of q4d × 4. The mice weight 
and tumor sizes were measured every other day [tumor size was calculated as: ½ × (width)2 
× (length)]. All the mice were sacrificed on Day 18 and upon sacrifice the tumors of all the 
mice were removed and weighed. (A) Mice weight; (B) Tumor size; (C) Tumor weight. Data 
are presented as the mean ± SEM. (* p < 0.05, ** p < 0.01) 
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Figure 4.15 Pharmacokinetic and biodistribution studies of C22-PX BTM NPs in a 4T1 
mammary carcinoma mouse model at the dose of 10 mg PX/kg. The BALB/c female mice (n 
= 3 per group) were s.c. injected with 1 × 106 4T1 cells and i.v. tail vein injected different 
formulations when the tumors reached to 200-300 mm3. (A) Drug concentrations in mouse 
plasma; (B) PX concentrations from Taxol; (C) C22-PX concentrations from C22-PX NPs; 
(D) Drug concentrations in tumor. Data are presented as the mean ± SD. 
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Figure 4.16 Pharmacokinetic and biodistribution studies of C22-PX BTM NPs in a 4T1 
mammary carcinoma mouse model at MTD. The BALB/c female mice (n = 3 per group) 
were s.c. injected with 1 × 106 4T1 cells and i.v. tail vein injected different formulations when 
the tumors reached to 200-300 mm3. (A) Drug concentrations in mouse plasma; (B) PX 
concentrations from Taxol; (C) C22-PX concentrations from C22-PX NPs; (D) Drug 
concentrations in tumor. Data are presented as the mean ± SD. 
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Figure 4.17 The flow chart of PX extraction from Taxol, PX NPs, or C22-PX NP formulations 
in plasma. Waters Oasis® HLB cartridge (1 cc/10 mg) was applied to extract PX from plasma 
samples. The cartridge was first conditioned by 20% method in dichloromethane, methanol 
and deionized water. The plasma samples were then loaded on the cartridge and washed 
by 5% methanol and 55% methanol in deionized water, respectively. Next, the collection 
samples were eluted by 20% method in dichloromethane, then the organic solvent was 
evaporated and residues were dissolved in the mobile phase for further LC/MS analysis. 
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Figure 4.18 Quantification of PX by HPLC/MS/MS system. Chromatographic separations 
were achieved by using a SunFire™ C18 column (2.1 × 30 mm, 3.5 µm particle size, 
Waters) at 25ºC. The mobile phase consisted of 55% methanol and 45% (v/v) of 0.1% 
formic acid in deionized water for 0.2 min, then linear gradients to 70:30 (v/v) in 6 min and 
went back to 55:45 (v/v) in 8 min. The flow rate was 0.5 mL/min. Mass spectrometric 
analysis was performed by Thermo Scientific TSQ Quantum Access with positive ionization. 
M/z 876.3 → 308.0 for PX and its 7-epimer, and m/z 830.0 → 549.0 for DTX were used for 
quantification of analytes. DTX was added as the internal standard. 
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Figure 4.19 Pharmacokinetic and tumor uptake studies of Taxol and PX BTM NPs in mice. 
(A) Pharmacokinetic profile of Taxol and PX BTM NPs. SKH1-E mice (n= 3 per group) were 
i.v. injected with Taxol or PX BTM NPs at dose of 2.25 mg PX/kg. The mice were sacrificed 
at various time points and PX concentration in plasma was determined by LC/MS analysis; 
(B) Tumor uptake of Taxol and PX BTM NPs. Female nude mice (n = 3 per group) were s.c. 
injected with 4 × 106 NCI/ADR-RES cells and i.v. tail vein injected Taxol or PX BTM NPs at 
dose of 4.5 mg PX/kg when the tumors reached to 300-500 mm3. The mice were sacrificed 
at various time points and PX concentration in the tumor was determined. Data are 
presented as the mean ± SD. 
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Chapter V 
 
Summary and Future Experiments 
 
5.1    Summary 
The overall goals of the present studies were to develop lipid-based NPs of 
anthracyclines (IDA and DOX) and taxanes (PX) for cancer therapy. The lipid-based NP 
formulations were engineered using a microemulsion precursor strategy proposed and 
developed in the Mumper laboratory [124]. This NP engineering method has some 
advantages, which include easy adaption to many different excipients, engineering of 
reproducible and uniform NPs, avoidance of expensive and/or damaging high-torque 
mechanical mixing, microfluidization, or homogenization.  
Two types of lipid-based NPs were developed, one was SLNs for the delivery of IDA 
and DOX, and the other one was oil-filled nanocapsules for the delivery of PX and C22-PX. 
For both types of NPs, Brij 78 served as the surfactant and TPGS was utilized as the 
cosurfactant. The difference between the NPs was the oil phase, where emulsifying wax 
was utilized in SLNs while Miglyol 812 was used in oil-filled nanocapsules. In SLNs, 
emulsifying wax was in a solid state at room temperature but was melted when heated to 
65°C during NP preparation process due to its low melti ng point of ~50°C. Upon cooling to 
ambient temperature, emulsifying wax solidified and returned to a solid state. In contrast, 
Miglyol 812 was in a liquid state at room temperature; therefore, no solidification process 
was involved for the oil-filled NPs. The benefit of the liquid core is that it serves as an idea
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solvent for the drugs that have high melting points and are prone to crystallization, such as 
PX. This was confirmed by the higher drug loading and entrapment efficiency, and slower in-
vitro release profile of PX-loaded nanocapsules than PX SLNs [125, 278-280].  
5.1.1   IDA and DOX SLNs 
The objectives of the studies with IDA and DOX SLNs were: 1) to investigate and 
compare IDA SLNs and DOX SLNs against P-gp-mediated MDR in-vitro and in-vivo; and 2) 
to test the feasibility of the SLNs as potential drug carriers for MDR-related cancer therapy. 
The hypotheses driving the research were: 1) negatively-charged lipids and/or polymers will 
form ion-pair complex with IDA and DOX, where they not only neutralize cationic charge of 
drugs but also increase drug lipophilicity; 2) The ion-pair complex will be stable in PBS and 
could be encapsulated in lipid-based NPs; 3) IDA and DOX lipid-based NP formulations will 
overcome P-gp-mediated resistance both in-vitro and in-vivo.  
To test the above hypotheses, various ion-pair agents were screened based on the  
following criteria: 1) ion-pair agent is synthetic; 2) ion-pair agent must quantitatively form 
precipitates with IDA and DOX from aqueous solution; 3) ion-pair complex is lipophilic and 
miscible in oil phase; 4) ion-pair complex is not soluble in PBS; 5) must reproducibly form 
monodisperse NPs at drug concentrations at least 200 µg/mL but ideally up to 500-800 
µg/mL; 6) IDA and DOX are released slowly in-vitro versus free drug; 7) NPs overcome P-gp 
in-vitro and in-vivo. Different ion-pair agents were tested and it was concluded that STDC 
and STS were the most effective ion-pair agents in IDA and DOX SLNs. Titration of an 
aqueous solution of IDA or DOX with aqueous solution of STDC or STS resulted in 
immediate formation of ion-pair complex as red precipitates. This complexation process was 
very efficient in that more than 95% of the drugs ion-paired with the counter-ions of STDC or 
STS. The ion-pair complexes were successfully encapsulated into SLNs with particle size of 
< 100 nm and high drug entrapment efficiency > 80%. The more concentrated of IDA and 
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DOX NPs up to 800 µg/mL were also produced without changing particle size and PI values. 
In PBS, about 80% DOX was released from DOX-STS NPs in 24 h in PBS, which was 
slower than IDA from IDA-STDC NPs and this was likely due to the enhanced stability of the 
STS ion-pair complex in PBS as compared to the STDC ion-pair complex.  
In in-vitro cytotoxicity studies, the prepared DOX NPs were 9-fold more cytotoxic than 
free DOX in resistant P388/ADR cell line. In contrast, IDA NPs and free IDA had comparable 
IC50 values in both resistant P388/ADR and HCT-15 cells. The in-vivo antitumor efficacy 
studies were well correlated with in-vitro  studies where DOX NPs demonstrated significantly 
improved tumor inhibitory activity compared to their free drug solution in resistant P388/ADR 
tumor-bearing mice. In contrast, IDA NPs exhibited comparable antitumor efficacy in-vivo in 
P-gp resistant tumor mouse models. It was hypothesized that this was due to the more 
lipophilic property of IDA resulting in IDA being a poorer P-gp substrate. As a consequence, 
IDA NPs did not show any benefit versus free drug in resistant cells. In contrast, DOX is a 
good P-gp substrate and is effluxed out of cells by P-gp. However, in contrast, NP 
formulations enter the cells via endocytosis and bypass and/or inhibit P-gp. In summary, the 
SLNs may offer potential to deliver anticancer drugs for the treatment of P-gp-mediated 
MDR; however, selection of target drug may be very important.  
5.1.2   C22-PX Nanocapsules 
The objectives of the studies were to develop C22-PX lipid-based NPs to treat 
metastatic breast cancer. The following five hypotheses were proposed: 1) more lipophilic 
C22-PX could be successfully synthesized and will have greater solubility in the oil phase of 
Miglyol 812 and exhibit much higher entrapment efficiency in our BTM NPs compared to PX; 
2) C22-PX BTM NPs will be less toxic and enhance MTD than Taxol due to the elimination 
of Cremophor EL/Ethanol; 3) C22-PX will be slowly released from BTM NPs and convert to 
PX by esterases in the body; 4) C22-PX NPs will have long circulation time in blood thus 
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take full advantage of EPR effect to preferably accumulate in tumor site; 5) C22-PX 
conjugate NPs will exert better in-vivo antitumor efficacy, improved pharmacokinetics and 
tumor uptake than Taxol.  
To test the above hypotheses, a C22-PX conjugate was synthesized via a one-step 
esterification reaction of PX and behenoyl chloride. The formation of the product was 
confirmed by NMR, TLC, LC/MS, and HPLC analyses. The solubility of C22-PX in the oil 
phase of Miglyol 812 enhanced 25-fold compared to PX. This C22-PX was successfully 
formulated into nanocapsules and the drug entrapment efficiency was significantly increased 
compared to PX using GPC method. It should be noted that the conjugate was less potent 
than PX which was confirmed by in-vitro cytotoxicity and tubulin polymerization studies. 
C22-PX was released from C22-PX nanocapsules and partly converted to more active form 
of PX in 4T1 tumor homogenates. Because C22-PX NPs completely eliminated Cremophor 
EL and ethanol in Taxol formulation, the MTD of C22-PX NPs increased 6-fold in 4T1 tumor-
bearing mice, which indicated C22-PX NPs were better tolerated than Taxol. In a 4T1 
subcutaneous mouse model, C22-PX NPs exhibited significantly better in-vivo antitumor 
efficacy than Taxol at MTD. In-vivo pharmacokinetic and biodistribution studies, C22-PX 
NPs demonstrated prolonged circulation time and half-life in blood, and greater tumor 
uptake than Taxol at MTD. All the above results support the proposed hypotheses, which 
suggest C22-PX NPs may offer the potential to treat metastatic breast cancer. 
5.2    Future Experiments 
The lipid-based NPs developed in our laboratory were demonstrated to overcome 
MDR both in-vitro and in-vivo. A series of in-vitro assays were performed to investigate the 
mechanisms of the NPs, such as uptake/efflux, ATP, membrane integrity, mitochondrial 
membrane potential, apoptosis, metabolism, cytotoxicity. It was concluded that the 
increased uptake/retention of drug inside cells, P-gp inhibition of NPs, and ATP depletion 
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were the major reasons responsible for the NP activity in resistant cells and the results were 
published in Cancer Research [125]. However, all the mechanism experiments were 
conducted in-vitro. It is known that the in-vitro results may not be translated to in-vivo, 
therefore, in-vivo studies should be performed to better understand the mechanisms how 
the lipid-based systems to overcome P-gp-mediated resistance. Moreover, how the NPs get 
into cells and release of the drug are largely unknown, although it was suggested the 
endocytosis may be responsible for the entry of NPs into cells based on the facts that the 
drug cellular uptake was temperature dependent [125, 279]. In addition, since MDR is 
complicated and multifactorial, it is better to investigate other MDR mechanisms as well, 
such as MRP (pump resistance), BCL-2 and p53 (non-pump resistance). Is it feasible to co-
deliver both chemotherapeutic agents (IDA, DOX, or PX), and BCL-2 siRNA or MRP1 
inhibitor, for example, to exert synergistic effects for better antitumor efficacy? Furthermore, 
PEGylation of NPs could also be optimized. Specifically, what content of PEG should be 
enough to coat on the surface of NPs, what is the optimal molecular weight of PEG, how to 
add PEG into NP formulations (pre- or post-insertion). All of these will affect the ‘stealth’ 
properties of the NPs in-vivo.  
5.2.1   IDA and DOX SLNs  
IDA and DOX SLNs were developed to address P-gp associated MDR both in-vitro 
and in-vivo. Since SLNs commonly consist of lipids and surfactants, they are particularly 
useful for the delivery of lipophilic drugs due to the high partition of the drugs in the lipid 
phase. However, the commercial available forms of anthracyclines (IDA and DOX) are 
hydrochloride salt, therefore they are water-soluble. For this reason, free base forms of the 
drugs could be used for NP formulation preparation. In addition, the cationic charges of 
these salts may pose an obstacle for efficient drug incorporation into lipid particles. In these 
studies, STDC and STS were identified and selected as the best ion-pair agents to 
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neutralize the charge and enhance entrapment of IDA or DOX in terms of drug entrapment 
efficiency and release profiles. However, the release rate was faster than expectation and a 
burst release effect occurred as well. Therefore, other ion-pair agents may be identified and 
tested based on the criteria mentioned before.  
It should be noted that the cardiotoxicity is a severe side effect of anthracyclines, 
therefore, it is needed to perform the in-vivo biodistribution studies and compare drug 
concentration in heart between IDA or DOX SLNs and their free forms. The parameters and 
conditions of lyophilization process, such as cryoprotectants, sample pre-treatment method, 
primary and secondary drying programs, may be further optimized to retain physicochemical 
and biological properties of NPs before and reconstitution after lyophilization. In addition, 
nanocapsule formulations could be utilized as carriers for the delivery of DOX and IDA. In 
this case, the burst release effect and lyophilization product should be improved based on 
the previous results of PX nanocapsules [125, 280]. Last but not least, immuno-NPs could 
be engineered, for example, targeting to CD3 antigen [407] and neuropilin-1 receptor [408] 
in leukemic cells, for better leukemia therapy. 
5.2.2   C22-PX Nanocapsules 
In the present studies, C22-PX was synthesized to improve the lipophilicity of PX and 
this conjugate was incorporated into oil-filled nanocapsules. Although the solubility of C22-
PX in Miglyol 812 significantly enhanced compared to PX, it could be further improved using 
other liquid oils, such as different types of vegetable oils. In the meanwhile, fatty acids with 
different carbon chain length could be conjugated onto PX molecule to alter its solubility 
profile, which will potentially control the drug release from NPs according to Ansell’s studies 
[292]. Based on our results, the conversion from C22-PX to PX was not that efficient 
because 1) only about ~5-7% C22-PX converted to PX in in-vitro in tumor homogenates; 2) 
PX derived from C22-PX NPs declined fast in-vivo in tumor tissues while C22-PX was 
177 
 
retained at high concentration, which indicated some difficulty of C22-PX conversion to PX 
and this may be due to either saturation of esterases or the slow kinetic conversion 
behavior. The results partly explained why C22-PX NPs did not show better antitumor 
efficacy than Taxol at the same dose of 25 mg PX/kg. If fast hydrolysis of fatty acid-PX 
conjugate is required, electron withdrawing group can be introduced. Currently 2’-α-
bromohexadecanoyl-PX has been synthesized and is under investigation in our laboratory. 
In addition, C22-PX NPs accumulated mainly in liver and spleen, therefore, it is better to test 
the toxicity of C22-PX NPs to these tissues. For example, alanine aminotransferase (ALT) 
test may be used to determine the liver injury of C22-PX NP formulations. 
It should be noted that the BTM NPs were able to overcome P-gp mediated MDR, 
however, the 4T1 murine cell line in these studies was not resistant [386]. Therefore, a PX 
resistant 4T1 subline may be developed by continuous exposure of PX into the cells. 4T1 
luciferase 4T1 cell line is also available and this cell line may be utilized to visualize 
metastatic events and the treatment effect of NP formulations versus Taxol in real time. In 
addition, this 4T1 cell line is very aggressive; therefore, other metastatic breast cancer cell 
lines, such as MDA-MB-468, may be an alternative option. In the present studies, 
subcutaneous tumor-bearing mouse models were utilized. Other more clinically relevant 
models, such as orthotopic and/or genetically engineered mouse (GEM) models can be 
utilized. Furthermore, since the current NPs are non-targeted formulations, EGFR or folic 
acid targeted NPs may be engineered for potentially improved anticancer efficacy and 
reduced toxicity.  
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